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ABSTRACT
THE ROLE OF BACTERIOCINS IN MEDIATING INTERACTIONS OF BACTERIAL
ISOLATES FROM CYSTIC FIBROSIS PATIENTS
February 2011
E. SUPHAN BAKKAL, B.SC. MOLECULAR BIOLOGY AND GENETICS,
BOGAZICI UNIVERSITY, TURKEY
M.SC. BIOLOGICAL SCIENCE AND BIOENGINEERING PROGRAM
SABANCI UNIVERSITY, TURKEY
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Margaret A. Riley
Cystic Fibrosis (CF) is a common autosomal genetic disorder in Caucasian
populations. CF is caused by mutations in the cftr gene, which encodes the CF
transmembrane conductance regulator (CFTR). CFTR regulates chloride and sodium ion
transport across the epithelial cells lining the exocrine organs. Mutations in the cftr result
in a failure to mediate chloride transport, which leads to dehydration of the mucus layer
surrounding the epithelial cells. The mucus coating in the lung epithelia provides a
favorable environment for invasion and growth of several opportunistic bacterial
pathogens resulting in life threatening respiratory infections in CF patients.
Pseudomonas aeruginosa (Pa) and Burkholderia cepacia complex (Bcc) are
associated with chronic lung infections and are responsible for much of the mortality in
CF. Little is known about interactions between these two, often co-infecting, species.
When in competition, it is not known whether Bcc replaces the resident Pa or if the two
species co-exist in the CF lung.
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Bacteriocins are potent toxins produced by bacteria. They have a quite narrow
killing range in comparison to antibiotics and have been implicated in intra-specific and
inter-specific bacterial competition brought on by limited nutrients or niche space. Both
Pa and Bcc produce bacteriocins known as pyocins and cepaciacins, respectively. More
than 90% of Pa strains examined to date produce one or more of three pyocin types: R, F,
and S. A limited number of phenotypic surveys suggest that approximately 30% of Bcc
also produce bacteriocins.
The goals of my thesis study were to determine if clinical strains of Pa and Bcc
produce bacteriocins and to determine whether these toxins play a role in mediating intraand inter-specific bacterial interactions in the CF lung. The final goal was to identify
novel bacteriocins from clinical Pa and Bcc strains.
First, I designed a phenotypic bacteriocin survey to evaluate bacteriocin
production in 66 clinical Pa (38) and Bcc (28) strains procured from CF patients. This
study revealed that 97% of Pa strains and 68% of Bcc strains produce bacteriocin-like
inhibitory activity. Further phenotypic and molecular based assays showed that the source
of inhibition is different for Pa and Bcc. In Pa, much of the inhibitory activity is due to
the well known S- and RF-type pyocins. S-and RF pyocins were the source of within
species inhibitory activity while RF pyocins were primarily implicated in the between
species inhibitory activity of Pa strains. In contrast, Bcc inhibition appeared to be due to
novel inhibitory agents. Finally, I constructed genome libraries of B. multivorans, B.
dolosa, and B. cenocepacia to screen for genes responsible for the inhibitory activity
previously described in Bcc. ~10,000 clones/genome were screened, resulting in fifteen
clones with the anticipated inhibition phenotype. Of these fifteen, only five clones had
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stable inhibitory activity. These clones encoded proteins involved in various metabolic
pathways including bacterial apoptosis, amino acid biosynthesis, sugar metabolism, and
degradation of aromatic compounds. Surprisingly, none of Bcc clones possessed typical
bacteriocin-like genes. These data suggest that, in contrast to all bacterial species
examined in a similar fashion to date, Bcc may not produce bacteriocins. Instead, Bcc
may be using novel molecular strategies to mediate intra- and inter-specific bacterial
interactions.
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CHAPTER 1
BACKGROUND AND SIGNIFICANCE
"Woe is the child who tastes salty from a kiss on the brow, for he is cursed, and soon
must die.“
Northern European Folklore
Preface
Cystic Fibrosis (CF) was defined as a fibrocystic disease of secretory organs in
the 1930s. In 1938, Dorothy Anderson, MD published a comprehensive study, which
categorized 49 CF patients between 0-14.5 years old based on the age of death and
clinical manifestations (Andersen, 1938). The major conclusion of this case study was
that the disease creates diverse effects on multiple body systems, in particular the
digestive and respiratory systems. Further, the majority of patients (44) died due to
respiratory infections (Andersen, 1938). During the past 60 years, a vast amount of data
has provided support to the notion that the disease was the causative agent of the
resulting clinical outcomes; these clinical observations included salty-tasting skin,
vitamin-A deficiency, poor growth, greasy, bulky stools, persistent coughing, wheezing,
shortness of breath, malformation of pancreatic ducts, fertility problems, and lung
infections (Darling et al., 1953; Freedman et al., 2000a; Freedman et al., 2000b). One of
the most important milestones in the history of CF was the discovery of the cystic fibrosis
transmembrane regulatory receptor (cftr) gene, whose mutation is responsible for this
disease (Kerem et al., 1989; Riordan et al., 1989; Rommens et al., 1989).
Today, we define CF as an autosomal recessive genetic disorder, mainly affects
Caucasian population with an average incidence of 1 in 3000 live births (Morrissey et al.,
2003). CF patients ultimately die in their mid-30s due to chronic lung infections that are
1

associated with high mortality (Govan & Deretic, 1996). Staphylococcus aureus,
Heamophilius influenzae, Stenotrophomonas maltophilia, Pseudomonas aeruginosa, and
Burkholderia cepacia complex are commonly isolated species from CF patients (Jones &
Webb, 2003).
This thesis is focused on two bacterial species: Pseudomonas aeruginosa and
Burkholderia cepacia complex. Both species are multi-drug resistant and became the
major concern for CF patients in the past 30 years (Govan & Deretic, 1996).
Pseudomonas aeruginosa is the most common infectious agent involved, which is
normally acquired shortly after birth. Approximately 80% of adult CF patients have
chronic Pseudomonas infections, which result in high levels of mortality (CFF2008;
Govan & Deretic, 1996). In contrast, the Burkholderia cepacia complex affects a smaller
portion of CF patients (~3%). However, colonization by Burkholderia, usually leads to
rapid lung failure (Jones et al., 2004; Kalish et al., 2006; Tablan et al., 1985).
There are numerous bacterial proteins thought to be associated with the
pathogenicity of bacteria in CF lungs (Govan & Deretic, 1996; Mahenthiralingam et al.,
2005). In this thesis, I will specifically focus on bacteriocins produced by clinical
Pseudomonas aeruginosa and Burkholderia cepacia complex. These bacteriocins are
narrow spectrum toxins used by bacteria to kill strains of related species (Riley & Wertz,
2002a; Riley & Wertz, 2002b). I investigated (i) bacteriocin production of Pseudomonas
aeruginosa and Burkholderia cepacia complex and their role in mediating both within
and between species inhibitory activity; (ii) bacteriocin types produced by Pseudomonas
aeruginosa and Burkholderia cepacia complex; (iii) putative bacteriocin genes of
Burkholderia cepacia complex.
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The following sections will provide general information about CF, CF symptoms,
current treatment regiments, mechanism of the disease, bacteria colonizing CF lung (in
particular Pseudomonas aeruginosa and Burkholderia cepacia complex), interaction
between Pseudomonas aeruginosa and Burkholderia cepacia complex, bacteriocins of
Pseudomonas aeruginosa and Burkholderia cepacia complex, and finally the significance
of the project.

1.1 The Genetics of Cystic Fibrosis
1.1.1 The cftr gene
Cystic Fibrosis is an autosomal recessive genetic disorder, which is caused by
mutations on the Cystic Fibrosis Transmembrane Regulator (cftr) gene (Morrissey et al.,
2003). The cftr gene is located on the long arm of chromosome 7 (7q.31.2). It spans a 215
kb region and consists of 27 exons and 26 introns (Figure 1-1a). The cftr gene encodes a
transmembrane protein with two membrane-spanning domains (MSD), one regulatory
domain (R), and two nucleotide-binding domains (NBD) (Figure 1-1b) (Riordan et al.,
1989).

1.2 The CFTR Protein
The CFTR protein is an apical membrane Cl- ion channel on epithelial cells. The
pore size of the channel is ~5.3 A (Linsdell et al., 1997). It is selectively permeable to Clions. Water, urea, and ATP may also permeate through the CFTR channel (Hasegawa et
al., 1992).
Site directed mutagenesis studies have revealed the functions of each domain of
the CFTR: The MSD domains contribute to ion selectivity and formation of Cl- channels;
3

The R domain connects two halves of the protein, and also has multiple sites for
phosphorylation by protein kinase A and C (Figure 1-1b) (Riordan et al., 1989).
The R domain controls channel gating activity by phosphorylation and
dephosphorylation, and the NBD domains hydrolyze ATP to regulate channel gating
(Sheppard & Welsh, 1999).
The two MSDs are composed of six transmembrane segments (M) (Figure 1-1b).
There are six conserved residues K95 (M1), R134 (M2), R334 (M6), R335 (M6), R347
(M6), and R1030 (M10). A mutation in either arginine residue (R334 and R347) is
associated with the onset of disease symptoms (Riordan et al., 1989). These mutations
lead to more than a 70% decrease in Cl- ion conductance (Tabcharani et al., 1993).
Positively charged arginine residues are required to interact with the negative charge on
Cl- during Cl- conductance. Further, mutations in two basic lysine residues (K95 and
K335) to acidic aspartate (D) and glutamate (E) changed ion selectivity of CFTR channel
from Br->Cl->I->F- to I->Br->Cl->F- (Anderson et al., 1991b). Finally. Cheung and
Akabas used the substituted cysteine accessibility method to identify pore-lining residues
in M1 and M6. They revealed 11 residues (I331, L333, R334, K335, F337, S341, I334,
R347, T351, R352, and Q353) along M1 and M6, which contribute formation of Clchannel (Akabas et al., 1994; Cheung & Akabas, 1996).
The residues at intracellular and extracellular loops (ICL and ECL) of CFTR are
important for membrane localization and functioning of the CFTR protein. Mutations in
internal loops (ICL) altered gating behavior and channel regulation and no effect on pore
formation. Mutations in ICL 1 and 2-increased mean closed time of the CFTR channel
while ICL 3 and 4-decreased mean opened state of the channel (Seibert et al., 1996).
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Further, mutations in extracellular loops (ECL) contribute CFTR pore functioning
(Sheppard & Welsh, 1999).
The NBDs of CFTR has three conserved domains (Walker A, Walker B, and
LSGGQ) to interact with ATP (Walker et al., 1982). These domains are associated with
many CF-related mutations. The CFTR channel is tightly regulated by kinase and
phosphatase activity, and also presence of cellular ATP levels (Anderson et al., 1991a;
Gadsby & Nairn, 1999). Activation of cAMP dependent protein kinase A (PKA) causes
phosphorylation of serine residues on the R domain, which is followed by ATP
hydrolysis at NBDs, opening the Cl- channel. Dephosphorylation of serine residues by
protein phosphatases return the Cl- channel to a closed state (Gadsby & Nairn, 1999;
Ostedgaard et al., 2001).
There are two main models proposed for ATP-dependent gate opening of CFTR.
In the first model (Figure 1-2a), there are three closed states (C1, C2, and C3) and two
open states (O1 and O2). ATP binds NBDs in a closed state. At C1 state, both NBDs are
empty. Then R domain phosphorylation results in ATP binding to the NBDs sequentially,
first to NBD2 (C2 state) and then to NBD1 (C3 state). Hydrolysis of ATP at NBD1 opens
the channel (O1 state). Then ATP at NBD2 hydrolyzed (O2 state) (Sheppard & Welsh,
1999). In the second model (Figure 1-2b), there are two closed (C1 and C2) and two open
states (O1 and O2). The ion gate opens after R domain phosphorylation followed by ATP
binding at NBD2 (O1 state). ATP hydrolysis at NBD2 (O2 state) followed by R domain
phoshorylation and ATP binding at NBD1 leads to channel closing (Sheppard & Welsh,
1999).
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1.3 Mutations Resulting in Disease
According to a 2004 World Health Organization (WHO) report, the incidence of
CF in newborns in specific regions is as follows: US (1/3500), Europe (1/2-3,000), Africa
(1/7056). We also see ranges of disease occurrence in Asia and the Middle East of (1/1040,000) and (1/2-15,000), respectively (WHO 2004 CF Report) (Figure 1-3).
The most common CF mutations are missense mutations, point mutations of one
nucleotide, which account for 48.7% of all CF mutations (Lommatzsch & Aris, 2009).
There have been 1720 point mutations detected from CF patients, all of which are
documented in the CF Genetic consortium database.
Mutations are classified into 5 classes (Class I-V) based on CFTR function
(Figure 1-4). Class I mutations create premature stop codons due to frameshift or
nonsense mutations, leading to truncated mRNA. Therefore, the CFTR protein is not
expressed (Figure 1-4) (Gibson et al., 2003). Class II mutations are the most common
mutation and cause misfolded CFTR proteins. CFTR proteins does not fold into proper
tertiary structures and therefore are degraded in the endoplasmic reticulum instead of
being trafficked to the epithelial membrane (Figure 1-4) (Gibson et al., 2003;
Lommatzsch & Aris, 2009). The ΔF508 deletion (a 3 bp deletion in exon 10) is the most
common mutation in class II mutations. Approximately 70% of CF patients have ΔF508
deletion (Bobadilla et al., 2002). ΔF508 deletion affects the interaction between the Nterminus NBD1 and C-terminus of transmembrane segment-4, which is involved in
channel gating (Lommatzsch & Aris, 2009). Class I and II mutations are the most
frequently observed in CF patients. Their clinical manifestations are severe since
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functional CFTR protein is not presented on the surface of the epithelial cell (Zielenski,
2000).
Class III mutations affect ATP binding to NBD1, NBD2, and therefore ATP
hydrolysis, which is involved in channel activation. CFTR channels are not activated
(Gibson et al., 2003; Lommatzsch & Aris, 2009). Class IV mutations mostly occur in
transmembrane domain 1, which is associated with pore forming. Therefore Class IV
mutations affect chloride ion conductance (Akabas et al., 1994). The CFTR is fully
translated and trafficked to the membrane in Class III and IV mutations so the effect of
these mutations are milder than those of Classes I and II (Zielenski, 2000).
Class V mutations affects the number of functional CFTRs on the membrane.
Splice mutations are most common in this class. The disease phenotype may range from
mild to severe since functional CFTR copying differs from patient to patient as well as in
the epithelial cells of various organs (Nissim-Rafinia & Kerem, 2002; Nissim-Rafinia et
al., 2004).

1.4 Diagnosing CF
1.4.1 Early warning signs
CF patients are diagnosed with the disease in infancy and/or early childhood
(Koch & Hoiby, 2000). The majority of patients are diagnosed in early childhood due to
respiratory infections (50.5%), malnutrition (42.9%), or both (Rosenstein & Cutting,
1998). Nineteen percent of CF patients are diagnosed at birth due to meconium ileus, an
intestinal obstruction leading to a twisting of the bowel and abdominal infection
(Rosenstein & Cutting, 1998). Vomiting a few hours after birth is the first sign of
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meconium ileus (Donnison et al., 1966). Knowledge of family history accounts for 16.8%
of CF diagnoses. Another symptom of the disease is steatorrhea (the presence of excess
fat in stool), which occurs in 35% of CF patients (Rosenstein & Cutting, 1998).

1.4.2 Clinical Tests for CF
Sweat tests, DNA mutation analysis, and nasal potential difference test are
diagnostic tests used to detect CF in patients (Koch & Hoiby, 2000; Rosenstein &
Cutting, 1998). In most cases, more than one test is used since diagnostic tests may be
inconclusive due to various clinical manifestations depending on the type of mutation
(Koch & Hoiby, 2000; Rosenstein & Cutting, 1998).

1.4.2.1 The Sweat Test
Testing sodium and chloride concentration in sweat (Sweat test) is a noninvasive
routine method used to diagnose CF (Koch & Hoiby, 2000). In this procedure, two
electrodes are attached to the patient’s arm. One of the straps has a disk with pilocarpine,
which induces sweat glands. An electrical pulse stimulates pilocarpine diffusion through
skin. Then a special sweat collection device is attached the skin where sweat glands are
stimulated. A minimum of 15 µl sweat must be collected during a 30-minute period
(Naehrlich, 2007). A healthy person has 30-40 mM sodium and chloride concentration in
their sweat while a CF patient has greater than 60-70 mM of sodium and chloride. This
concentration difference is due to nonfunctional CFTR channels in the CF patient (Green
et al., 1985; Hodson et al., 1983; Kirk & Westwood, 1989). However, this test is not
100% accurate. Some CF patients have normal salt levels in their sweat, which are
dependent on the type of mutation in the cftr gene. This test also does not take into
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account the fluctuation of sweat chloride levels with age (Lyczak et al., 2002). Therefore,
additional diagnostic tools are required to verify this test’s findings.

1.4.2.2 DNA Mutation Analysis
DNA mutation analysis is a genetic test, which identifies the mutation in the cftr
gene. DNA is isolated from either saliva or blood and is screened for the presence or
absence of common CF mutations. These DNA screening kits (ex Tag-It™ Cystic
Fibrosis Kit) are commercially available to physicians. The USA CF foundation
recommends that all newborns be screened with this test since more than 10 million
American are asymptomatic carriers of CF (CFF, 2008). The downside of this test is that
it only detects the 70 most prevalent CF mutations, yet there are 1720 mutations listed in
CF Genetic consortium database (CFF Consortium).

1.4.2.3 Nasal Potential Difference Testing
Nasal potential difference testing is used as a complementary diagnostic tool
where sweat and genetic tests are inconclusive (Delmarco et al., 1997). Sodium and
chloride ion transport through CFTR on epithelial cells create transepithelial electrical
potential (TEP). The nasal potential difference testing directly measures the
transepithelial electrical potential through the ion channels. In this test, an electrode is
placed in the nose of a patient and a series of solutions are applied to the nose. The
solutions are a Ringer’s saline solution (a salt solution used to obtain the baseline
potential difference), amiloride solution that blocks sodium channels, a chloride-free
solution, and finally isoproterenol solution that stimulates CFTR. A typical CF patient
has a more negative baseline potential (-60 mV vs. -40 mV), a larger inhibition of TEP
9

after addition of amilorate, and a little or no change in TEP after addition of the chloridefree and isoproterenol solutions (Rosenstein & Cutting, 1998).

1.5 Pulmonary Symptoms of Cystic Fibrosis: A Vicious Cycle
CF is a genetic disease affecting the epithelium surrounding secretory organs, in
particular the lung epithelium (Davies & Bilton, 2009). While the other secretory organs
are also affected, the predominantly life-threatening symptoms occur within the lungs
(Gibson et al., 2003). Defective and/or deficient CFTR causes thick, viscous mucous
secretions in the airways, which are associated with an abnormal airway surface
environment (Figure 1-5). Abnormal airway epithelia cause airway obstruction, which is
followed by infection, inflammation, and finally bronchiectasis. The presence of
infection, inflammation, and bronchiectasis leads to more obstruction in the bronchi,
which leads to more infection and inflammation, which are the major driving forces in
this vicious cycle.

1.6 Pulmonary Structure: Setting the Stage
The lungs are organized as right and left lobes, connected through trachea. The
trachea branches into two bronchi, which branch into tubular extensions- bronchioles.
Finally, bronchioles branch into alveoli where oxygen is transported into capillaries
through alveoli epithelia (Figure 1-6a).
The lung epithelium serves as a continuous lining around the lungs and provides a
selective surface where ions and oxygen are transported into and out of the lung tissue
(Matthay et al., 2002). Airway portions of the lungs (bronchi and bronchioles) are
covered with basal, ciliated and mucous secretory (Goblet) epithelia cells (Figure 1-6b).
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Goblet cells are located distally and secrete mucin (MUC5AC, MUC5B) to form a mucus
layer surrounding the epithelia (Figure 1-6b). Clara cells replace Goblet cells at the
proximal portion of the airways. Finally, the alveoli are composed of type I and type II
epithelial cells (Figure 1-6b and 1-6c) (Matthay et al., 2002).
Type I cells are very large, thin, squamous epithelial cells with 50-100 µm in
diameter and constitute 95% of the alveolar surface (Figure 1-6c). They provide
structural support to alveoli. Type II cells are cuboidal epithelial cells, approximately 10
µm in diameter (Figure 1-6c). Type II cells function to secrete surfactant (e.g.
phospholipids) to reduce surface tension in the lungs during pressure changes (Matthay et
al., 2002; Matthay et al., 2005). Both types of cells are involved in active ion transport
(or vectorial ion transport) at the proximal portion of the alveoli to maintain osmotic
balance, and keep the lungs free of pathogens (Saumon & Basset, 1993).
Osmotic balance is required to keep the thickness of airway surface liquid (ASL)
at optimum height for the efficient mucociliary clearance. ASL is a thin water surface,
which lines the airway portion of the epithelial cells (Figure 1-7). It consists of a mucus
layer (7 to 70 µm thickness) and a periciliary liquid layer (PCL) (Gibson et al., 2003)
(Figure 1-7). The mucus layer traps foreign particles while the PCL layer separates the
mucus layer from the epithelial cells. The osmotic balance is important to keep the
thickness of the PCL at optimum height (approximately 7 µm) so cilia can outbeat and
clear the foreign particles trapped in the mucus (mucociliary clearance) (Figure 1-7)
(Boucher, 2004).
Osmotic balance in the lungs is maintained via sodium influx through apical
amilorate-sensitive epithelial Na+ channels (ENaC) in response to an electrochemical
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gradient generated by basolateral quabain-inhibitable Na+/K+/ATPase (Matthay et al.,
2002). Type II cells are easy to culture and they form monolayers with intact tight
junctions in 3-4 days (Matthay et al., 2005). These cells express apical amiloratesensitive epithelial Na+ channels (ENaC), basolateral quabain-inhibitable Na+/K+/ATPase
pump, apical Ca+2 activated Cl- channel, CFTR, and basolateral Na+/K-2Cl cotransporter
to mediate Na+ absorption and to secrete Cl-, respectively. Protein expression and
immunocytochemical studies revealed the presence and distribution of two subunits of
Na+/K+-ATPAse (α1 and α2) in type I cell in rats (Ridge et al., 2003). However, the role
of type I cells in the vectorial ion transport is not certain due to inability to culture
polarized type I alveolar cells and perform electrophysiological studies (Matalon &
Davis, 2003).

1.7 Mucociliary Clearance and Bacterial Colonization of the Lung
Most CF patients are born with a normal lung function, followed by bacterial
colonization of the lung, leading to chronic infections in the lungs within just a few years
of life (Boucher, 2004). More than 80% of CF patients die due to bacterial infections
(Lyczak et al., 2002). Defective mucociliary clearance (MC) is the major cause of
bacterial colonization in the lungs. MC is an important part of the body’s innate defense
mechanism, which traps and clears inhaled pathogenic organisms from the airways in less
than 6 h under normal conditions (Knowles & Boucher, 2002). This mechanism is
arrested in CF patients, allowing bacteria to enter the lungs and begin the invasion.
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1.7.1 Mucociliary Clearance (MC)
MC utilizes three components to clear foreign bodies: cilia, a mucus layer, and a
PCL (Figure 1-7). The height of the PCL is important to maintain osmotic balance in
order to maintain effective MC. The optimum thickness of PCL is approximately 7 um.
This height is required for efficient ciliary beating.

1.7.2 Inhibiting MC Clearance
Both absorption of Na+ and Cl- secretion is important to keep periciliary layer
(PCL) height (or volume) constant. In CF patients, nonfunctional CFTR leads to impaired
Cl- secretion to the ASL, causing accelerated Na+ absorption via ENaC. Thus, water is
transported into the epithelial cell due to reverse osmosis. Water diffusion leads to
depletion of the PCL layer, which in turn causes the formation of mucus plaques since
mucus secretion continues from goblet cells. The continuous supply of mucus thickens
the mucus plaques to more than 100 µM in thickness, where oxygen is limited.
Thickened mucus plaques reduce the mucociliary transport of the foreign molecules.
Further, oxygen is depleted into the deep surface of the epithelial cells leading to mucus
hypoxia, which is a favored environment for certain bacterial species, in particular
Pseudomonas aeruginosa (Worlitzsch et al., 2002).

1.7.3 Resisting Bacterial Infection
Thick mucus blocks the airways (airway obstruction), which results in infection
and inflammation. The presence of pathogens in the airways induces the secretory
apparatus (Goblet and Clara cells) to secrete antibacterials (proteins lysozyme,
lactoferrin, secretory phospholipase A2, and secretory leukocyte protease inhibitor
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(SLPI) to kill pathogens. Neutrophils are the first immune cells to arrive at the site of
infection. They recognize chemicals (chemoattractants) produced by pathogens and/or
damaged tissue. Cytokines (IL-1, IL-8, tumor necrosis factor alpha (TNF-α)), leukotrines
(LTB-4), anaphylatoxin C5a, and bacterial proteins (LPS, exotoxins) are the major
chemoattactants for neutrophil to the infection site (Konstan & Berger, 1997).
Oxidants and proteases like elastase released by neutrophils degrade bacterial
proteins as well as host lung tissue. This leads to a release of host DNA, which thickens
the mucus further and is associated with pulmonary exacerbations, worsening due to
infection and inflammation. Further, elastase induces genaration of more
chemoattractants, which induce attraction of more neutrophils to the area of infection,
resulting in more tissue damage. Both inflammation and infection lead to structural
damage of the lung, this is known as bronchiectasis (Boucher, 2004).
The common belief is that inflammation occurs after infection. A massive amount
of neutrophil attraction to the site of infection is the signature of a CF lung. Some studies
performed with infants revealed that the lungs are at the proinflammatory state before
bacterial colonization (Khan et al., 1995; Muhlebach et al., 1999; Rosenfeld et al., 2001).
Studies show elevated levels of proinflammatory markers like adhesion molecules at
which neutrophils recognize and bind (ICAM-1), chemoattactants (IL-6 and IL-8) and
deficiency of IL-10, which inhibits production of chemoattactants-IL-6, IL-8, TNF
(Elizur et al., 2008). There is no direct link between the cftr gene mutation and the
proinflammatory reaction observed in CF patients. However, other studies suggest
inflammation might precede infection (Khan et al., 1995; Muhlebach et al., 1999;
Rosenfeld et al., 2001).
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1.8 The Bacteria of Cystic Fibrosis
“Understanding the genetic defect underlying cystic fibrosis is only half the battle.
Identifying the specific bacterium infecting CF patients is just as important”.
John E. Herst and Karen E. Elliot
Bacterial infection is the main reason for high mortality in CF (Gibson et al.,
2003; Govan & Deretic, 1996). CF patients are born with a sterile lung, and then shortly
after birth they start to develop bacterial infections (Boucher, 2004). It is believed that
susceptibility of CF patients to certain bacterial species is age-related. CF patients
become infected with Staphylococcus aureus and Haemophilus influenzae in early years
and then Pseudomonas aeruginosa and Burkholderia cepacia complex replace these
species during adolescence (Govan & Deretic, 1996). Stenotrophomonas maltophilia and
Achromobacter xylosoxidans are the other species isolated from CF patients.
Staphylococcus aureus:
Staphylococcus aureus (Sa) is a gram positive, non-motile, non-spore forming
bacteria that is part of human upper respiratory tract flora (Williams, 1961). Forty percent
of CF patients have Sa colonization during their first year of their life (CFF, 2008). In
fact, it is usually the first pathogen to cause infection in CF patients (McCaffery et al.,
1999). Most of these initial infections result from endogenous colonization with patients’
own organism (Govan, 2000).
In the pre-antibiotic era, most CF patients died due to Staph infections (Govan &
Deretic, 1996). Today, CF patients are either under prophylactic (preventive) or
intermittent treatment with antibiotics until the Staphylococcus is eradicated from their
sputum cultures (McCaffery et al., 1999). Penicillin, cephalosporins, macrolide, and
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tetracycline antibiotics are among the commonly prescribed antibiotics (Beardsmore et
al., 1994; Szaff & Hoiby, 1982; Weaver et al., 1994). It has been shown that prophylactic
treatment of CF patients with floxacillin (penicillin-derivative) is beneficial and is
associated with fewer hospital visits, reduced morbidity, and lower rates of infection,
when compared to intermittent antibiotic treatment (Weaver et al., 1994). However,
another study revealed that prophylactic antibiotic therapy of patients under age 6 leads
to significantly higher rates of Pseudomonas aeruginosa acquisition (approximately 50%
more) when compared to patients with intermittent antibiotic treatment (Ratjen et al.,
2001). Further, aggressive antibiotic treatment is also associated with the emergence of
resistant Staphylococcus, in particular methicillin resistant Sa (MRSA), one of the most
vexing resistance challenges worldwide (Nordmann et al., 2007). A recent survey of CF
patient registry data from the US recorded between January 1996 and December 2008 has
shown that detection of MRSA in CF patients is associated with more rapid lung failure
and a significant decrease in life expectancy (Dasenbrook et al., 2010).
Haemophilus influenzae:
Haemophilus influenzae (Ha) is among the most commonly isolated opportunistic
pathogens from CF patients, in particular from newborns and children under the age of 10
years (CFF, 2008). The prevalence of Ha infection is approximately 30% among patients
between 0-5 years old (Razvi et al., 2009).
Ha infections are treated after detection of asymptomatic colonization or after the
development of an infection. Amoxicillin, ciprofloxacin, and azithromycin are the most
commonly prescribed antibiotics to treat Ha infections (Doring & Hoiby, 2004).
Ciprofloxacin resistance has been observed in 40% of Ha strains isolated from CF
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patients (Perez-Vazquez et al., 2007). Further, vaccination of infants is used as a
preventive approach. However, infections with uncapsulated and therefore non-typable
Ha reduce the chance of success via vaccination (Bilton et al., 1995).
The role of Ha infection in CF pathogenicity is unknown. It may form biofilms in
lung epithelia and induce inflammatory reactions in the lower respiratory tract (Starner et
al., 2006). Inflammation due to Ha colonization at an early age causes lung damage in CF
patients, which in turn provides an ideal environment for further colonization,
particularly by Pseudomonas(Govan & Deretic, 1996; Lyczak et al., 2002).
Stenotrophomonas maltophilia:
Stenotrophomonas maltophilia (Sa) is gram-negative, motile bacteria present in
the natural environment (such as on plants and in soil) and the hospital environment. Sa is
also present in approximately 13% of CF patients (CFF, 2008). Acquisition of Sa is
mostly from the environment (Denton & Kerr, 1998). Doxycyclin, ceftazidime,
tobramycin, and ciprofloxacin are the most frequently used antibiotics to treat these
infections. The exact role of Sa infections in CF pathogenicity is unknown. The common
belief among clinicians is that these infections are more harmful to patients with already
damaged lungs (Gladman et al., 1992; Karpati et al., 1994).
Pseudomonas aeruginosa:
Pseudomonas aeruginosa (Pa) is a gram-negative, multi-drug resistant versatile
bacterium grows in soil, water, on plant, and animal tissues (Govan & Deretic, 1996). It
is the most common infectious agent involved in the CF lung and it is often acquired
shortly after birth (Li et al., 2005). The prevalence of Pa infection is 30% of infants, 60%
of adolescents, and 80% of adults with CF (CFF, 2008).
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The initial source of Pa infection is unknown. Natural environment is one
potential source of a CF patient’s first acquisition (Barben et al., 2005; Regnath et al.,
2004). Indeed, a recent genotype study of clinical Pa strains from newly infected CF
patients and Pa strains isolated from various surfaces of the patients’ houses revealed that
5.9% of the environmental isolates share the same genotypes with clinical isolates
(Schelstraete et al., 2008). Further, samples from hospital settings, including sinks, soap,
tables, and tap water, are also contaminated with Pa (Doring et al., 1996; Zimakoff et al.,
1983). The prevalence of Pa is 72% from patient’s toilets, 44% on sinks, and 1.5% on
other hospital surfaces (Festini et al., 2007). The risk of potential Pa acquisition of a CF
patient from clinical settings at each visit is 5.4% (Festini et al., 2007).
Patient-to-patient contact is another route for Pa transmission. Speert et al., 1987
showed that patients sharing the same hospital room are colonized with the same Pa
strain (Speert & Campbell, 1987). Another study performed on patients attending the
same CF holiday camp revealed that ¼ of the patients are infected with the same strain
(Brimicombe et al., 2008). Further, a genome fingerprinting study performed on siblings
from 13 families showed that one to three Pa strains are identical in all siblings in 8
families (Grothues et al., 1988).
During infancy, Pa is isolated intermittently from CF patients. Screening the
presence of Pa in oropharyngeal (OP) and bronchoalveolar lavage (BAL) cultures are
routine approaches. Patients are (i) intermittently infected if 50% or less of the preceding
12 months the patients are Pa culture positive, (ii) chronically infected if more than 50%

18

of the preceding 12 months they are culture positive, (iii) free if no Pa is detected (Lee et
al., 2003).
The first step in colonization is the attachment of Pa to the epithelial cell surface
(Davies & Bilton, 2009). As described above, defective MC traps bacteria on the viscous
mucus ASL where Pa is in close contact with the epithelial cell surface. Early Pa
colonizers isolated from CF airways are motile (Gibson et al., 2003). Pa flagellar mutants
cause milder disease phenotypes in a murine model, suggesting that motility is important
for early bacterial attachment and colonization (Feldman et al., 1998). Further, recent
studies suggested that Pa pili bind CFTR and epithelial cell receptor ganglioside asialoGM1, which have been proposed as Pa receptors (de Bentzmann et al., 1996; Pier et al.,
1996; Pier et al., 1997). Interaction of Pa with ganglioside asialo-GM1 receptor induces
NFΚ-B mediated expression of pro-inflammatory cytokines, which are major neutrophil
attractants (Davies & Bilton, 2009). Therefore, colonization directly induces
inflammation, which is associated with tissue destruction and additional infection cycles,
as described above.
Attachment of Pa to the CFTR channel is followed by internalization into
epithelial cells where the bacterium colonizes, forms a biofilm, and may secrete virulence
factors to further invade lung tissue, all of which results in the development of chronic
lung infections (Davies & Bilton, 2009). Pa employs a variety of exoproducts to invade
lung tissue, such as elastase, protease, exotoxin A, siderophores, and antibiotic resistance
proteins. Elastase and alkaline phospahates are proteases, which cleave host immune
proteins including immunoglobulins, cytokines (Heck et al., 1990). Exotoxin A inhibits
phagocytosis and siderophores (iron-binding proteins), like pyocyanin, slows down
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ciliary beat frequency in the ASL and destroys tight junctions at epithelia, leading to lung
tissue destruction (Haas et al., 1991).
The most vexing feature of Pa lung invasion is the emergence of alginate forming
mucoid variants over time (Hentzer et al., 2001). Levy et al, 2008 showed that nearly half
of the patients in his study developed mucoidy Pa variants during the course of study.
These data revealed that gender, presence/absence of the ΔF508 deletion, Forced
Expiratory Volume (FEV), and sputum type are all indicators of the potential
establishment of mucoid Pa (Levy et al., 2008).
Mucoid Pa form dense biofilms, which are virtually impossible to eradicate once
established (Hentzer et al., 2001). Biofilms are defined as polysaccharide matrixenclosed, differentiated micro-colonies of bacteria growing on solid surfaces. Many
bacterial pathogens adapt to their hosts by shifting from a free living planktonic mode of
growth to biofilm formation when exposed to host defenses, nutrient deprivation, and
oxidative or osmotic stresses (Fuqua et al., 2001) (Jefferson, 2004). Biofilm formation in
the lungs of CF patients creates a major health challenge. This is due in part to the fact
that biofilms result in 10 to 1000-fold increase in antibiotic resistance and an increase in
the ability to withstand host defense systems. Indeed, the formation of biofilms is the
primary contributor to the mortality of CF patients (Giwercman et al., 1991; Hoyle et al.,
1992; Miller & Bassler, 2001). The elevated levels of antibiotic resistance and virulence
are due primarily to the phenotypic heterogeneity within the biofilm structure, to reduced
growth rate of cells in biofilm, to the limited access of antibiotics into the interior regions
of the biofilm structure, and to the impact of quorum signaling based-induction of the
virulence genes (Lewis, 2001; Stoodley et al., 2002). Quorum signaling (QS) is a cell20

density dependent communication between bacteria that occurs via secreted signaling
molecules (acylated homoserine lactones (AHLs)). Pa has two hierarchical quorum
signaling systems: LasI/LasR and RhlI/RhlR (Van Delden & Iglewski, 1998). A recent
study has shown that QS mutants of Pa possess higher susceptibility to antibiotic
treatment compared to wild type Pa (Shih & Huang, 2002).
Despite high levels of antibiotic resistance in CF lung biofilms, antibiotic
treatment remains the major therapeutic approach to treatment. The most promising drugs
for treating Pseudomonal infections are TOBI , which is a solution of the anti®

pseudomonal tobramycin designed for inhalation, and azithromycin, in either an oral
suspension or capsules. These antibiotics differ in their modes of action. Tobramycin is
an aminoglycoside, which inhibits protein synthesis and thus kills the target pathogen.
Azithromycin is a macrolide, which improves the patients’ lung function by reducing
inflammation and alginate production, which is the main component of a biofilm’s
structure (Giamarellos-Bourboulis, 2008).
Long-term exposure of Pa to antibiotics selects for multi-drug resistant strains. In
fact, nearly half of adult CF patients are chronically infected with multi-drug resistant Pa,
which is associated with a more rapid decline in lung function (Lechtzin et al., 2006). An
antibiotic susceptibility study of Pa strains from sixty-seven CF centers revealed high
levels of resistance, on average 75% of the strains were resistant to the 10 drugs
examined, including tobramycin, gentamycin, ciprofloaxacin (Saiman et al., 1996). In
addition, Pa strains are intrinsically multi-drug resistant. Genome sequencing studies
revealed that the genome of at least one Pa strain (PAO1) genome has five different drug
efflux pumps (Lomovskaya & Watkins, 2001). Finally, a recent study revealed a novel
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drug efflux mechanism in Pa, one that specifically mediates biofilm resistance to
tobramycin, gentamycin, ciprofloxacin, which are among the most commonly prescribed
antibiotics to treat CF lung infections (Zhang & Mah, 2008).
Burkholderia cepacia complex:
Members of the Burkholderia cepacia complex (Bcc) are gram-negative bacteria
found in numerous environments including soil, water, as well as the roots of various
plants (Mahenthiralingam et al., 2005). The Bcc comprises a group of genetically diverse,
but phenotypically similar bacteria, including nine genomovars: Burkholderia ambifaria,
Burkholderia anthina, Burkholderia cenocepacia, Burkholderia cepacia, Burkholderia
dolosa, Burkholderia multivorans, Burkholderia pyrrocinia, Burkholderia stabilis, and
Burkholderia vietnamiensis (Mahenthiralingam et al., 2000). In the 1930s, Burkholderia
were classified as members of the Pseudomonas genus. Yabuuchi et al. 1992 proposed to
re-classify these Pseudomonas species under the new genus Burkholderia, based on 16s
rRNA sequences, phenotypic characteristics, and DNA-DNA hybridization (Yabuuchi et
al., 1992).
B. cepacia strains may be either pathogenic, beneficial or commensal, depending
on the environment in which they are found. B. cepacia causes soft onion rot disease,
which is a type of root tissue damage associated with yellow/brown coloring
(Mahenthiralingam et al., 2005). Further, a type IV toxin from B. cenocepacia and B.
vietnamiensis causes a type of plant tissue destruction called plant-tissue water soaking
(Engledow et al., 2004). B. cepacia degrades chlorinated aromatic substrates found in
pesticides and herbicides. For example B. vietnamiensis degrades toluene and decreases
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the concentration of toluene in the water present in a sand aquifer (Mahenthiralingam et
al., 2005).
In the 1970s, members of the Bcc were first identified in the airways of CF
patients (Govan & Deretic, 1996). Although these species remain a relatively rare source
of infection in the CF lung (roughly 3% of CF patients are colonized with B. cepacia), the
clinical manifestations can be severe (2008). Colonization may be asymptomatic or can
result in progressive decline in lung function over a period of months. A smaller number
of such infections (20%) result in cepacia syndrome, which is a fatal pneumonia that
causes rapid death, within weeks to months (Jones et al., 2004; Kalish et al., 2006;
Tablan et al., 1985). B. multivorans and B. cenocepacia are the species from the Bcc
most frequently isolated from CF patients with a prevalence of 38% and 50%,
respectively (LiPuma et al., 2001). However, all genomovars have been recovered from
CF patients (Mahenthiralingam et al., 2000; Mahenthiralingam et al., 2005).
Various disease outcomes are explained by host and strain dependent factors.
Although the process of Bcc colonization is unclear, these species encode numerous
virulence factors (Mahenthiralingam et al., 2005). A pathogenicity island is located in
many of the Bcc genomes, which is absent in non-epidemic strains and rarely detected in
environmental strains (Mahenthiralingam et al., 1997). Surveys reveal that the presence
of this islands is various between geographic regions. For example, the strains of B.
cepacia infecting CF patients in Canada are more likely (80%) to encode the
pathogenicity island than are strains from US patients (23%) (LiPuma et al., 2001). The
pathogenicity island contains quorum signaling factors, genes involved in fatty acid and
amino acid metabolism, and several genes whose functions are unknown (Baldwin et al.,
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2004). Baldwin et al., 2004 also revealed that mutations in the amidase and quorumsensing genes result in lower levels of strain persistence and reduced levels of
inflammation in the lungs of a CF rat model. Additional pathogenicity is conferred by
cell surface lipopolysaccharides (LPS), which provide resistance to cationic antibiotics
(Shimomura et al., 2003). Flagellar genes also contribute to strain virulence. Mutations in
fliG gene, which encodes the ATPase subunit of the flagella, prevent attachment and
invasion of the epithelial cells (Tomich et al., 2002).
It is now becoming clear that both environment and clinical settings are potential
reservoirs for Bcc infections. LiPuma et al., 2002 used DNA sequence data to determine
that a B. cepacia strain found in an epidemic, was also isolated from an unrelated soil
sample (LiPuma et al., 2002). However, frequently, patients are colonized with B.
cepacia during a hospital visit or while at a CF camp (Gibson et al., 2003). It is clear that
B. cepacia strains can be transmitted from person to person (contagious) (LiPuma et al.,
1990). In response, National CF organizations prepared an infection control consensus
document, which recommends segregation of CF patients infected with Bcc from those
not infected. Further, they urge that CF patients remain at least three feet away from one
another, even if neither is infected with Bcc (Mahenthiralingam et al., 2005).
Treatment of Bcc pulmonary infections is problematic due to the intrinsic
antibiotic resistance of most strains. The Bcc genomes possess multi-drug efflux pumps,
LPS, and chromosomally encoded beta-lactamases, which provide resistance to various
classes of antibiotics including aminoglycosides, chloramphenicol, quinolones, and
cationic peptides (Aronoff, 1988; Burns et al., 1989; Burns et al., 1996; LiPuma, 1998a;
LiPuma, 1998b). Combinatorial application of multiple antibiotics is the current method
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of choice. These drug combinations usually include meropenem due to the low levels of
meropenem resistance observed so far in Bcc (Aaron et al., 2000; Lewin et al., 1993).
Minocyclin, amikacin, and ceftazidime are among the other antibiotics used in
combination with meropenem (Gibson et al., 2003).

1.9 Interaction of Pseudomonas aeruginosa (Pa) and Burkholderia cepacia complex
(Bcc)
Pa is the persistent species in CF lung infections. Bcc colonization is more rare,
and, usually, follows an initial Pa colonization (Govan & Deretic, 1996). The outcome of
these multiple rounds of colonization depends upon the patient and the bacterial species
and strains involved. B. cenocepacia and B. multivorans are the most frequently isolated
members of the Bcc (LiPuma et al., 2001). It is not known why some Bcc species and
strains are effective lung colonizers while others are not. Certainly there are interactions
between the Pa and Bcc species in CF lungs.
The first evidence of communication between these two species comes from
McKenney et al., 1995. In this study, spent media, used to grow B. cepacia was
supplemented with a cell free extract of Pa and the expression of siderophore, elastase,
protease and lipase was monitored in B. cepacia. The levels of these virulence-related
proteins were increased (McKenney et al., 1995).
Weaver and Kolter (2004) investigated the effect of B. cepacia cell free extract on
the expression of Pa genes. The genes upregulated in Burkholderia conditioned medium
are the same as those induced under iron-limited conditions. These data reveal that
Burkholderia conditioned medium has iron chelating activity (Weaver & Kolter, 2004).
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Additionally Pa and Bcc strains interact through a process mediated by quorum
signaling (QS). However, this communication is unidirectional, with Bcc strains capable
of perceiving the QS molecules, acylated homoserine lactones (AHLs), released by Pa
(Riedel et al., 2001). Geisenberger et al. (2000) analyzed the AHL profiles of Pa strains
in CF patients co-infected with both species and revealed that during co-infection a
dramatic reduction of AHL production occurs in the Pa (Geisenberger et al., 2000). Thus,
the two species communicate, and the interaction results in an increased production of
virulence factors. However, the final outcome, in terms of the patients’ health, is also
dependent upon strain- and patient-specific factors, which might explain why a mixed
infection results in such dramatic differences in infectivity, pathogenicity and host
response.

1.10 Bacteriocins
Bacteriocins are narrow spectrum antibacterial proteins, which are produced by
most bacterial species (Riley & Gordon, 1999; Riley & Wertz, 2002a; Riley & Wertz,
2002b). They are classified based upon the producer species; such as colicins produced
by E. coli, pyocins produced by Pa (formerly named pyocyania), and pesticins of Yersinia
pestis. Colicins are one of the most thoroughly studied bacteriocin and are used as a
model system to study bacteriocin structure, function, and evolution (Riley & Gordon,
1999; Riley & Wertz, 2002a; Riley & Wertz, 2002b).
Bacteriocins are high molecular weight proteins, produced by bacteria, usually
under conditions of stress, such as then resources are limited (Riley & Gordon, 1999).
They are encoded on both plasmids and chromosomes. The genes encoding bacteriocins
are often found in clusters of genes, which include a toxin, immunity, and lysis genes.
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The immunity gene encodes a protein, which confers immunity to that toxin, while the
lysis gene encodes a protein that aids in the release of the toxin from the cell – often
resulting in cell death. (Riley & Wertz, 2002a).

1. 10.1 Bacteriocins of Pseudomonas aeruginosa (Pa) and Burkholderia cepacia
complex (Bcc)
1.10.1.1 Pyocins: Bacteriocins of Pa
Francois Jacob was the first scientist to describe the production of bacteriocins
(known as pyocins) in Pa (formerly P. pyocyanea). He detected a UV induced, protease
resistant compound, which causes lysis of a susceptible bacterium (Jacob, 1952). Pa is
one of the most prolific bacteriocin producing species. More than 90% of Pa isolates
produce pyocins (Govan & Deretic, 1996).
Pyocins fall into three types, known as R-, F-, and S pyocins. The R and F-type
pyocins were the first pyocins described (Michel-Briand & Baysse, 2002). They share
three key features: they can resist to proteases, resemble phage tails, and kill sensitive
cells by depolarizing the cell membrane (Michel-Briand & Baysse, 2002). Two
representative R and F-type pyocins, R2 and F2, are encoded in a large gene cluster,
spans greater than 40 kb, located between the trpE and trpF genes in the genome of Pa
strain PAO1 (Nakayama et al., 2000). There are 44 open reading frames associated with
the R2/F2 phenotypes, which include regulatory, lysis and toxin genes. The R2 and F2
pyocins show sequence similarity to the tail fiber genes of P2 and lambda phage,
respectively (Nakayama et al., 2000).
There are several R-type pyocins (R1, R2, R3, R4, and R5), which consist of
extended sheets of 34 subunits, a base plate, tail fiber, and a core structure (Figure 1-8a).
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A single bacterium is capable of producing 200 R-pyocins (Shinomiya, 1972). R-pyocin
binds to membrane lipopolysaccharide (LPS) via the tail fiber (Ikeda & Egami, 1969).
Contraction of tail fiber penetrates the cell membrane and produces a channel, or pore.
The sensitive cell is then lysed due to the resulting depolarization of the cytoplasmic
membrane (Uratani & Hoshino, 1984).
There are three F-type pyocins (F1, F2, and F3), which are flexible, noncontractile rods, 106 nm in length and 10 nm in width (Figure 1-8b). The rod structure
consists of 23 annuli and a fiber structure consisting of both long and short filaments
(Michel-Briand & Baysse, 2002).
The four known S-type pyocins (S1, S2, S3, and AP41) are protease sensitive
bacteriocins, which resemble colicins in terms of their genetic structure and modes of
action. They kill cells via DNAse activity located at the C-terminal end of the toxin
protein. Different S-pyocins may recognize different receptors; S2 and S3 recognize type
I and II ferripyoverdine receptors, respectively (de Chial et al., 2003).
The typical S-pyocin operon spans an approximately 2 kb region of DNA and
includes two genes: the toxin gene which provides the killing activity and the immunity
gene which provides immunity to that pyocin. There are four domains in the toxin
protein: domain I produces receptor binding activity; the function of domain II is
unknown; domain III enables translocation of the toxin through the plasma membrane;
and domain IV provides killing activity (Michel-Briand & Baysse, 2002).
Two proteins regulate the synthesis of R, F and S pyocins: ptrN and ptrR, both of
which are located upstream of the R2F2 gene cluster. PtrN is a transcriptional activator,
which bind the regulatory sequence P-box located approximately 60-100 bp upstream of
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the ribosome-binding site. The P-box consists of a10-12 nt consensus sequence ATTGnn(n)GT-nn(n). PtrR is a transcriptional repressor protein, which binds to PtrN,
preventing its binding to the P-box. Under conditions of stress, such as DNA damage
RecA cleaves PtrR, releasing PtrN. The binding of PtrN to the P box induces
transcription of pyocin genes (Matsui et al., 1993; Michel-Briand & Baysse, 2002;
Nakayama et al., 2000).

1.10.1.2 Cepaciacins: Bacteriocins of Bcc
The bacteriocin produced by B. cepacia (known as Pseudomonas cepacia at that
time) are called cepaciacins (Govan & Harris, 1985). Govan et al, 1985 has assayed a
collection of Pseudomonas cepacia, as they were known then, using pyocin producer and
sensitive strains as indicator strains to phenotypically identify bacteriocins produced by
B. cepacia. This study revealed that 30% of P. cepacia strains possess bacteriocin-like
killing activity. Further, the cepaciacins looked like phage-tails when viewed under an
electron microscope. Unfortunately, Govan’s study is the only publication on
cepaciacins. No further molecular characterizations have been published.

1.11 CF Treatment Regimens
1.11.1 Physical therapy
Physical therapy is applied to CF patients to clear mucus from their airways.
Chest physical therapy, oscillating positive expiratory pressure, high frequency chest wall
oscillation therapy, active cycle of breathing technique, autogenic drainage are all
commonly employed approaches in treating CF patients (George et al., 2009). These
methods are noninvasive and aim to dislodge and clear mucus from lungs.
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1.11.2 Anti-inflammatory therapy
The goal of anti-inflammatory therapy is to suppress inflammation in the lungs,
which causes tissue destruction and results in further infection. Ibuprofen and
azithromycin are the most frequently used anti-inflammatory drugs (George et al., 2009).

1.11.3 Mucus thinning drugs
Mucus thinning therapy reduces the mucus, which clogs the airways of CF
patients. This also results in a reduction of the bacterial load in the CF lungs. Pulmozyme
is the most frequently prescribed mucus-thinning drug. Pulmozyme is a DNAse, inhaled
via a nebulizor, which degrades the patients own DNA that was released during
inflammation (Frederiksen et al., 2006).

1.11.4 Antibiotic therapy
Antibiotics are used to treat pulmonary bacterial infections. Pa and Bcc infections
are the most problematic to treat since both species are intrinsically multi-drug resistant.
Antibiotics can be administrated orally, intravenously, and are inhaled. The most
common therapeutic approach involves application of a cocktail of antibiotics, usually a
combination of beta-lactamases and aminoglycosides to treat chronic Pa infections. A
combination of meropenem and another class of antibiotic (tetracycline, aminoglycoside
and/or cephalosporins) is used to treat Bcc, based on the sensitivity phenotype of the
strains isolated from the lung (Gibson et al., 2003).
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1.11.5 Bronchodilator therapy
A bronchodilator is a medicine that dilates bronchi and bronchioles. This therapy is
administrated during airway obstruction when mucus clogs the airways, and the patient
having difficulty breathing (Eggleston et al., 1991).

1.11.6 Lung transplantation
Lung transplantation is the therapy applied to CF patients, which are at the endstage of the disease. The lifespan of CF patients might increase up to 10 years. However,
post transplantation infections in particular Pa infections are common and observed up to
90% of patients (Morton & Glanville, 2009).

1. 12 Research Questions
The following research questions were the focus of my doctoral research:
1. Do clinical strains of Pa and Bcc isolated from CF lungs produce bacteriocins?
2. If so, what types of bacteriocins are produced and how specific or broad are their
killing activity?
3. What roles do these bacteriocins serve in mediating intra- and inter-specific
interactions of bacterial isolates from cystic fibrosis patients?

1.13 Problem Statement
Over the past 60 years, a vast literature has focused on the bacteriocins produced
by Pa and Bcc. Within the CF research community, most of this research has focused on
phenotypic screens of pyocin and cepaciacin production of the two species (Edmonds et
al., 1972b; Farmer & Herman, 1969; Farmer & Herman, 1974; Fyfe et al., 1984; Govan
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& Harris, 1985; Jones et al., 1973; Jones et al., 1974a; Jones et al., 1974b; Kageyama et
al., 1979; Moroz et al., 1984; Pitt, 1988; Richardson et al., 1991; Shriniwas, 1975;
Zabransky & Day, 1969). However, none of this research has explored the potential role
of bacteriocins in mediating within and between species killing of clinical Pa and Bcc
strains. Given the high levels of bacteriocin production by both species, and the clear
necessity that they interact during co-infections of the CF lung, this absence of research is
striking.

1.14 Purpose of this study
The major goals of this study are to:
1. Determine if clinical strains of Pa and Bcc isolated from the CF lung produce
bacteriocins.
2. Determine whether these toxins play a role in mediating intra- and inter-specific
interactions of bacterial isolates from cystic fibrosis patients.
3. Identify bacteriocins produced by the two species.

1.15 Methodology
1. Employ phenotypic screens of bacteriocin production to determine which isolates
from CF lungs produce bacteriocin-like inhibition phenotypes.
2. Employ phenotypic assays (protease digestion, freezing, and filtration) to assess.
whether the phenotypes observed are due to bacteriocins, phage or some unknown
mechanism.
3. Employ multilocus pyocin sequence typing to determine the bacteriocin genes present
in this strain collection.
32

4. Screen genomic libraries to identify bacteriocin genes that failed to amplify in the
sequence typing characterization.

1.16 Significance
Pa and Bcc infections are the cause of significant mortality in patients with cystic
fibrosis. Pa is the primary, persistent species found in CF lung infections. This species is
hard to treat due to its intrinsic resistance to many antibiotics. Bcc causes secondary lung
infections, usually colonizing the CF lung after initial Pa colonization. Little is known
about how these two species interact during the strain invasion and establishment
process. This study seeks to contribute to our understanding of the role bacteriocins serve
in mediating the bacterial strain and species interactions in the CF lung. First, an
extensive strain by strain survey reveals the inhibition potential of both species. Second,
the same survey provides insight into the role these toxins play in mediating intra- and
inter-species interactions in the CF lung. Finally, the molecular characterization reveals
which bacteriocins are produced by CF strains. The data produced in this study are the
first step in understanding the role of bacteriocins in mediating bacterial strain
interactions in the CF lung.
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Figure 1-1 Cystic Fibrosis Transmembrane Regulator (cftr) gene and its encoded
protein presented on epithelial cells.
a. The cftr gene spans 215 kb region and consists of 27 exons and 26 introns; b-The cftr
gene encodes a transmembrane protein with two membrane spanning domains (MSD),
regulatory domain (R ), and two nucleotide binding domains (NBD) (Zielenski et al.,
2000; Sheperd et al., 1999).
a. cftr gene and CFTR protein

b. CFTR protein topology
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Figure 1-2 Models of ATP dependent gating of CFTR channel
a. Model 1 has three closed states (C1, C2, and C3), and two open states (O1 and O2).
Sequential hydrolysis of ATP at NBDs opens the channels; b. Model 2 has two closed
(C1 and C2) and two open states (O1 and O2). ATP hydrolysis at NBD2 (O2 state)
followed by R domain phosphorylation, which leads to channel closing (Sheperd et al.,
1999).

a. Model 1

b. Model 2
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Figure 1-3 Worldwide incidence of CF
Cystic Fibrosis affects mostly Caucasian population in North America, Europe, and
Australia (WHO 2004 CF Report).
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Figure 1-4 Functional classification of CFTR mutations
Mutations causing unfunctional or defective CFTR protein is classified into five classes
(Class 1-5) (Gibson et al., 2003).
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Figure 1-5 Cystic Fibrosis: the vicious cycle
Pathogenesis of lung disease in CF is described as vicious cycle, in which abnormal
airway surface cause airway obstruction, which is followed by infection, inflammation,
and bronchiectasis (Konstan, 1997)
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Figure 1-6 Human lung epithelium
a-Pulmonary structure of the lungs. Bronchus branches into bronchioles, which branch
into alveoli; b- Pulmonary cells. Type I, type II epithelial cells, mucous secretory cells
(Clara and Goblet) are epithelial cell types in lungs; c- Type I cells are large squamous
epithelial cells and type II cells are cuboidal epithelial cells in lungs (Matthay et al.,
2002; Livraghi et al., 2007)

a.

b.

c.
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Figure 1-7 Airway surface liquid (ASL)
ASL is a thin water surface, which lines the airway portion of the epithelial cells. ASL
composed of mucous layer and periciliary liquid (PCL) (Boucher, 2004).

ASL
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Figure 1-8 Structures of R- and F- type pyocins
a. R-type pyocin. R-type pyocins consist of extended sheets (ES), a base plate (BP), tail
fiber (TF), and a core structure (CS); b-F-type pyocin. F-type pyocins consist of 23 annuli
and a fiber (Fi) structure consists of both short and long filaments (Michael-Briand,
2002).

a. R-type pyocin

b. F-pyocin
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CHAPTER 2
THE ROLE OF BACTERIOCINS IN MEDIATING INTERACTIONS OF
BACTERIAL ISOLATES TAKEN FROM CYSTIC FIBROSIS PATIENTS

2.1 Abstract
Pseudomonas aeruginosa (Pa) and Burkholderia cepacia complex (Bcc) lung
infections are responsible for much of the mortality in cystic fibrosis (CF). However,
little is known about the ecological interactions between these two, often co-infecting,
species. This study provides the first report of the intra- and inter-species bacteriocin-like
inhibition potential of Pa and Bcc strains recovered from CF patients. A total of 66 strains
were screened and shown to possess bacteriocin-like inhibitory activity (Pa - 97% and
Bcc - 68%), much of which acts across species boundaries. Further phenotypic and
molecular based assays reveal that the source of this inhibition differs for the two species.
In Pa, much of the inhibitory activity is due to the well known S and RF pyocins. In
contrast, Bcc inhibition is due to unknown mechanisms, although RF-like toxins are
implicated in some strains. These data suggest that bacteriocin-based inhibition may play
a role in governing Pa and Bcc interactions in the CF lung and may, therefore, offer a
novel approach to mediating these often-fatal infections.
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2.2 Introduction
Individuals with cystic fibrosis (CF) face a lifelong battle with chronic bacterial
lung infections. Pseudomonas aeruginosa (Pa) is the predominant infectious agent in the
lungs of adult CF patients and most individuals are infected shortly after birth (CFF,
2008). Alginate-producing mucoid variants emerge over the course of several years and
form dense bacterial biofilms in the CF lung. Once established, eradication of these
infections is generally not possible (Govan & Deretic, 1996; Hentzer et al., 2001).
In the 1970s, members of the Burkholderia cepacia complex (Bcc) of species
were first identified in the airways of CF patients (Govan & Deretic, 1996). Although few
patients colonized with Bcc (~3%), the clinical manifestations of these infections can be
severe (CFF, 2008; Kalish et al., 2006). Colonization by Bcc may be asymptomatic or
result in progressive decline in lung function. A smaller number of infections result in
“cepacia syndrome”, a fatal pneumonia that results in death (Jones et al., 2004; Kalish et
al., 2006; Tablan et al., 1985).
Given that CF patients are initially infected with Pa, Bcc strains must either
compete with or act in synergy with established Pa biofilms (Al-Bakri et al., 2004). How
such interactions occur is unknown. In fact, little is known about the process of Bcc
invasion and its outcomes. Do the strains from the two species peacefully co-exist? Do
Bcc strains out-compete and displace pre-existing Pa strains? Few studies have sought to
address how these two bacterial species interact in the CF lung (Al-Bakri et al., 2004;
McKenney et al., 1995; Weaver & Kolter, 2004).
One factor known to mediate bacterial interactions is the production of potent
toxins known as bacteriocins (Riley & Gordon, 1999). Unlike traditional antibiotics,
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many bacteriocins have a relatively narrow killing range. They have been implicated in
intra-specific competition brought on by limited nutrients (Riley & Wertz, 2002a). In
some cases, however, bacteriocins are also able to kill more broadly and have been
implicated as a primary mechanism for mediating microbial diversity (Kerr et al., 2002).
Much is already known about pyocins, the bacteriocins produced by
Pseudomonas. In fact, more than 90% of all Pa strains examined to date produce one or
more of three pyocin types: S, R, and F (Fyfe et al., 1984). S pyocins are high molecular
weight proteins, which resemble the well-known colicins produced by Escherichia coli.
They are protease sensitive and most kill by DNA degradation (Michel-Briand & Baysse,
2002). Four S-pyocins (S1, S2, S3, and AP41) have been studied extensively (Duport et
al., 1995; Sano & Kageyama, 1981; Sano et al., 1993a; Sano et al., 1993b; Sano, 1990)
(Figure 2-1a). All S-pyocin operons share the presence of two genes: the larger (toxin
gene) provides the killing activity, while the smaller (immunity gene) provides immunity
against killing by that pyocin. The toxin gene is comprised of four domains: Domain I produces receptor binding activity, which enables a pyocin to recognize a specific target,
Domain II - has an unknown function, Domain III - enables translocation of the toxin
through the plasma membrane, and Domain IV - produces the killing (DNAse) activity
(Michel-Briand & Baysse, 2002).
The R and F pyocins, which resemble bacteriophage tails, are resistant to both
nuclease and protease digestion and kill by depolarizing the cell membrane. The genes
encoding these pyocins are found in a cluster (which is why they are often referred to as
RF pyocins), and are located between trpE (anthranilate synthase component I) and trpG
(anthranilate synthase component II) genes (Nakayama et al., 2000; Shinomiya et al.,
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1983). Figure 2.1(b) shows the genetic organization of pyocin R2F2 genes. The open
reading frames (PRF3-PRF43) include regulatory, lysis, and R and F pyocin genes. The
lysis genes (PRF9, PRF24, PRF25, and PRF26) are similar in sequence to the lysis
cassettes of P2 and lambda phages (Nakayama et al., 2000). There are 16 R and F pyocin
genes (PRF10-23 and PRF28-43) (Nakayama et al., 2000). The encoded proteins show
high levels of sequence similarity to tail genes of P2 and lambda phage, respectively
(Nakayama et al., 2000). The function of PRF5-8 is unknown.
The S, R, and F pyocins are controlled by the same ptrN and ptrR regulatory
genes (Figure 2-1b) (Michel-Briand & Baysse, 2002; Nakayama et al., 2000). PtrN is a
transcriptional activator, which is repressed by PtrR (Matsui et al., 1993). Under DNA
damage, RecA protein cleaves the PtrR repressor protein, which leads to expression of
ptrN. PtrN binds to the regulatory sequence (P-box), thus inducing transcription of pyocin
genes (Matsui et al., 1993).
Stress conditions, such as might be encountered in a CF lung, may induce pyocin
production. Microarray analysis of Pa genomes revealed that pyocin transcription is upregulated by hydrogen peroxide and ciprofloxacin (Brazas & Hancock, 2005; Chang et
al., 2005). White & Curtis (2009) investigated the effect of pyocins in mixed-culture
biofilms under aerobic and anaerobic conditions and revealed that pyocins sensitivity
increased under anaerobic conditions. Further, Heo et al., 2007 revealed that R pyocins
provide a competitive advantage during growth in planktonic conditions.
Far less is known about cepaciacins, the bacteriocins produced by Burkholderia.
Approximately 30% of Burkholderia cepacia (formerly Pseudomonas cepacia) strains
produce cepaciacins (Govan & Harris, 1985). The few characterized cepaciacins
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resemble R-type pyocins, as they are resistant to trypsin digestion and appear phage-taillike when viewed under the electron microscope (Govan & Harris, 1985). Nothing further
is known about the abundance, diversity or molecular biology of these toxins.
The goal of the present study is to determine if clinical strains of Pa and Bcc
isolated from the CF lung produce bacteriocins and, if so, whether these play a role in
mediating intra- and inter-specific bacterial interactions in the CF lung. To this end, a
collection of clinical Pa and Bcc strains from CF patients was screened for bacteriocin
production and sensitivity. This collection consists of strains isolated either as pairs (one
strain of Pa and one of Bcc isolated from the same lung) or unpaired. Phenotypic screens
for bacteriocin production coupled with typing methods to identify individual
bacteriocins reveal a diversity of inhibitory mechanisms. Further, the patterns of within
and between species inhibition suggests a role for these toxins in mediating bacterial
interactions in the CF lung.

2.3 Materials and Methods
2.3.1 Bacterial strains
The bacterial strains used in this study include a total of 66 clinical strains of Pa
(38) and Bcc (28) obtained from Children’s Hospital, Boston MA. The study protocol
was approved by the Committee on Human Research at Children’s Hospital Boston and
written informed consent was obtained. The clinical collection can be divided into two
groups. The first is composed of 14 Pa and 7 Bcc paired isolates procured from 7 patients
with CF. Each pair of Pa and Bcc strains was isolated from the same CF patient. The
second group is composed of 24 Pa and 21 Bcc unpaired isolates, which were isolated
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from 31 patients. The Bcc strains include 4 genomovars (1 Burkholderia vietnamiensis,
12 Burkholderia multivorans, 11 Burkholderia dolosa, and 4 Burkholderia cenocepacia).
The reference strain collection includes bacteriocin producer strains which are Pa strains
known to produce the following pyocins: S1, R4 (PML28), AP41 and F3 (PAF41), S2, R,
F (NIH18), S2, R2, F2 (PAO1) (Ito, 1970; Kuroda & Kageyama, 1981; Nakayama et al.,
2000; Sano, 1990; Seo & Galloway, 1990). The reference collection also includes
indicator strains sensitive to various combinations of pyocins: PML1516d
(S1SS2SAP41S), NIH3 (S1SS2SAP41S), NIH3S1R (S1RS2SAP41S), NIH3S2R
(S1SS2RAP41S), NIH3AP41R (S1SS2SAP41R), 3295 (AP41S), 3012 (AP41SF3S), 7NSK2
(S1SS3S), 7NSK2-fpvA (S1SS3R), PML14 (S1SR1SR2SR3SR4SR5S), 13s
(S1SR1SR2SR3SR4SR5S), NIH5 (ATCC 25317) (F1SF2SF3S) (de Chial et al., 2003;
Kageyama et al., 1979; Kuroda & Kageyama, 1981; Sano & Kageyama, 1981; Sano et
al., 1993a; Williams et al., 2008). Additionally, four cloned S-pyocins (S1, S2, S3, and
AP41) were employed to detect S-pyocin sensitivity of clinical Pa and Bcc strains
(Duport et al., 1995; Sano & Kageyama, 1993; Sano et al., 1993b). There is no
corresponding set of Bcc reference strains.

2.3.2 Bacteriocin production and sensitivity screen.
The patch assay was used to identify bacteriocin-like inhibition, which involves
overnight growth in 10 ml Luria Broth (LB) at 37 0C, shaken at 250 rpm. Six ml. of LB
top agar (0.6%, w/v) mixed with 3 µl of Mitomycin C (0.5 µg ml-1; Sigma) and 100 µl of
indicator cells (108 cells) were plated as a lawn on an LB plate (Pugsley & Oudega,
1987). The producer strain (~106 cells) was spotted on the indicator overlay by toothpick.
Two spots per strain were applied. After overnight incubation at 37 0C the plates were
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scored. If a strain produces an inhibition factor, such as a bacteriocin, active against the
lawn, a zone of inhibition appears. The clinical collection was screened in an all-by-all
assay, i.e. each strain was used as a potential inhibitor producer and indicator. The all-byall patch assay was done in duplicate. All positive results were tested a third time.
The one-tailed Mann-Whitney U test was used for nonparametric comparison of
inhibitory activities in order to identify significant differences in inhibition frequencies
(Zar, 1999).

2.3.3 Phenotypic bacteriocin identification.
The clinical collection was screened against the indicator strains using the patch
assay. In addition, a cell-free extract of each putative bacteriocin-producing strain was
subjected to trypsin digestion, filtration, and freezing to distinguish between protease
sensitive and phage-like bacteriocins (Pugsley & Oudega, 1987; Riley et al., 2003). Cell
free extracts of putative producer strains were digested with trypsin (5mg ml-1) for 30 min
at 25 0C, which inactivates protease-sensitive bacteriocins, frozen at -70 0C, which tends
to fracture phage tail type bacteriocins, and filtered in a 100 kDa Microcon YM-100
Centrifugal Filter Device (Millipore) using centrifugation at 14000 rpm for 12 min,
which tends to retain phage tail-like bacteriocins. The treated cell free extracts were
tested on the lawns of pyocin sensitive reference and clinical strains.

2.3.4 Molecular Screening
Genomic DNA was isolated using the DNeasy Tissue kit (QIAGEN). The Gramnegative protocol was applied to 2X109 cells from an overnight culture. A standard PCR
protocol was used to screen genomes for the presence of all previously characterized S48

type pyocin genes (encoding S1, S2, S3, and AP41) and their corresponding immunity
genes (Duport et al., 1995; Sano & Kageyama, 1993; Sano et al., 1993b). Multiple primer
sets were designed based on existing pyocin sequences to amplify different regions of
each S-pyocin and corresponding immunity genes (Appendix III). Further, primer sets
specific to the regulatory region (P-box) of pyocins S1, S2, and AP41were employed.
Primers designed to amplify the RF-type pyocins targeted PRF-10, PRF-31, and PRF-38
genes were taken from the literature (Nakayama et al., 2000). NCBI accession numbers
of the sequenced pyocins, primer positions, primer sequences, amplicon sizes, and
identities are given in Appendix III.

2.4 Results
2.4.1 Inhibitory activity in Pa and Bcc strains
A phenotypic screen for inhibitory activity and sensitivity was conducted on a
collection of 66 clinical strains of Pa (38) and Bcc (28) isolated from CF patients. The
collection consists of strains isolated as pairs, i.e. one Pa and one Bcc isolated from the
same patient (taken from 7 patients, and resulting in 14 pairs; 14 Pa paired with 7 Bcc
strains), and unpaired (24 Pa and 21 Bcc). Bacteriocin production and sensitivity was
assayed in an all-by-all comparison, i.e. each strain was used as a putative producer and
sensitive strain.
In this screen, Pa and Bcc strains showed different levels of inhibitory activity.
The majority of the Pa strains (97%) were inhibitory (Table 2-1). Most (76%) inhibit both
Pa and Bcc species, resulting in similar levels of intra- (92%) versus inter- (81%) specific
inhibition. Only 3% of Pa strains show no inhibitory activity.
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The Bcc strains showed lower levels of overall inhibitory activity (68 %) (Table
2-1). The one-tailed Mann-Whitney U test confirms significantly higher levels of total
inhibition by Pa versus Bcc strains (P<0.0005). Similar to Pa, most Bcc strains (43%)
inhibit both species, again resulting in similar levels of intra- (54%) versus inter- (57%)
specific inhibition. A much larger fraction of Bcc strains (32%) display no inhibitory
activity.
When the CF strain collection is divided into strains isolated as pairs or unpaired,
the paired and unpaired Pa showed similar levels of total inhibition (Table 2-1). All
paired and most unpaired (96%) Pa isolates possess inhibitory activity. Most of the paired
Pa strains (86%; 12/14 strains) inhibit both species, while the remainder inhibit either Bcc
(7%; 1/14 strains) or Pa (7%; 1/14 strains). Two of the paired Pa strains inhibit their Bcc
pair mates. The inhibitory unpaired Pa show similar patterns of inhibition, 71% (17/24
strains) inhibit both species and the remainder inhibit either Bcc (4%; 1/24 strains) or Pa
(21%; 5/24 strains).
The paired Bcc strains show significantly different inhibition patterns than their
Pa pair mates (Table 2-1). Only 43% of paired Bcc isolates (3 strains) possess inhibitory
activity, significantly lower levels than paired Pa (0.025<P<0.05), and all of these strains
inhibit both species, but not their pair mates (Table 2-1). The inhibition patterns of
unpaired Bcc isolates are quite similar to those of unpaired Pa strains. Most of the
unpaired Bcc are inhibitory (76%; 16/21 strains) and most of these (43%; 9/21 strains)
inhibit both species. The remainder inhibit only Bcc (14%; 3/21 strains) or only Pa strains
(19%; 4/21 strains) (Table 2-1).
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Inhibition haplotypes (Pa and Bcc strains inhibited by a putative producer strain)
were determined for each producer. The 37 Pa and 19 Bcc producers displayed 36 and 18
haplotypes, respectively (Figure 2-2). Further, all Pa isolates inhibit multiple Pa and Bcc;
12 Pa inhibit 1-10 strains (11 inhibition haplotypes), 8 inhibit 11-20 strains (8 inhibition
haplotypes), 11 inhibit 21-30 strains (11 inhibition haplotypes), and 3 inhibit 31-40
strains (3 inhibition haplotypes). Three of the paired Pa isolates were able to inhibit most
of the strains in the collection (41-50 strains). The Bcc isolates have a more limited
inhibition range. The majority (17 strains) inhibit 1-10 strains (16 inhibition haplotypes).
Two Bcc strains are more broadly inhibitory, acting against 13 or 24 strains.

2.4.2 Bacteriocins of clinical Pa and Bcc strains are a source of inhibitory activity
A series of phenotypic assays were employed to assess whether the observed
inhibitory activities were due to bacteriocin or bacteriophage production. Cell free
extracts of each producer were subjected to filtration (to retain phage-like bacteriocins),
protease digestion (to digest protein moieties), and freezing (to fracture phage-like
bacteriocins). These assays revealed that 13% of Pa produce substances that appear to be
protease sensitive bacteriocins, 11% produce phage-like bacteriocins, and 63% produce
both (Figure 2-3). Finally, eleven percent of the Pa could not be further characterized due
to the loss of inhibitory activity in the cell-free extract.
Surprisingly, all of the Bcc producers lost inhibitory activity in their cell-free
extracts. This result was further explored by concentrating the extracts 20 fold. One strain
(4%) showed phage-like bacteriocin activity (Figure 2-3). None showed only proteasesensitive bacteriocin activity. Eleven percent showed both. One Bcc strain (4%) produced
phage plaques indicating that the inhibitory activity is due to lytic activity of a
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bacteriophage. Finally, fifty percent could not be characterized due to the complete loss
of inhibitory activity even after 20-fold concentration of the extract (Figure 2-3).

2.4.3 Clinical strains have the potential to produce multiple bacteriocins
A set of Pa reference strains enabled us to identify the source of some or all of the
inhibition identified above. These reference strains are either producers of or are sensitive
to specific S, R and F pyocins (de Chial et al., 2003; Ito, 1970; Kageyama et al., 1979;
Kuroda & Kageyama, 1981; Nakayama et al., 2000; Sano, 1990; Seo & Galloway, 1990;
Williams et al., 2008). Additionally, cloned pyocins (S1, S2, S3, and AP41) were also
employed as references to identify S-pyocin sensitivity of clinical Pa and Bcc strains
(Duport et al., 1995; Sano & Kageyama, 1981; Sano et al., 1993b). There are no
corresponding reference strains for Bcc bacteriocins.
All strains were assayed for bacteriocin-like inhibitory activity against the Pa
reference collection. The bacteriocin phenotypes predicted from these inhibition
haplotypes are given in Table 2-2. Among the 37 Pa producer strains, 76% inhibit one or
more of the reference strains. Strains predicted to possess the most bacteriocins (Pa I: S1,
S2, S3, AP41, R2, R4, F2, F3 and Pa II: S1, S2, AP41, R2, R4, F2, F3) are the most
common phenotypes encountered in the clinical Pa strains. These two phenotypes inhibit
an average of 31 and 23 strains, respectively. Pa II strains possessing all but the S3
phenotype (PaIIS3-) experience a 42% decrease in Bcc inhibition in comparison to Pa I.
The Pa III (S1, R2, R4, F2) phenotype is found in only one strain, however it inhibits the
greatest number of clinical strains, an average of 44 strains. Pa strains with Pa IV (S1,
R2, R4, F2, F3) and Pa V (S1, S3, AP41, R2, R4, F2, F3) phenotypes inhibit the least
number of clinical strains, an average of 6.5 and 9, respectively. Strains with the Pa VI
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(S1, S2, AP41) phenotype kill an average of 17 clinical strains. Nine Pa producers (Pa
VII) do not inhibit any of the reference strain and have the lowest level of inhibition, an
average of 2.4 clinical strains inhibited. Among the 19 Bcc producer strains, only 16%
inhibit any of the Pa reference strains. These three possess the Bcc I (S1, S2, AP41, F3),
Bcc II (F3) and Bcc III (R2, F2) phenotypes (Table 2-2). Fifteen Bcc producers (Bcc IV)
do not inhibit any of the reference strains and inhibit an average of 5.8 clinical strains.

2.4.4 Clinical strains show sensitivity to multiple bacteriocins.
The clinical strains were exposed to cloned S-pyocins (Duport et al., 1995; Sano
& Kageyama, 1981; Sano et al., 1993b) and 89% were sensitive (Table 2-3). Sixty-two
percent were sensitive to a single pyocins and 38% to multiple pyocins. Finally, none of
the Bcc are sensitive to the cloned S-pyocins (Table 2-3).

2.4.5 Source of the intra- and inter-specific inhibitory activity of clinical strains
Based on inhibition haplotypes, 28 Pa are predicted to produce combinations of S
and RF type pyocins, which kill within and between species (Figure 2-4). Two inhibit
intra-specifically with S-pyocins, 24 with RF-type pyocins, and 25 with S and/or RF
pyocins. Twenty-five act inter-specifically, all with RF-type pyocins. Finally, 14 produce
novel bacteriocins that act intra-specifically (50%) or inter-specifically (50%).
In contrast, the majority of Bcc strains produce novel bacteriocin-like activity
(Figure 2-4). Three produce RF-like factors and 12 produce novel bacteriocins, all of
which act intra-specifically. Further, three produce RF-like, one produces S- and/or RFlike pyocins, and the remainder (13) produce novel inhibitors to inhibit inter-specifically
(Figure 2-4).
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2.4.6 Molecular Screening: Clinical Pa strains possess multiple pyocin genes
PCR primers specific to S-type (S1, S2, S3, and AP41) (Duport et al., 1995; Sano
& Kageyama, 1981; Sano et al., 1993b) and RF-type (PRF-10, 31, and 38) pyocin genes
were employed to screen for the presence of known pyocin-encoding genes (Appendix
III). All Pa strains were amplification positive for one or more of the pyocin genes
(Figure 2-5). Ninety-five percent possess one or more S-pyocin genes; 71% amplify the
S1 gene, 71% S2 gene, 42% S3 gene, and 63% AP41 gene. A further 16% amplified from
the pyocin AP41 immunity gene, but not the corresponding toxin gene. Ninety-five
percent of the strains were amplification positive for one or more RF pyocin genes; 68%
for PRF-10, 45% for PRF-31, and 24% for PRF38 (Figure 2-5). Finally, none of the Bcc
strains were amplification positive for any of the pyocin genes (data not shown).

2.5 Discussion
Individuals with cystic fibrosis (CF) face a lifelong battle with chronic bacterial
lung infections (Govan & Deretic, 1996). Pseudomonas aeruginosa is the most prevalent
species in the CF lung and is associated with high mortality (Emerson et al., 2002). CF
patients are first colonized with nonmucoid Pa in childhood, which is replaced by mucoid
variants in adulthood (Gibson et al., 2003). Mucoid Pa form biofilms, which are virtually
impossible to eradicate even with aggressive antibiotic therapy (Hentzer et al., 2001).
Secondary bacterial infections, such as with Burkholderia cepacia, although less
common, are of particular concern because they are often associated with faster decline in
lung function and may result in cepacia syndrome, which is a rapidly progressing and
fatal pneumonia (Huang et al., 2001; Lambiase et al., 2006). What is remarkable about
these secondary infections is that they require a strain to compete with, and perhaps even
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displace, the established Pseudomonas strain (Lambiase et al., 2006; Ledson et al., 1998;
Ledson et al., 2002; McManus et al., 2004). Further, the time interval between exposure
and invasion may be as short as days to weeks (Ledson et al., 1998; Tablan et al., 1985;
Whiteford et al., 1995). This ability of Bcc strains to compete with, or even displace, the
resident Pa strains stands in sharp contrast with our seeming inability to significantly
impact long standing Pseudomonas lung infections with even the most aggressive use of
broad spectrum antibiotics.
Bacteriocins, narrow spectrum antimicrobials, are recognized as one of the most
common mechanisms by which bacteria mediate population and community level
interactions (Kerr et al., 2002; Riley & Gordon, 1999; Riley & Wertz, 2002a). Pa is a
well-characterized and prolific bacteriocin producer. Indeed, studies indicate that nearly
all clinical and only slightly fewer environmental (~70%) Pa strains produce pyocins
(B.Bouhaddioui, 2002; Farmer & Herman, 1969; Jones et al., 1974b; Zabransky & Day,
1969). Typing of a much smaller number of Burkholderia cepacia strains from clinical
sources (previously known as Pseudomonas cepacia) revealed far fewer producers (30%)
of putative bacteriocin-like toxins (labeled cepaciacins) (Govan & Harris, 1985). What
little we know about cepaciacins suggests that some may be similar to the phage-tail like
R-pyocins (Govan & Harris, 1985).
In an attempt to understand how Pa and Bcc strains interact in the CF lung,
isolates of both species were surveyed for the production of bacteriocins. Not
surprisingly, both species are prolific producers of bacteriocin-like toxins, with 97% of
Pa and 68% of Bcc capable of inhibition (Table 2-1). For Pseudomonas, most of the
inhibitory activity detected (76%) is due to S and RF pyocins (Table 2-2). In contrast, for
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Burkholderia, most of the inhibition could not be characterized (Table 2-2). Only a small
fraction (16%) was attributable to bacteriocin-like proteins (Table 2-2).
More surprisingly, the levels of between species inhibition is high, 81% of the Pa
and 57% of the Bcc producers inhibit the other species (Table 2-1). Previous studies of
Gram-negative bacteriocins have described bacteriocins as narrow spectrum toxins,
referring to the observation that they are active against members of the same species and
generally display restricted levels of inhibition outside of the producing species (Riley &
Wertz, 2002a; Riley & Wertz, 2002b). A similar survey in closely related Klebsiella
species revealed that only 20% of strains show inter-specific inhibitory activity (Riley et
al., 2003).
The high levels of inter-specific inhibition detected for Pa and Bcc may reflect the
competitive interactions that occur between these species in the CF lung. Prior studies
have suggested that these two species actively inhibit each other’s growth. McKenney et
al. (1995) revealed that the addition of cell free Pa exo-products to the growth medium
used to cultivate Bcc enhances the production of siderophores, lipases and proteases.
Further, Weaver & Kolter (2004) examined the impact of cell free extracts of Bcc on Pa
gene expression and revealed that most of the up-regulated genes of Pa are normally
induced under iron-limited conditions. The authors concluded that iron-limited conditions
might be created in these pairwise growth conditions due to the iron chelator-ornibactin
produced by Bcc. Indeed, iron-siderophores and S-pyocins (S2, S3) share the same
receptors (type I and II ferripyoverdines, respectively) (Denayer et al., 2007). Thus, Spyocins are better absorbed by sensitive strains under iron-limited conditions (Ohkawa et
al., 1980). Given these facts, Bcc colonization in the CF lung may induce intra-specific
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Pa inhibitory activity. Clearly, the effect of iron on inter-specific inhibitory activity of
pyocins and cepaciacins bears further investigation. For these purposes, identification of
cepaciacins and the corresponding cell surface receptors is required.
The majority of Pa inter-specific inhibitory activity is due to RF type pyocins
(Figure 2-4). In fact, R pyocins inhibit a variety of Gram-negative bacteria (Blackwell et
al., 1979; Filiatrault et al., 2001). This study provides the first substantial report of the
potential role of RF pyocins in clinical Bcc inhibition. The remainder of the Pa interspecific inhibitory activity is due to novel virulence factors. The majority of Bcc interspecific inhibitory activity is due to novel factors, which require further investigation
(Figure 2-4).
Another intriguing observation reported here is that most isolates of Pa from the
CF lung produce multiple bacteriocins (Table 2-2 and Figure 2-5). In fact, the most
frequently encountered bacteriocin types (Pa I-II) include essentially all characterized S
and RF-pyocins. The observation of such high levels of Pa bacteriocin diversity is good
news for those interested in the potential use of bacteriocins as narrow spectrum
antimicrobials. Although the bacteriocin-like production patterns are complex, they offer
a wide range of inhibition specificities.
Given the lack of effective antibiotic therapies for adult patients with CF, it is
intriguing that these strains are inhibited by a diversity of Pa and Bcc bacteriocins
(characterized and putative). Bacteriocins may be an effective alternative for mediating
some of these long-standing infections in the CF lung. One requirement would be the
production of bacteriocin sensitivity profiles to permit identification of the appropriate
therapeutic bacteriocins. Of course, such treatment will select for bacteriocin resistance
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(e.g. protease sensitivity, lipopolysaccharide (LPS) receptor modification) (Loutet et al.,
2006). However, given the plethora of potential bacteriocins, cocktails of toxins could be
created, which would result in far lower rates of resistance evolution (Riley, personal
communication). Bacteriocins are now frequently being considered for such therapeutic
use (Gillor et al., 2005). For example, they are employed as antibiotics for use in mastitis
in dairy cows (Diez-Gonzalez, 2007), and to inhibit growth of pathogenic Escherichia
coli in newborn piglets and foals (Gillor et al., 2005).
The most striking difference between Pa and Bcc inhibition patterns involves their
breadth of activity. Almost all Pa isolates are able to inhibit a wide range of Pa and Bcc
strains (Figure 2-2). In contrast, Bcc strains, on average, inhibit a much more limited
number of strains. Further, the Bcc inhibitory substances appear to be phenotypically
unique. For example, standard bacteriocin assays are highly successful when applied to
most species of Gram-negative bacteria (Pugsley & Oudega, 1987; Riley et al., 2003).
And yet, these methods are far less effective when applied to Bcc. Most intriguing was
the complete loss of all inhibitory activity in Bcc cell free extracts when extracts are
concentrated 20-fold concentrations. Inhibitory activity was not recovered despite its
presence on plate-based screens. In fact, the most successful protocols for obtaining Bcc
inhibition involved concomitant growth of both the producer and sensitive strains on a
solid surface. Perhaps inhibition production requires severely restricted resources and/or
high levels of competition. An alternative explanation could be the presence of unstable
phage particles in lysates from producer strains (Summer et al., 2004). We note that we
were unable to propagate bacteriophage activity, only one Bcc strain was clearly shown
to inhibit via phage (Figure 2-3). Recent studies on the bacteriophages of Bcc revealed
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that bacteriophages are able to inhibit different Bcc genomovars. However, these phages
had a relatively limited ability to inhibit Pa strains (Langley et al., 2003; Seed & Dennis,
2005). Clearly, this intriguing loss of inhibitory activity for the majority of Bcc
producers requires further investigation.
Pa strains are usually the persistent, resident bacterial species in the adult CF
lung. A recent study revealed a clear example of how R-pyocins may play a role in
mediating intra-specific competition and succession of Pa strains (Heo et al., 2007).
Further, pyocin production has been shown to impact intra-specific interactions in mixed
biofilms (Waite & Curtis, 2009). It is rare for a Bcc strain to be able to invade these
established populations. In the relatively infrequent cases of co-existence, (i.e. the paired
strains in this study), the Pa and Bcc strains are usually unable to inhibit each other. Only
two Pa (via RF pyocins) and none of the Bcc strains in this study were able to inhibit
their pair-mates (Table 2-1 and Figure 2-4). This observation may simply reflect the
outcome of prior competition, if one or the other was able to inhibit the invader or
resident strain, they would not now coexist. Clearly most unpaired Pa and Bcc strains can
inhibit each other (75% vs. 62%, respectively) even while the pair mates cannot (Table 21).
Future efforts will focus on two significant features of bacteriocin biology
revealed by this study. First, it is surprising that no molecular investigations of
cepaciacins exist. Given the importance of Bcc in human disease, the presence of these
potent toxins should have generated prior interest. In contrast, numerous studies have
focused on the characterization of pyocins. Preliminary studies designed to provide a
molecular characterization of cepaciacin identified here caution us that this may not be a
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simple exercise. To date, our efforts have not yet resulted in a single cloned cepaciacins,
or even a bacteriocin-like inhibitory function from these Bcc strains. Second, the
suggestion that bacteriocin-like inhibition may play a role in mediating strain dynamics in
the CF lung serves as inspiration for future studies designed to characterize the potential
of these narrow spectrum antimicrobials to serve in future CF therapeutics. Clearly, such
toxins are able to mediate inter-specific interactions of Pa and Bcc. Whether we can
employ these toxins for our own purposes in a clinical setting remains to be seen.
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Table 2-1. Inhibitory activity of Pa and Bcc from the CF lung
Number of Pa isolates (%)
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*

Number of Bcc isolates (%)

PI*

UPI

‡

Total

PI*

UPI

‡

Total

n=14

n=24

N=38

n=7

n=21

N=28

No inhibition

0 (0)

1 (4)

1 (3)

4 (57)

5 (24)

9 (32)

Inhibits only Pa

1 (7)

5 (21)

6 (16)

0 (0)

4 (19)

4 (14)

Inhibits only Bcc

1 (7)

1 (4)

2 (5)

0 (0)

3 (14)

3 (11)

Inhibits both Pa and Bcc

12 (86)

17 (71)

29 (76)

3 (43)

9 (43)

12 (43)

Total inhibition

14 (100)

23 (96)

37 (97)

3 (43)

16 (76)

19 (68)

Paired inhibition

2 (14)

NA

2 (5)

0 (0)

NA

0 (0)

PI: Paired isolates; ‡UPI: Unpaired isolates. NA: Not applicable

61

Table 2-2 Bacteriocin phenotypes of clinical Pa and Bcc strains

Producer
species*

Phenotype
Bacteriocin phenotype‡
designation
Pa I
Pa II
Pa III
Pa IV
Pa V
Pa VI
Pa VII
Bcc I
Bcc II
Bcc III
Bcc IV

Pa

Bcc
62
*
‡

Number of
strains

S1, S2, S3, AP41, R2, R4, F2, F3
S1, S2, AP41, R2, R4, F2, F3
S1, R2, R4, F2
S1, R2, R4, F2, F3
S1, S3, AP41, R2, R4, F2, F3
S1, S2, AP41
S1, S2, AP41, F3
F3
R2, F2
-

10
12
1
2
1
2
9
1
1
1
15

Average
number of
Pa inhibited
19
16
18
5.5
6
8.5
1.8
6
4
1
2.8

Pa: Pseudomonas aeruginosa; Bcc: Burkholderia cepacia complex
S type pyocins: S1, S2, S3, AP41; RF type pyocins: R2, R4, F2, F3
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Average
number of
Bcc inhibited
12
7
26
1
3
8.5
0.6
4
2
2
3

Total number
of strains
inhibited
31
23
44
6.5
9
17
2.4
10
6
3
5.8

Table 2.3 S-pyocin sensitivity of clinical Pa and Bcc strains

Source of pyocin

Pyocin sensitivity
phenotype‡

Cloned
S-pyocins

S1
S2
S3
AP41
S1, S2
S1, S3
S1, AP41
S2, S3
S2, AP41
S3, AP41
S1, S2, AP41
S1, S3, AP41
S2, S3, AP41
S1, S2, S3, AP41
Total sensitivity

Number of Pa
strains (%)
n=38
3
0
13
5
6
0
1
0
0
3
1
2
0
0
34 (89)

Number of Bcc
strains (%)
n=28
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0 (0)

‡ Phenotypes are according to sensitivity to S-pyocin producing clones,
e.g. S1: only S1 sensitivity; S1, S2: S1 and S2 sensitivity
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Figure 2-1 Genetic organization of exemplar pyocin genes
adapted from Michel-Briand & Baysse, 2002
a) S3 pyocin: P-box refers to the binding site for PrtN (not shown); The toxin
gene is divided into four domains, labeled I-IV.
b) R2F2-pyocin. Arrows indicate the direction of transcription.

64

Figure 2-2 Inhibition haplotypes of clinical Pa and Bcc strains
Pa and Bcc strains inhibited multiple strains. For example, 12 Pa inhibit 1-10 strains.
The Bcc isolates have a more limited inhibition range in comparison to Pa isolates.
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Figure 2-3 Inhibition types produced by clinical Pa and Bcc strains
Pa strains showed protease sensitive, phage-like, and/or both types of inhibition.
Most of Bcc strains are nontypable. One Bcc strain showed phage activity.
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Figure 2-4 Source of the intra- and inter-specific inhibitory activity of clinical Pa
and Bcc strains
Source of inhibitory activity of Pa and Bcc are different. In Pa, much of the intra- and
inter-specific inhibitory activity was due to the activity of S- and RF-type pyocins, In
Bcc, inhibitory activity is mostly novel or due to RF-like pyocins.
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Figure 2-5 Pyocin gene distribution in the genomes of clinical Pa and Bcc
PCR primers were used to screen genomes of clinical Pa for the known S-pyocins (S1,
S2, S3, AP41) as well as RF pyocins (PRF10-, PRF31, PRF38). All Pa bacteriocin
producers (100%) possessed one or multiple S- and RF pyocin genes in their genome.
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CHAPTER 3
CONSTRUCTION OF GENOMIC LIBRARIES TO IDENTIFY PUTATIVE
GENES INVOLVED IN BACTERIOCIN-LIKE INHIBITORY ACTIVITY OF
B. CEPACIA COMPLEX

3. 1 Abstract
A recent survey revealed a potential role for bacteriocins in mediating bacterial
interaction in Cystic Fibrosis (CF) lungs. This study showed that 68% of Burkholderia
cepacia complex (Bcc) strains isolated from lungs of CF patients possess potent
inhibitory activity, which appears similar to the bacteriocin-like inhibition produced by
many other bacterial species. Since most adult CF patients have pre-existing
Pseudomonas aeruginosa (Pa) infections, Bcc strains must either compete with or act in
synergy with the Pa already established in the lungs. Although this prior study made a
compelling case for the potential role for these inhibitory substances in mediating
bacterial interactions in the lungs, it could not identify the substances in question. In this
study, genomic libraries of B. multivorans, B. dolosa, and B. cenocepacia were
constructed to screen for genes responsible for the inhibitory activity previously
described. ~10,000 clones/genome were screened, resulting in fifteen clones with the
anticipated inhibitory activity. Of these fifteen, only five had stable inhibition activity,
and were pursued further. These clones encoded proteins involved in various metabolic
pathways including bacterial apoptosis, amino acid biosynthesis, sugar metabolism, and
degradation of aromatic compounds. Surprisingly, none possessed typical bacteriocin-like
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genes. These data suggest that Bcc may use novel inhibitory agents to mediate intra- and
inter-specific interactions.

3.2 Introduction
B. cepacia complex species, most of which are temperate soil saprophytes and
plant pathogens, are associated with severe, often fatal, pulmonary infections in persons
with cystic fibrosis.
Summer et al., 2007

3.2.1 B. cepacia complex (Bcc)
In 1950, plant pathologist Walter Burkholder showed that Pseudomonas cepacia
was different from other members of the Pseudomonas genus: they could grow on mhydroxy benzoate or tryptamine as carbon sources (Mahenthiralingam et al., 2005).
Further, they are able to catabolize more than 200 organic carbon sources; demonstrating
enormous metabolic versatility (Lessie et al., 1996). In 1992, Pseudomonas cepacia,
Pseudomonas solanacearum, Pseudomonas pickettii, Pseudomonas glandioli,
Pseudomonas mallei, Pseudomonas pseudomallei, and Pseudomonas caryophylli were
incorporated into a new genus, Burkholderia, based on 16S rRNA sequences, DNA-DNA
homology, lipid and fatty acid compositions, and phenotypic characteristics (Yabuuchi et
al., 1992).
In 1997, molecular and biochemical assays were performed on 128 tentatively
classified B. cepacia strains. This study revealed five phenotypically similar, but
genotypically distinct, Burkholderia species (genomovars), classified as the B. cepacia
complex (Bcc). These species were named as B. cepacia (genomovar I), B. multivorans
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(genomovar II), B. cenocepacia (genomovar III), B. stabilis (genomovar IV), and B.
vietnamiensis (genomovar V) (Vandamme et al., 1997). Later, B. dolosa (genomovar VI),
B. ambifaria (genomovar VII), B. anthina (genomovar VIII), and B. pyrrocinia
(genomovar IX) were added to the Bcc (Coenye et al., 2001a; Coenye et al., 2001b;
Vandamme et al., 2002).

3.2.2 B. cepacia complex: Friend or Foe?
Burkholderia species are opportunistic pathogens (Mahenthiralingam et al.,
2005). B. cepacia was the first pathogen identified in the genus. It is the causative agent
of soft rot in onions (Sotokawa & Takikawa, 2004). Subsequently, B. glumae, B.
plantarii, B. glandioli, and B. phytofirmans were shown to cause diseases in such
economically important crops such as rice, maize, potato, and tomatoes (Coenye &
Vandamme, 2003; Sessitsch et al., 2004). Members of the genus also engage in activities
that are beneficial to humans, such as serving as bioremediation and biocontrol agents
(Parke & Gurian-Sherman, 2001). Various species degrade aromatic compounds, crude
oil, herbicides, and xenobiotics (Sousa et al., 2010). Further, they produce antibiotics and
iron scavenging siderophores that repress fungal growth (Chiarini et al., 2006; Parke &
Gurian-Sherman, 2001).
Members of the genus are also associated with human disease and are responsible
for numerous nosocomial infections in immunocompromised patients, such as those with
cancer or HIV (Mann et al., 2010; Verghese et al., 1994). The focus of this study,
however, is their role in Pa-Bcc interaction in lungs of patients with cystic fibrosis (CF)
(Mahenthiralingam et al., 2005). Bcc infections in CF patients were first observed in the
early 1980 (Tablan et al., 1985), and remain relatively rare, only 3% of CF patients are
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infected with a member of this species complex (CFF, 2008). However, clinical outcomes
of such infections are both unpredictable and potentially severe, ranging from
asymptomatic, to chronic, and even fatal infections (Mahenthiralingam et al., 2002;
Whiteford et al., 1995). Nearly 20% of Bcc infected CF patients develop cepacia
syndrome, a fatal, rapid onset pneumonia, occurring within days or weeks of their
introduction into the lung (Govan & Deretic, 1996). The varied colonization outcomes
may be due to strain, patient or treatment-based factors. Metabolic versatility, insertion
sequences, genomic islands, bacteriophages, proteases, and exotoxins in Bcc are potential
factors, which may serve to enhance their ability to invade and colonize the CF lung
(Mahenthiralingam et al., 2001; Mahenthiralingam et al., 2005).
Bcc species have large genomes, up to 6-9 Mb, which are organized as multiple
chromosomes, with 67% GC content (Holden et al., 2009; Parke & Gurian-Sherman,
2001). The number of chromosomes and the total genome size varies among strains as
well as within a genomovar (Table 3-1). Currently, the genomes of 38 Burkholderia
strains have been sequenced, eleven of which are members of the Bcc species complex;
including five strains of B. multivorans, two of B. cenocepacia, two B. ambifaria, one B.
cepacia, and one B. vietnamiensis (NCBI, ; Pathema).
Bcc genomes are rich in insertion sequence (IS) elements, which are transposable
DNA sequences ranging between 700-2500 bp in length. A recent study revealed one
strain with 79 IS elements in its genome (Holden et al., 2009). IS elements are capable of
inserting themselves at multiple sites in the genome, leading to a variety of genetic
rearrangements such as duplications, deletions, and inversions. Studies have revealed that
several IS elements in P. cepacia can activate gene expression (Wood et al., 1991) and
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play a role in plasmid rearrangement (Byrne & Lessie, 1994). The presence of IS
elements is proposed as one of the major driving forces of the versatility and adaptation
of bacteria in different environmental niches (Mahillon & Chandler, 1998; Mira et al.,
2002).
Genomic islands (GI), which are clusters of genes in bacterial genomes also
involved in adaptation of bacteria in different environments as well as involved in
virulence, antibiotic resistance, and other metabolic processes (Hacker & Carniel, 2001).
GIs range in size from 10-100 kb in length and are often associated with horizontal gene
transfer events (Hacker & Carniel, 2001). These islands are often called pathogenicity
islands (PI), if the genes are associated with increased pathogenicity.
Bcc genomes are rich in genomic islands. Fourteen GIs were identified in the
recently published genome of B. cenocepacia J2315, distributed across all three
chromosomes, some of which are unique to epidemic strain (Holden et al., 2009). One
GI, cci, encodes virulence and metabolism genes, including arsenic and antibiotic
resistance genes, quorum sensing genes, amino acid and fatty acid metabolism genes, and
transcriptional regulator genes (Baldwin et al., 2004; Holden et al., 2009). A second,
BcenGI2 possesses genes that code for plasmid conjugation, while others, BcenGI9, 12,
and 13, encode prophage genes (Baldwin et al., 2004; Holden et al., 2009).
The presence of bacteriophages in pathogen genomes is frequently associated
with enhanced virulence (Wagner & Waldor, 2002). Bacteriophages can be lytic or
lysogenic. Lytic phages can multiply in host cells using the host’s transcription and
translation machinery. The host cell is then lysed, disseminating phage progeny.
Lysogenic phages integrate their DNA into the host chromosome; there is no subsequent
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phage multiplication or host cell lysis. The phage DNA in this repressed state is called a
prophage because it has the potential to produce phage progeny (Casjens, 2003; Synder &
Champness, 2003). The host is not apparently adversely affected by the presence of
prophage and the phage may persist in this state until induction by the presence of an
inducing agent such as UV or oxidative stress (Barnhart et al., 1976; Los et al., 2010).
A number of bacteriophages have been isolated from members of Bcc strains.
These include lysogenic (BcepMu, KS8, KS9, KS10, KS11, BcP15, DK4, CP1, CP75)
and lytic (KS1, KS2, KS3, KS5, KS6) phages (Cihlar et al., 1978; Hens et al., 2005;
Langley et al., 2005; Matsumoto et al., 1986; Summer et al., 2004; Summer et al., 2006).
Seed et al., 2005 performed a study to determine the host range of these bacteriophages
by infecting 24 strains from the Bcc complex with them. The study revealed that the lytic
bacteriophages (KS1, KS5, and KS6) have broader host ranges, including B. cepacia, B.
multivorans, B. cenocepacia, B. ambifaria. The lysogenic phages are restricted to a more
limited number of host species, including B. cenocepacia and B. ambifaria (Seed &
Dennis, 2005).
Genomes of some bacteriophages in Bcc do encode putative proteins, which may
be potential virulence factors involved in host cell lysis. Gene 53 from epidemic strain B.
cenocepacia ET12 encodes acyltransferase, which modifies lipopolysaccaharides (LPS),
resulting in strain serotype conversion. The gp8 gene from the same strain resembles the
ExeA protein of Aeromonas hydrophilia, which is involved in the secretion of toxins such
as aerolysin (Summer et al., 2007).
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3.2.3 Burkholderia and Pseudomonas interaction
P. aeruginosa (Pa) is the predominant infectious agent in the lungs of adult CF
patients (Govan & Deretic, 1996), found in approximately 30% of infants and 80% of
adult CF patients (CFF). Chronic Pa infection is one of the primary health concerns for
adult CF patients, ultimately resulting in death of the patient (Lyczak et al., 2002).
Secondary Bcc infections have become a major concern over the past 30 years
(Tablan et al., 1985). Although all Bcc species can infect the lung, B. multivorans and B.
cenocepacia are the species most frequently identified, with a prevalence of 38% and
50%, respectively (LiPuma et al., 2001). In most cases, Bcc acquisition occurs in CF
patients already colonized with Pa (Govan & Deretic, 1996). During this secondary
infection it has been suggested that Bcc strains directly compete with the established Pa
strains, although it is not known how such interactions occur. However, it is clear that
Bcc-Pa co-infections are rare, suggesting that Bcc strains can successfully compete with
and displace the resident Pa strains (Lambiase et al., 2006; McManus et al., 2004).
Unfortunately, few studies have focused on these multi-species bacterial
interactions in the CF lung. What we do know from the limited studies available is that
strain replacement is only observed among members of Bcc (Govan et al., 1993; Ledson
et al., 1998; Mahenthiralingam et al., 2001). A recent study revealed that in ~7% of CF
patients examined, Bcc strains are replaced over time with other species of Bcc
(Bernhardt et al., 2003). Further, Yang et al., 2006 revealed that co-infection with more
than one Bcc strain may occur in the early phases, but is rare after the development of a
chronic infection (Yang et al., 2006). None of these studies focused on the factors that
mediate such interactions.
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Bacterial antagonism is common due to competition for limiting resources. Iron is
one of the main limiting factors, which bacteria utilize during colonization and invasion.
Weaver and Kolter have shown that members of the Bcc species complex compete more
effectively for iron than strains of Pa (Weaver & Kolter, 2004). They investigated the
effect of Bcc presence on Pa gene expression by incubating the Pa strain in the presence
and absence of a Bcc cell free extract. Pa virulence gene expression is enhanced by the
presence of Bcc in iron-limited environments. Further, their data showed that the Bcc
iron scavenging siderophore (ornibactin) limits available iron to Pa, leading the induction
of Pa virulence genes (Weaver & Kolter, 2004).
Bacteriocin production is another factor mediating bacterial antagonistic
interactions. Aside from one recent study (Bakkal et al., 2010), there are no additional
publications that focus on the effect of bacteriocin production on bacterial interactions in
the CF lungs. The Bakkal et al., 2010 study revealed bacteriocin production in 97% of
Pa and 68% of Bcc strains isolated from CF lungs (Bakkal et al., 2010). In Pa, much of
the inhibitory activity was shown to be due to S- and RF-type pyocins, bacteriocins of Pa.
In Bcc, the source of inhibitory activity appears to be bacteriocin-like, but no bacteriocins
of Bcc (cepaciacins) have been described (Bakkal et al., 2010).
The goal of the present study is to identify the sources of the observed Bcc
inhibitory activity. Three genome libraries were created from B. multivorans, B. dolosa,
and B. cenocepacia and screened for inhibition against sensitive Pa and Bcc strains. Five
clones from the B. multivorans library had inhibitory activity against the Pa strain. DNA
sequences of these clones were determined and their putative functions were identified.
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They include bacterial apoptosis, amino acid biosynthesis, sugar metabolism, and
degradation of aromatic compounds.

3.3 Materials and Methods
3.3.1 Bacterial strains
Genomic libraries were prepared from B. multivorans (ATCC 17616), B. dolosa
(AUO158), B. cenocepacia (02-228-1429). Pseudomonas aeruginosa (327-6-1422), B.
vietnamiensis (03-260-0635), and B. dolosa (04-053-0423) were used as sensitive lawns
to detect inhibitory activity produced during the library screen (Bakkal et al., 2010). The
genomes of Pseudomonas aeruginosa (PAO1), which encodes pyocin S2, and
Pseudomonas aeruginosa (NIH3), which does not encode bacteriocins, served as positive
and negative controls during the library screens (Bakkal et al., 2010, ; Matsui et al., 1993;
Nakayama et al., 2000) PA01 produces a pyocin (S2). Escherichia coli XL1 Blue MRF’
(Stratagene, Agilent Technologies) was used as the recipient strain for the genomic
libraries.

3.3.2 Construction of genomic library
Genomic libraries were constructed according to the method described in Ausubel
et al., 2004 (Ausubel et al., 2004). Genomic DNA was produced using the Gentra
Puregene kit (QIAGEN), with the gram-negative DNA isolation protocol and 5X109 cells
from an overnight culture. Bam HI (10 U/µl; NEB) and/or Bfu CI (10 U/µl; NEB) were
used to partially digest the genomic DNA at 37 0C for 30-50 minutes. The reaction was
terminated by incubation at 65 0C and then run on a 0.6% SEAKEM® GTG agarose gel
(FMC BioProducts) at 80 V for 5 hours. DNA fragments in the size range of 4-5 kb were
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isolated from the gel using the QIAquick gel extraction kit (QIAGEN). These fragments
were then ligated into a BamHI digested and dephosphorylated pUC19 plasmid vector
(NEB) (Figure 3-1). The ligated DNA was chemically transformed into E. coli XL1 Blue
MRF’ supercompetent cells (Stratagene, Agilent Technologies) (Figure 3-1). Blue/white
colony screening was carried out on Luria Broth (LB) plates supplemented with 100
µg/µl ampicillin (Sigma), 40 mM IPTG (Sigma), and 0.08% X-Gal (Sigma). X-gal
(bromo-chloro-indolyl-galactopyranoside) is a colorless substrate, which is metabolized
by β-galactosidase to form an insoluble blue product (5-bromo-4 chloroindole). IPTG
(Isopropyl β-D-1-thiogalactopyranoside) is used to induce transcription of the gene coding
for β-galactosidase. If the ligation is successful, the insert DNA will interfere with the
transcription of the β-galactosidase gene, resulting in white bacterial colonies; if the
ligation is unsuccessful, the colonies will appear blue (Figure 3-1).

3.3.3 Phenotypic screening of genomic clones
The patch assay was used to identify Pa and Bcc inhibitory activity among the
genomic clones. Strains were grown overnight in 10 ml LB at 37 0C, shaken at 250 rpm.
Six ml of LB top agar (0.6%, w/v) mixed with 100 µl of 10 mM IPTG, and 100 µl of
sensitive cells (108 cells) were plated as a lawn on an LB plate. All resulting white
colonies from the genomic library were spotted on the sensitive Pa and/or Bcc lawn by
toothpick. B. multivorans (ATCC17616) and XL1 Blue MRF’ transformed with pUC19
plasmid were spotted on each lawn as positive and negative controls, respectively. After
overnight incubation at 37 0C the plates were scored for the presence of inhibitory
activity. More than 10,000 white colonies were screened per genomic library, resulting in
2-fold coverage of each genome. Each positive clone was screened a second time.
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Plasmids were isolated from overnight cultures of genomic clones with putative
inhibitory activity, and digested with EcoRI (10 U/µl; NEB) to identify the presence or
absence of the DNA insert. Finally, inhibition phenotypes of the genomic clones were
visualized and photographed using a Leica MZ 16 FA fluorescent dissecting scope.

3.3.4 Nucleotide sequencing
Plasmid DNAs were isolated from overnight cultures of genomic clones using a
plasmid isolation kit (QIAGEN). Plasmid DNAs were sequenced using Big Dye
Terminator Cycle Sequencing mix with pUC19-forward (5’-AGC GGA TAA CAA TTT
CAC ACA GGA-3’) and pUC 19- reverse (5’-CGC CAG GGT TTT CCC AGT CAC
GAC-3’) primers (Applied Biosystems, Foster City, CA). The sequencing reaction was
performed at 96 oC for 1 min, followed by 96 oC for 30 sec, 50 oC for 15 sec, and 60 oC
for 4 min through 25 cycles. Homology searches were performed using the NCBI
nucleotide–nucleotide Blast (blastn) algorithm on the combined GenBank/EMBL/DDBJ
database. Further, gene annotations were performed via SEED, which is an annotation
and analysis tool provided by the fellowship for interpretation of genomes (University of
Chicago).

3.4 Results
3.4.1 Genomic Library Construction
The Bcc species chosen for this study represent the most frequently isolated
species from CF patients. B. multivorans and B. cenocepacia are isolated from 38% and
50% of CF patients, respectively (LiPuma et al., 2001). The incidence of B. dolosa from
CF patients is only 2% (Coenye et al., 2001a), but it is one of the most frequently isolated
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species (39%) from our previous phenotypic bacteriocin screening study (Bakkal et al.,
2010).
Partially digested genomic DNAs of B. multivorans (ATCC17616), B. dolosa
(AUO158), and B. cenocepacia (02-228-1429) were ligated to BamHI digested and
dephosphorylated pUC19 plasmids to construct genomic libraries of these strains. The
genomes of B. multivorans (ATCC 17616) and B. dolosa (AUO158) have previously
been sequenced and annotated in NCBI (NCBI, ; Pathema).
The Pa strain, PAO1, was used as a positive control in the genomic library
construction. Pa PAO1 produces pyocin S2, an S-type bacteriocin (Seo & Galloway,
1990). It has been shown that PAO1 inhibits the growth of Pa NIH3 via the DNAse
activity of pyocin S2. Thus, Pa NIH3 was used as a lawn to detect the pyocin S2 activity
of the corresponding genomic clones of Pa PAO1.
Approximately 10,000 white colonies/genome were screened on sensitive lawns
of PA01 and Bcc strains. A total of fifteen clones with inhibitory activity were identified,
twelve from B. multivorans (ATCC 17616), two from B. dolosa (AUO158), and one from
B. cenocepacia (02-228-1429). Additionally, three clones were identified from the
genomic library of PAO1, the positive control for screening.

3.4.2 Phenotypic screening of genomic clones
The phenotypic bacteriocin assay was repeated to verify inhibitory phenotypes of
these fifteen genomic clones. Only six clones (Table 3-2) produced repeatable inhibitory
activity (Figure 3-2a), five from B. multivorans (ATCC17616) and one from Pa (PAO1)
(Figure 3-2a). B. multivorans (ATCC17616) showed an inhibition phenotype on a
sensitive lawn of P. aeruginosa (327-6-1422), which consisted of the inhibition of growth
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of the sensitive lawn under the producer Bcc colony (Figure 3-2b). Thus, the killing
phenotype was defined as the loss of visible lawn growth under the putative producer
clone. Genomic library clones (clones 2, 4, 6, 7, and 9) of B. multivorans (ATCC17616)
possessed the described inhibitory phenotype (Figure 3-2a).
Pa (PAO1) showed an inhibition phenotype on the sensitive lawn Pa (NIH3)
(Figure 3-2b). This phenotype consists of a thin inhibition zone around the producer
PAO1 colony. The PAO1 genomic colony also possessed the same phenotype as the
pyocin S2 producer Pa (PAO1) (Figure 3-2a).

3.4.3 Nucleotide sequencing
Forward and reverse sequencing primers of the pUC19 plasmid were used to
sequence the clones. The resulting DNA sequences were employed in BLAST screens
against existing genome sequences of B. multivorans (ATCC17616) and Pa (PAO1)
(Table 3-2).
Genomic clone 2 had an insert of 714 nucleotides (nt), located on chromosome 1
of B. multivorans (ATCC17616). The NCBI blast showed that the DNA sequence
corresponded to the DNA sequence of a hypothetical protein (Bm 1615) with an
unknown function (Figure 3-3a). The flanking DNA sequences of Bm1615 encode
another hypothetical protein (Bm1614) and a membrane protein (seven transmembrane
helix protein) (Bm1616) (Figure 3-3a). The DNA sequence alignment of Bm1615 and
clone 2 has shown that DNA sequence of the clone 2 covered majority of the hypothetical
protein (453 nt) including its start codon (Figure 3-3b). Finally, the last 22 nt of Bm1516
are excluded in the clone 2.
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Clone #4 had a DNA insert of 3,498 nt, containing genes encoding poly-betahydroxyalkanoate depolymarase, glucoamylase, and 3-carboxymuconate cyclase proteins
(Figure 3-4a). These genes are also located on chromosome 1 of B. multivorans
(ATCC17616).
Glucoamylase is an extracellular enzyme, common in fungus Aspergillus. This
enzyme hydrolyzes starch into glucose via catalyzing hydrolysis of α-1,4 and α-1,6
glycosidic bond (Sauer et al., 2000). Glucoamylase also induces biosynthesis of fungus
toxin (aflatoxin), which causes infection in plant tissue (Mellon et al., 2007). Genomic
clone 4 contained 1929 nt of DNA sequence, encoding full length glucoamylase enzyme
(Figure 3-4b)
The DNA insert of clone 4 also possessed partial DNA sequences, encoding polybeta-hydroxyalkolonate depolymerase and 3-carboxymuconate cyclase (1222 nt and 210
nt, respectively)(Figure 3-4a and b). Both enzymes are involved degradation of aromatic
hydrocarbons.
Poly-beta-hydroxyalkolonate depolymerase is an enzyme involved in degradation
of polyhydroxyalkanoates (PHAs) (Madison & Huisman, 1999). PHAs are biopolyesters,
which are synthesized by Archea, Gram-positive, and Gram-negative bacteria in response
to nutrient limitations. Bacteria accumulate PHAs into inclusion bodies and store them in
their cytoplasm. The PHAs are then degraded via enzymatic reaction and used as carbon
and energy resources (Madison & Huisman, 1999).
3-carboxymuconate cyclase is also among the enzymes, responsible for
degradation of aromatic hydrocarbons. It is one of the enzymes in the 3-oxodipate
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pathway in fungi and bacteria. The 3-oxodipate pathway involves the conversion of
hydroxybenzoate and catechol to succinate and acetyl-CoA (Cook & Cain, 1974).
Clone # 6 consisted of a 677 nt insert, which corresponded to a partial DNA
sequence of amidohydrose II and 4-hydroxybenzoate transporter (285 nt and 423 nt,
respectively) (Figure 3-5a and b). These genes are located on chromosome 3 of B.
multivorans (ATCC17616).
Amidohydrolase II belongs to the functional category of enzymes with unknown
specificity (Pathema). The protein belongs to the amidohyrolase superfamily consisting
of hydrolase enzymes that catalyzes the cleavage of C-N, C-C, C-O, C-Cl, C-S, O-P
bonds of organic substances. The group includes 771 enzymes, which are known to
catalyse nonhydrolytic reactions including decarboxylation and hydration (Aimin et al.,
2007).
4-hydroxybenzoate transporter is also involved degradation of aromatic benzoate.
This enzyme belongs to beta-ketoadipate pathway, which degrades 4-hydrozybenzoate to
succuniyl-CoA and Acetyl-CoA (Wright, 1993).
The blast result of clone 7 contained a 3,956 nt long DNA sequence,
corresponding to the DNA sequence encoding 3-isopropyl malate dehydrogenase (1066
nt), 3-isopropyl malate dehydratase small subunit (651 nt), 3-isopropyl malate
dehydratase large subunit (411 nt), aspartate semialdehyde dehydrogenase genes (1122
nt), and entericidin AB (132 nt) (Figure 3-6a and b). These genes are possessed by
chromosome 2 of B. multivorans (ATCC17616).
3-isopropyl malate dehydrogenase, 3-isopropyl malate dehydratase small subunit,
and 3-isopropylmalate dehydratase large subunit are among the enzymes responsible for
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leucine biosynthesis. Leucine biosyntesis requires expression of four contigious genesleuABCD as a single operon in E. coli. The leuA and leuB genes encode 2isopropylmalate synthetase and 3-isopropylmalate dehydrogenase, respectively. The leuC
and leuD genes encode large and small subunits of isopropylmalate dehydratase
(Tamakoshi et al., 1998). In some organisms, organization of these genes could be
different. For example, leuB is located separately from leuACD in Leptospira interrogans
(Ding & Yelton, 1993).
3-Isopropylmalate dehydrogenase belongs to a family of metal dependent
decarboxylating dehyrogenase enzymes. Thus, this enzyme requires divalent cations
(Mg+2 or Mn+2) to become active. 3-Isopropylmalate dehydrogenase catalyzes the
conversion of 3-isopropylmalate to 2-isopropyl-3-oxosuccinate (Hurley & Dean, 1994).
3-isopropylmalate dehydratase (or isopropylmalate isomerase) is composed of
large (Leu C) and small (LeuD) subunits, which catalyzes isomerisation of 2isopropylmalate and 3-isopropylmalate, via the formation of 2-isopropylmaleate. This
enzyme performs the second step in the biosynthesis of leucine, and is present in most
prokaryotes and many fungal species.
Aspartate semialdehyde dehydrogenase is one of the enzymes in lysine
biosythesis pathway. It catalyzes the conversion of beta-aspartly phosphate to L-aspartate
beta-semialdehyde, which is ultimately converted to L-lysine (Tunca et al., 2004).
Finally, this clone encodes for entericidin AB, which is a toxin-antitoxin gene pair
involved in bacterial apoptosis in E. coli (Bishop et al., 1998). Entericidins are small,
amphipathic alphahelical cationic lipoproteins, which bind to membrane
phosphospholipids. The genes are induced in stationary phase, when cells are starved for
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energy. The producing cell is lysed due to the resulting disruption in membrane stability
(Bishop et al., 1998).
Blast result of clone # 9 corresponded to 37 nt long sequence of the GGDEF
domain, which is 1479 nt long (Figure 3-7a and b). The GGDEF is a conserved domain
with unknown function, located on chromosome 1 of B. multivorans (ATCC17616)
(Pathema). This domain is found in a diversity of bacteria (Pei & Grishin, 2001). It has
been suggested that the domain is observed in multi-domain proteins such as those
involved in signaling pathways. For example, diguanylate cyclase (DGC) is an enzyme
involved in the synthesis of c-di-GMP, which is a secondary messenger involved in
various cellular processes including cell-to-cell signaling, motility, virulence, biofilm
formation, and antibiotic production (Tamayo et al., 2007).
Finally, the genomic clone of Pa (PAO1) had an insert of 4089 nt, which encodes
an hypothetical protein, pyocin S2 toxin, and immunity proteins (Figure 3-8 a and b).
Pyocin S2 is one of the S-type pyocins found in Pa(Michel-Briand & Baysse, 2002). The
genomic clone of PAO1 has DNA sequence, which covers the pyocin S2 toxin gene
(Pa1152) and the pyocinS2 immunity gene (Pa1153), which provides immunity to pyocin
S2 (Figure 3-8b).

3.5 Discussion
Patients with CF suffer from chronic lung infections that are associated with high
mortality (Lyczak et al., 2002). During infancy, the patient’s airways and lungs are
colonized intermittently with several species of bacteria, including Haemophilius
influenzae (H. influenzae), Staphylococcus aureus (S. aureus), Pseudomonas aeruginosa
(Pa), and B. cepacia complex (Bcc) (Hutchison & Govan, 1999). Infections may become
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chronic, resulting in decreased lung capacity, continuous inflammation and ultimately
result in the death of the patient (Govan & Deretic, 1996; Lyczak et al., 2002).
CF patients’ susceptibility to particular pathogen species may be age-related
(Govan & Deretic, 1996). H. influenzae and S. aureus colonize the lungs of infants
primarily, but can be found in the lungs through early childhood (Gibson et al., 2003). Pa
tends to colonize older patients, but can be found in up to 30% of young patients (2008).
Early Pa colonizers are planktonic (free living) and these infections are relatively easily
treated with broad-spectum antibiotics, usually a combination of beta-lactamases and
aminoglycosides (Hansen et al., 2008). Over time, alginate-forming mucoid Pa variants
emerge and dense biofilms develop in the lungs, resulting in chronic lung infections.
These chronic, biofilm-based infections are difficult to eradicate since the biofilms
enhance the innate antibiotic resistance of the strains (Hentzer et al., 2001).
In the past thirty years, Bcc has emerged as a lung pathogen in CF patients
(Govan & Deretic, 1996). Members of the species complex naturally reside in soil and on
plants (Mahenthiralingam et al., 2005). Bcc is known for its metabolic versatility, which
may contribute to its ability to survive, and even thrive, in numerous environments,
including the human lung. Although the prevalence of Bcc lung infections is low (~3% of
CF patients), the clinical outcomes are unpredictable and can be quite severe (Kalish et
al., 2006). A small portion of those infected (20%) develop cepacia syndrome, which is a
necrotizing pneumonia, leading to rapid lung failure and death (Jones et al., 2004; Kalish
et al., 2006; Tablan et al., 1985).
Bcc strains that invade the CF lung face numerous challenges, such as evading the
host immune system, competing with the resident bacteria and colonizing the host tissue.
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The focus of this study was an exploration of the virulence factors that play a role in one
feature of Bcc invasion, the competition between Bcc and the bacteria already resident in
the patient’s lungs.
Bcc colonization usually involves competition with a resident strain of Pa (Govan
& Deretic, 1996). In such a scenario, two kinds of species interactions may occur,
synergism and antagonism, resulting in either co-infection or extinction of one species.
The incidence of co-infection is quite low (Lambiase et al., 2006; McManus et al., 2004).
In either case, the presence of Pa has been shown to have a detectable impact on Bcc,
such as the promotion of virulence gene expression (Riedel et al., 2001). Riedel et al.
2005 revealed that Bcc recognizes acylated homoserine lactones (AHLs) secreted by Pa,
which are small molecules that induce expression of genes in Bcc involved in virulence
and biofilm formation. The AHL recognition is unidirectional, Bcc recognizes AHL’s
produced by Pa, while no recognition of Bcc AHLs by Pa is detected (Riedel et al.,
2001).
Another factor known to impact bacterial interactions is the production of
bacteriocins, which are potent toxins produced by bacteria to kill the strains of the same
or related species (Riley & Wertz, 2002a; Riley & Wertz, 2002b). Studies in which
bacteria are competed in vitro (on petri plates) and in vivo (in the mouse colon) reveal
that bacteriocins are highly effective in mediating intra- and inter-specific competition,
(Bakkal et al., 2010; Michel-Briand & Baysse, 2002).
Pa is a prolific producer of bacteriocins, with more than 90% of the strains
assayed identified as producers (Fyfe et al., 1984). In contrast, far fewer strains of Bcc
(~30%) produce bacteriocins (Govan & Harris, 1985). A survey of bacteriocin production

87

was undertaken with strains isolated from the lungs of CF patients. This study revealed
that 97% of Pa and 68% of Bcc strains produce bacteriocin-like inhibitory activity
(Bakkal et al., 2010).
Detailed studies of Pa bacteriocin production have resulted in the identification of
three pyocin types: S, R, and F (Michel-Briand & Baysse, 2002). S-pyocins are high
molecular weight proteins, which possess DNAse activity to inhibit (Sano & Kageyama,
1981; Sano & Kageyama, 1984; Sano et al., 1993a; Sano et al., 1993b). RF pyocins
resemble phage tails, which depolarize the cell membrane (Nakayama et al., 2000). The
bacteriocins of Bcc have not been studied extensively. In fact, there is no molecularly
characterized Bcc bacteriocin. One available phenotypic study revealed that Bcc
bacteriocins resemble phage tails (Govan & Harris, 1985)
We employed genomic library screens of B. multivorans, B. dolosa, and B.
cenocepacia to understand how Bcc mediates its interactions with Pa in the CF lung. The
screening involved lawns of sensitive Pa and Bcc strains (Bakkal et al., 2010). Fifteen
clones, from three Bcc genomic libraries, possessed a putative inhibitory activity as
revealed by inhibition zones on the sensitive lawns. However, the activity was lost in ten
of the clones in subsequent replications of the screen. We also lost the inhibitory activity
of two Pa PAO1 genomic clones (three clones identified in total).
The loss of inhibitory activity in ten Bcc and two Pa genomic clones can be
explained simply by the absence of DNA sequence encoding immunity protein in
genomic clones. In most bacteria, an immunity gene follows the bacteriocin gene (toxin),
which are transcribed and translated together in bacteria. Immunity protein confers
resistance to the toxin and thus, producer bacteria are immune to the produced bacteriocin
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(Riley & Wertz, 2002a; Riley & Wertz, 2002b). Therefore, absence of immunity gene in
genomic clones may result the lysis of E. coli recipient due to the toxicity of the cloned
protein(s). Indeed, one Pa PAO1 genomic clone possessed DNA, encoding both pyocin
S2 and corresponding immunity protein (Figure 3-8). In this clone, we observed clear
inhibition of the sensitive lawn (Figure 3-2). Another reason of the loss of inhibitory
activity might be the toxicity of Bcc and Pa bacteriocins (or novel toxins) to E. coli
recipient. However, the bacteriocin producer Bcc and Pa strains were previously tested on
E. coli XL1 Blue MRF’ recipient. E. coli XL1 Blue MRF’ recipient did not show
sensitivity against these Pa and Bcc strains, which were used in genomic library
construction.
The DNA isolated from the remaining five clones of B. multivorans was
sequenced. The genes identified correspond to four major functional categories: amino
acid biosynthesis, sugar metabolism, degradation of aromatic compounds, and bacterial
apoptosis (Table 3-2).

3.5.1 Amino Acid and Sugar Metabolism
An NCBI BLAST of the Bcc clones resulted in identification of genes for amino
acid and sugar metabolisms. 3-isopropyl malate dehydrogenase, 3-isopropyl malate
dehydratase small subunit, 3-isopropylmalate dehydratase large subunit, and aspartate
semialdehyde dehydrogenase are involved in leucine and lysine biosynthesis (Black &
Wright, 1954). The screen also revealed a sequence with homology to glucoamylase, a
hydrolytic enzyme involved in sugar metabolism in fungus and bacteria, which converts
starch into glucose (Sauer et al., 2000). Further, this enzyme is involved the induction of
a fungal toxin (aflatoxin). Thus, glucoamylase might have similar function in Bcc and
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causes induction of toxin genes. Partial aflatoxin gene (Genbank accession number:
AY864289.1) was blasted against 38 sequenced Bcc genomes to identify if these
genomes possess aflatoxin-like proteins. However, none of these genomes have proteins,
which share homology with aflatoxin of fungus Aspergillus.

3.5.2 Degradation of aromatic compounds
The BLAST search of the genes (4-hydroxybenzoate transporters, poly-beta
hydroxyalkonate) encoded in the Bcc genomic clones also revealed enzymes involved in
degradation of aromatic compounds such as benzoate and polyhydroxyalkanoates
(Nichols & Harwood, 1995). It is not clear how are these proteins can be involved in
mediating Bcc competition in the CF lung? The primary reason of metabolizing toxic
aromatic compounds is that they are used as energy sources where the nutrients are
limited (Madison & Huisman, 1999). Thus, the presence of a competitor strain (Pa) in
nature, as well as on solid LB agar medium, or even in a biofilm in the CF lung, may
induce their expression, resulting in inhibition of Pa growth. It is also possible that the
encoded proteins have secondary functions, which result in Pa inhibition.

3.5.3 Bacterial apoptosis
The BLAST search revealed the presence of a bacterial apoptosis gene
(entericidinAB) (Bishop et al., 1998). Entericidins are produced at stationary phase,
where nutrients are limited. These proteins bind to membrane phosphospholipids, and
inhibit the cells via disruption of membrane stability (Bishop et al., 1998). No further
functional information is known about entericidin AB in Bcc.
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The gene organization of the locus is similar to that of the bacteriocins of
numerous Gram-negative bacteria, including E. coli (colicin) and P. aeruginosa (pyocin).
An immunity gene follows the toxin gene, which are transcribed and translated together
(Figure 3-9). Entericidin AB locus also has toxin/antitoxin gene pair. Entericidin A
provides immunity to the toxin entericidin B. However, no sequence similarity was
detected between entericidin AB and colicins/pyocins. Finally, there is no information
about the ability of entericidin AB to lyse strains other than the producer. Our study is the
first report suggesting that entericidin AB might be responsible for Bcc inhibitory
activity.

3.5.4 Proteins with unknown functions
BLAST searches of the remaining sequences obtained from the genomic clones
also revealed the presence of genes with unknown functions, amidohydroyse II, GGDEF
domain, and a hypothetical protein. Amidohydrolase II catalyzes the cleavage of C-N, CC, C-O, C-Cl, C-S, O-P bonds of organic substances (Aimin et al., 2007). Thus, it may be
involved in hydrolysis of vital proteins in Pa.
The GGDEF is a conserved domain, which is observed in multi-domain proteins
such as those involved in signaling pathways including cell-to-cell signaling, motility,
virulence, biofilm formation, and antibiotic production (Pei & Grishin, 2001; Tamayo et
al., 2007). Thus, GGDEF domain could be present in any protein involved in virulence
signaling pathways, and in that manner, may play a role in Bcc inhibitory activity.
In summary, genomic screens for inhibitory activity in Bcc revealed a surprising
absence of traditional bacteriocin genes. The five clones explored here possessed genes
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involved in amino acid biosynthesis, energy metabolism, degradation of aromatic
compounds, and bacterial apoptosis.
Why does Bcc, in contrast with all Gram-negative species examined to date, not
have any identifiable bacteriocin genes? One simple explanation might be genomes of
Bcc possess bacteriocins, which we were unable to identify in this study due to technical
challenges. As it was mentioned, we lost the inhibitory activity in ten Bcc and two Pa
genomic clones, which might be due to either toxicity of the cloned protein or lack of the
corresponding immunity gene in the genomic clone. Additionally, Bcc bacteriocins might
be relatively big proteins or phage tails, which might not be possible to identify with our
approach since we cloned 4-5 kb DNA sequences. Thus, cloning larger DNA inserts of
Bcc genome might allow us to identify bacteriocins of Bcc.
Another explanation is that Bcc has evolved a different solution to the challenge
of bacterial competition. One solution may be found in the fact that Burkholderia has
significantly more genes that encode proteins involved in such major metabolic pathways
as energy metabolism, transport, and binding proteins are among these categories (Figure
3-10). Bcc genomes have ability to gain additional genes via horizontal gene transfer
(Mahillon & Chandler, 1998; Tyler et al., 1996; Wood et al., 1991). For example, the
glucoamylase gene identified in the Bcc clone 4 is originally detected in Aspergillus,
which uses this enzyme to become pathogenic to plants (Mellon et al., 2007). Perhaps
these extra metabolic genes might provide a level of flexibility to Bcc, whose members
has to adapt living in different environments (soil, plant, human tissue), where the level
of bacterial competition is high.
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This study revealed that members of Bcc might be using a different strategy to
compete with Pa strains in our experimental conditions, where two species are in close
contact. The genomic clones with inhibitory activity possess genes involved in major
metabolic pathways, whose induction might provide Bcc strains a better growth
advantage in the environment where competition is high and nutrients are limited.
Revealing the exact roles of these genes is critical to our understanding the interaction
between Pa and Bcc strains in CF lungs. Therefore, future efforts will focus on cloning of
these genes identified in the genome library clones of Burkholderia multivorans
(ATCC17616) to further characterize their potential roles in Bcc inhibitory activity.
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Table 3-1 Chromosomes and genome size of members of B. cepacia complex
The number of chromosomes and the total genome size varies among strains as well as
within the same genomovar.

Genomovar

Strain ID

Genomovar I
(B. cepacia)
Genomovar II
(B. multivorans)
Genomovar III
(B. cenocepacia)
Genomovar IV
(B. stabilis)
Genomovar V
(B. vietnamiensis)
Genomovar VII
(B. ambifaria)

ATCC 25416
ATCC 17759
ATCC17616
C5274
C4455
CEP024
LMG14294
LMG7000
ATCC53617
LMG18836
ATCC17760
BcF

Size of
chromosomes
(Mb)
3.5, 3.1, 1.1
3.5, 3.3, 1.1
3.4, 2.5, 0.9
3.3, 2.4, 1.3
3.9, 3.0, 1.0
3.4, 2.7, 0.9
3.7, 2.3, 1.3
3.9, 3.3, 1.4
3.4, 3.2, 1.2, 1.1
3.0, 1.8, 1.2
3.4, 1.3
3.5, 2.6, 1.3
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Overall
genome size
(Mb)
7.7
7.9
6.8
7.0
7.9
7.0
8.2
8.6
8.9
6.0
4.7
7.4

Table 3-2 Genomic library clones of B. multivorans (ATCC17616) and Pseudomonas aeruginosa (PAO1)
Inhibitory activity has detected in five genomic clones of B. multivorans (ATCC 17616) and one genomic clone of P. aeruginosa
(PAO1). Insert DNAs were sequenced from these genomic clones, which are involved in various metabolic pathways including
degradation of aromatic hydrocarbons, sugar metabolism, amino acid biosynthesis, and apoptosis in Bcc, and pyocin S2 synthesis in
Pa.

Producer
Strain

Clone
Number
2
4

95
B. multivorans
ATCC17616

Length
of the
cloned
DNA
fragment
(nt)
714
3498

6

677

7

3956

Gene
ID

Corresponding genes in the
cloned DNA fragment

Bm1615
Bm1065

Hypothetical protein
Poly-beta-hydroxyalkanoate
depolymerase
Glucoamylase
3-carboxymuconate cyclase
Amidohydrolase 2
4-hydroxybenzoate
transporter
Aspartate-semialdehyde
dehydrogenase
3-isopropylmalate
dehydrogenase
3-isopropylmalate
dehydratase small subunit
Entericidin AB
3-isopropylmalate
dehydratase large subunit
GGDEF domain
Hypothetical protein
Pyocin S2
Pyocin immunity

Bm1066
Bm1067
Bm6110
Bm6111
Bm4756
Bm4757
Bm4758
Bm4759
Bm4760

Pseudomonas
aeruginosa
PAO1

9

37

1

4089

Bm4824
Pa1151
Pa1152
Pa1153

95

Functional
Category
Unknown function
Degradation of
aromatic compounds
Sugar metabolism
Sugar metabolism
Unknown function
Degradation of
aromatic compounds
Amino acid
biosynthesis
Amino acid
biosynthesis
Amino acid
biosynthesis
Apoptosis
Amino acid
biosynthesis
Unknown function
Bacteriocin

Figure 3-1 Genomic library construction
Genomic DNA of bacteriocin producer strain was partially digested. DNA inserts were
ligated into Bam HI digested and dephosphorylated pUC19 vector. Blue/white colony
screening was performed on E. coli recipients transformed with pUC19 clones.

96

Figure 3-2 Inhibition phenotypes of genomic clones of B. multivorans (ATCC17616)
and Pseudomonas aeruginosa (PAO1)
a-Five B. multivorans (ATCC17616) clones (clone #2-9) and one P. aeruginosa (PAO1)
clones (PAOI clone) were detected as genomic clones with inhibitory activity. These
clones showed inhibitory activity on the sensitive Pa strains; b-Bm ATCC 17616 and Pa
PAO1 producer strains were tested on corresponding sensitive Pa strains as positive
control. E. coli with puC19 was used as negative control.
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Figure 3-3 Blast result of the clone 2 of B. multivorans (ATCC17616) genome library
a. Genomic organization of the clone 2 of B. multivorans (ATCC167616). Clone 2
encoded for a hypothetical protein (Bm1615).

Bm1614

Bm1615

Bm1616

Clone2
Bm1614: hypothetical protein
Bm1615: hypothetical protein
Bm1616: YbbM seven transmembrane helix protein

b. Alignment result of clone 2 and hypothetical protein of B. multivorans (ATCC17616)

Bm1615
clone2

-----------------------------------------------------------AGCGCTGAGCCGGCGCGTGGCCGGCATCGTCCGGTGCGCGCGCAACGAGTGGGCGGCCTG 60

Bm1615
clone2

-----------------------------------------------------------CGTTCGTACGCGTGGCGCCAGGCCGTATCCGCAGCCGGAGGCCATCGATACGAGCGCCAC 120

Bm1615
clone2

-----------------------------------------------------------GCGCGCGCGCTGCGGCCTCGCTTCACGCCGTTTCGCGCCGGGTCGATCCGCTGCGCCGCT 180

Bm1615
clone2

-----------------------------------------------------------CCATGGTTCGCGCGCCGCGTGACGCGATGCCGATGTCGCGCTATGCTCGCCGGCATCGTC 240

Bm1615
clone2

----------------------ATGAAACATCGAATGCGCGTGCTGCTGTCGGCCGTCGC 38
CCTCTCCGCCAACGACCCTCCGATGAAACATCGAATGCGCGTGCTGCTGTCGGCCGTCGC 300
**************************************

Bm1615
clone2

GTTCGTCGCGGCCCATGCGCAGGCCGCCGACGACTGCAGCTTCGTGAAGAAAGTCGCGCT 98
GTTCGTCGCGGCCCATGCGCAGGCCGCCGACGACTGCAGCTTCGTGAAGAAAGTCGCGCT 360
************************************************************

Bm1615
clone2

GCCGGCGCGGCAGCAGACGATCGTCGTGTCGAGCGGCGCACTCGAGCCGTGCTCGACCGG 158
GCCGGCGCGGCAGCAGACGATCGTCGTGTCGAGCGGCGCACTCGAGCCGTGCTCGACCGG 420
************************************************************

Bm1615
clone2

CAGCTATGCGGTGCGCGTCTATTCGACCGCGAACACGGCGCCCGGCTTCGATACCGACGA 218
CAGCTATGCGGTGCGCGTCTATTCGACCGCGAACACGGCGCCCGGCTTCGATACCGACGA 480
************************************************************

Bm1615
clone2

CTACGTGAGCGGCGCGCTGCATGCGCGCGACGGCACCGTCACCGATGCGTTCGTCGCCGA 278
CTACGTGAGCGGCGCGCTGCATGCGCGCGACGGCACCGTCACCGATGCGTTCGTCGCCGA 540
************************************************************

Bm1615
clone2

TCTCGGCGCGCGTGCGCCGCATGCGCTGATCGTGACGACGCGTTCGGCCGGCAGCGGCGG 338
TCTCGGCGCGCGTGCGCCGCATGCGCTGATCGTGACGACGCGTTCGGCCGGCAGCGGCGG 600
************************************************************

Bm1615
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Bm1615
clone2

CTACGTCGGCGCCCAGGCCTATCTGACGACGTCGCGCGCTGTGACGCTCGTCGCGTCGGT 398
CTACGTCGGCGCCCAGGCCTATCTGACGACGTCGCGCGCTGTGACGCTCGTCGCGTCGGT 660
************************************************************

Bm1615
clone2

CGACGGGCTCGCGCCCGATGCCGATGTCGCGGCGGCGCTGCGTCGCGCGCTCGGCGCACG 458
CGACGGGCTCGCGCCCGATGCCGATGTCGCGGCGGCGCTGCGTCGCGCGCTCGG------ 714
******************************************************

Bm1615
clone2

TCGCGGCACGCACTGA 474
----------------

Figure 3-4 Blast result of the clone 4 of B. multivorans (ATCC17616) genome library
a. Genomic organization of the clone 4 of B. multivorans (ATCC17616). ). Clone 4
encoded partially for 3-carboxymuconate cyclase and poly-beta-hydroxyalkolonate
depolymerase proteins. This clone also encoded for glucoamylase protein (full protein).

Bm1067

Bm1066

Bm1065

Clone 4
Bm1065: Poly-beta-hydroxyalkolonate depolymerase
Bm1066: Glucoamylase
Bm1067: 3-carboxymuconate cyclase
b. Alignment result of clone 4 and Bm1065-67 of B. multivorans (ATCC17616)
Bm1067
Bm1065-67
clone4

TTACTGCACCGGTACGAGCTTGAAATCGACCGGCTTGCCGACCGCCACCTTGCGCGGATT 60
------------------------------------------------------------

Bm1065-67
clone4

CGCAGCGAGCTGCCCGCTGCCGACGTCGCGGCCGAACACGTAGAACGTGTCGCTGTCCTG 120
------------------------------------------------------------

Bm1065-67
clone4

GTTGCCGACGATCAGCCACTTGCCGGTCGGATCGATCAGGAATTCGCGCGGCGTCCGGCC 180
------------------------------------------------------------

Bm1065-67
clone4

GAGGCTCGACTGGCGGCCGACGGTCTTCAGCCGGCCGTCGGCCTGGTTCACCGCGTAGAT 240
------------------------------------------------------------

Bm1065-67
clone4

CACGATCTCGTTCGCGTCGCCGCGGTTGCTCACGTACAGGAAGCGGCCGTCCGGCGACAG 300
------------------------------------------------------------

Bm1065-67
clone4

GTGGATCGCGCCACCGCCGACCTTGCCCTTGAAGCCGGGCGCGATCATCGACACGGTCTC 360
------------------------------------------------------------
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Bm1065-67
clone4

GATCGGCGTGAGCTTCCCGTCGTGATAGCCGAACACCTCGACCGACGCGTTCAGCTCGCT 420
------------------------------------------------------------

Bm1065-67
clone4

CGTCACATACGCGAACCGGCCGTCGGCACTGAACACGAGATGGCGCGGCCCCGCGCCGGC 480
------------------------------------------------------------

Bm1065-67
clone4

CTTCACCGGCGTATAACGCGTGTCGGTCGGGCTGATCAGCCCGCGGCTGCCGTCGACCGT 540
------------------------------------------------------------

Bm1065-67
clone4

GTAGCGATAGCCGTAGATCTTGTCGAGACCGAGATCCTGCACGAACAGATAGCGGCCGTC 600
------------------------------------------------------------

Bm1065-67
clone4

GGGCGAGAACACCGTCGAGTGGACGTGCGCGTTGTCCTGTCGCCCTCTGACGGGCCCCTT 660
------------------------------------------------------------

Bm1065-67
clone4

CCCTTCGTGGTGCACGCTGAGCACGGCCGGTGCGACGCCGCCGTCGTCGCGGACCGGAAA 720
------------------------------------------------------------

Bm1065-67
clone4

CAGCGCGAAGCTGCCGCCCGGATCGGCCGCGACCGAATAGTTGGCCGTCACCAGATACTT 780
------------------------------------------------------------

Bm1065-67
clone4

GCCGTCGGGCGACAGGCTCAAATAGCAAGGATCGTTCCCCTCTGACGATACGCGATCGAT 840
------------------------------------------------------------

Bm1065-67
clone4

GAAGGTGAGCGCGCCCGTCTTCGCATCGAAACGGAACGCGCTGATGCCGCCGCGCTGCGT 900
------------------------------------------------------------

Bm1065-67
clone4

CGCGGGCCCGTTGTCGCCGGGCAGTTCGTTGACCGCATACACGACGCGACCGTCGCGGCT 960
------------------------------------------------------------

Bm1065-67
clone4

CGGCAACAGATACGACGGGTTCACCGTCTTCGCCGACGATACCGGTGCGACACTACCGGT 1020
---------------CGGGTTCACCGTCTTCGCCGACGATACCGGTGCGACACTACCGGT 45
*********************************************

Bm1065-67
clone4

GCTCGTATCGAAGCGGTAAACGTAGATGCCGTCGCTGCCGGTGTCGGTATAGGTGCCGAC 1080
GCTCGTATCGAAGCGGTAAACGTAGATGCCGTCGCTGCCGGTGTCGGTATAGGTGCCGAC 105
************************************************************

Bm1065-67
clone4

GAGCAGGTTGTAGACGCCGTCGGCCGGTGCCGGCGATTGCTGCGCGAATGCATGGGTCGC 1140
GAGCAGGTTGTAGACGCCGTCGGCCGGTGCCGGCGATTGCTGCGCGAATGCATGGGTCGC 165
************************************************************

Bm1065-67
clone4

GGACAGGGAAAGCACGAACGCGAAACCTTTCATCCAGTGAGCGAGCCTAAGCGGGAACCC 1200
GGACAGGGAAAGCACGAACGCGAAACCTTTCATCCAGTGAGCGAGCCTAAGCGGGAACCC 225
************************************************************

Bm1065-67
clone4

TCGTGTCGAAGCGTGTGCGTCACGCTCGCGTAAACGGTTGGGCATTGAATCCTCCTTGCA 1260
TCGTGTCGAAGCGTGTGCGTCACGCTCGCGTAAACGGTTGGGCATTGAATCCTCCTTGCA 285
************************************************************

Bm1065-67
clone4

TCGAGTCGCTTCAAGTGTTGAGATAGGACGAAACGCCGGCCGTCATGCGCTCCGCCTTCG 1320
TCGAGTCGCTTCAAGTGTTGAGATAGGACGAAACGCCGGCCGTCATGCGCTCCGCCTTCG 345
************************************************************

Bm1065-67
clone4

ATCGAGTATACGGGGCGCGGCGCCAGCGCGTGAAGCTGTCCGTCCGCGGCCCGCATTGTG 1380
ATCGAGTATACGGGGCGCGGCGCCAGCGCGTGAAGCTGTCCGTCCGCGGCCCGCATTGTG 405
************************************************************

Bm1065-67
clone4

AACCCGAAACAAGGATTTGCCCGCCCATGCCCGCCTTGATCGAAGACTATGCCCTCGTCG 1440
AACCCGAAACAAGGATTTGCCCGCCCATGCCCGCCTTGATCGAAGACTATGCCCTCGTCG 465
************************************************************

Bm1066

100

Bm1065-67
clone4

GCGACGGCCACACGGCCGCGCTGATCGCAAAAGACGGCTCCGTCGACTGGCTGTGCTGGC 1500
GCGACGGCCACACGGCCGCGCTGATCGCAAAAGACGGCTCCGTCGACTGGCTGTGCTGGC 525
************************************************************

Bm1065-67
clone4

CCCGGTTCGACTCGGGCGCCTGCTTCGCGGCGCTCGTCGGCACACCCGAGCACGGTCGCT 1560
CCCGGTTCGACTCGGGCGCCTGCTTCGCGGCGCTCGTCGGCACACCCGAGCACGGTCGCT 585
************************************************************

Bm1065-67
clone4

GGCTGATCGCGCCGGCCGCCGACGTCGCGATTACGCATACGACACGCCGCTATCGCGGCG 1620
GGCTGATCGCGCCGGCCGCCGACGTCGCGATTACGCATACGACACGCCGCTATCGCGGCG 645
************************************************************

Bm1065-67
clone4

ACACGCTGATTCTCGAAACCGATTACGAAAGTGCCGACGGCGCCGTGACCGTCGTCGACT 1680
ACACGCTGATTCTCGAAACCGATTACGAAAGTGCCGACGGCGCCGTGACCGTCGTCGACT 705
************************************************************

Bm1065-67
clone4

TCATGCCGCCCGGCAACGGCTGGTCCGAGCTCGTGCGCATCGTCGTCGGCCGGCGCGGCA 1740
TCATGCCGCCCGGCAACGGCTGGTCCGAGCTCGTGCGCATCGTCGTCGGCCGGCGCGGCA 765
************************************************************

Bm1065-67
clone4

CGATGAAGATGCGGATGGAACTCGTGCTGCGCTTCGACTACGGCTTCTCAATCCCGTGGG 1800
CGATGAAGATGCGGATGGAACTCGTGCTGCGCTTCGACTACGGCTTCTCAATCCCGTGGG 825
************************************************************

Bm1065-67
clone4

TCACGCAGCTCACGCGCGAAGACGGGATGAAGGCGATCGCCGGCCCCGACACGGTCGTGC 1860
TCACGCAGCTCACGCGCGAAGACGGGATGAAGGCGATCGCCGGCCCCGACACGGTCGTGC 885
************************************************************

Bm1065-67
clone4

TGCGCACGCCGGTGCCGCTCACCGGCAAGAACCTGCATACGCTCGCGGAATTCACGGTCA 1920
TGCGCACGCCGGTGCCGCTCACCGGCAAGAACCTGCATACGCTCGCGGAATTCACGGTCA 945
************************************************************

Bm1065-67
clone4

GCGCCGACGAGCGCGTGCCGTTCTCGCTCGGCTATGCGCCCTCGCATCTGCGGCTGCCGC 1980
GCGCCGACGAGCGCGTGCCGTTCTCGCTCGGCTATGCGCCCTCGCATCTGCGGCTGCCGC 1005
************************************************************

Bm1065-67
clone4

CCGCGCGCGATCCGCTGTCGATGCTCGCGCGCACCGAGAACTACTGGCTCGAATGGTCGG 2040
CCGCGCGCGATCCGCTGTCGATGCTCGCGCGCACCGAGAACTACTGGCTCGAATGGTCGG 1065
************************************************************

Bm1065-67
clone4

GCCGCTGCCAGGTGCGCGGTCGCTATGCGGCCGCCGTGCGCCGTTCGCTGATCACGCTGA 2100
GCCGCTGCCAGGTGCGCGGTCGCTATGCGGCCGCCGTGCGCCGTTCGCTGATCACGCTGA 1125
************************************************************

Bm1065-67
clone4

AGGCGCTCGCCTACGAGCCGACCGGCGGGATCGTCGCCGCGCCCACCACGTCGCTGCCCG 2160
AGGCGCTCGCCTACGAGCCGACCGGCGGGATCGTCGCCGCGCCCACCACGTCGCTGCCCG 1185
************************************************************

Bm1065-67
clone4

AGAAGATCGGTGGCAACCGCAACTGGGACTACCGCTACTGCTGGCTGCGCGACGCGACGA 2220
AGAAGATCGGTGGCAACCGCAACTGGGACTACCGCTACTGCTGGCTGCGCGACGCGACGA 1245
************************************************************

Bm1065-67
clone4

TCACGCTGCTCGCGCTGATGCGCGGCGGCTACTACGACGAAGCGCGCGCGTGGCGCACGT 2280
TCACGCTGCTCGCGCTGATGCGCGGCGGCTACTACGACGAAGCGCGCGCGTGGCGCACGT 1305
************************************************************

Bm1065-67
clone4

GGCTCGGCCGCGTGATGGCCGGATCGCCCGAGCAGATTCAGATCATGTACGGGATCGCGG 2340
GGCTCGGCCGCGTGATGGCCGGATCGCCCGAGCAGATTCAGATCATGTACGGGATCGCGG 1365
************************************************************

Bm1065-67
clone4

GCGAGCGCCGCTTGCCCGAGATGGAGCTCGACTGGCTGCCCGGCTATCAGGACTCGAAGC 2400
GCGAGCGCCGCTTGCCCGAGATGGAGCTCGACTGGCTGCCCGGCTATCAGGACTCGAAGC 1425
************************************************************

Bm1065-67
clone4

CGGTGCGCGTCGGCAACGGCGCCGCGAACCAGCTGCAGCTCGACGTGTTCGGCGAAGTGA 2460
CGGTGCGCGTCGGCAACGGCGCCGCGAACCAGCTGCAGCTCGACGTGTTCGGCGAAGTGA 1485
************************************************************

Bm1065-67
clone4

TGGCCGCGCTGCATCTCGCGCGCGTCGGTGGTCTGCAGGCCGACGATACGGTGTGGTCGG 2520
TGGCCGCGCTGCATCTCGCGCGCGTCGGTGGTCTGCAGGCCGACGATACGGTGTGGTCGG 1545
************************************************************

Bm1065-67

TGCAGTGCGCGCTGCTCGATCACCTCGAGAAGATCTGGCAGGAGCCCGACGAAGGGATCT 2580

101

clone4

TGCAGTGCGCGCTGCTCGATCACCTCGAGAAGATCTGGCAGGAGCCCGACGAAGGGATCT 1605
************************************************************

Bm1065-67
clone4

GGGAAACGCGCGGCGGCCGCCGCCATTTCACGTTCTCGAAGGTGATGGCATGGGTCGCGT 2640
GGGAAACGCGCGGCGGCCGCCGCCATTTCACGTTCTCGAAGGTGATGGCATGGGTCGCGT 1665
************************************************************

Bm1065-67
clone4

TCGACCGCGCGATCAAGTCCGCGGAGATGTTCCGCCTGCCGGGCTCGCTCGAGCGCTGGC 2700
TCGACCGCGCGATCAAGTCCGCGGAGATGTTCCGCCTGCCGGGCTCGCTCGAGCGCTGGC 1725
************************************************************

Bm1065-67
clone4

GCGCGCTGCGCGACCGCATCCATGCCGACGTCTGCGAGAAGGCGTGGCACGACGGCAAGC 2760
GCGCGCTGCGCGACCGCATCCATGCCGACGTCTGCGAGAAGGCGTGGCACGACGGCAAGC 1785
************************************************************

Bm1065-67
clone4

AGGCGTTCGCCCAAAGCTACGGCAGCGACGAGCTCGACGCGAGCGTGCTGCTGATGCCGC 2820
AGGCGTTCGCCCAAAGCTACGGCAGCGACGAGCTCGACGCGAGCGTGCTGCTGATGCCGC 1845
************************************************************

Bm1065-67
clone4

TGCTCGGCTTCCTGCCGCCCGAGGATCCGCGCATCGTCGGCACGGTGGAGGCGATCGAGC 2880
TGCTCGGCTTCCTGCCGCCCGAGGATCCGCGCATCGTCGGCACGGTGGAGGCGATCGAGC 1905
************************************************************

Bm1065-67
clone4

GGGAATTGCTGCACGACGGGCTCGTGATGCGCTACCGCACGACCGAGTACGACGACGGCC 2940
GGGAATTGCTGCACGACGGGCTCGTGATGCGCTACCGCACGACCGAGTACGACGACGGCC 1965
************************************************************

Bm1065-67
clone4

TGCCGCCCGGCGAAGGCACGTTTCTCGCGTGCAGTTTCTGGCTCGTCGACAACTACGCGC 3000
TGCCGCCCGGCGAAGGCACGTTTCTCGCGTGCAGTTTCTGGCTCGTCGACAACTACGCGC 2025
************************************************************

Bm1065-67
clone4

TGCTCGGCCGGATCGACGACGCGCATCGGCTGTTCAGTCGCCTGCTCGCGCTGTCGAACG 3060
TGCTCGGCCGGATCGACGACGCGCATCGGCTGTTCAGTCGCCTGCTCGCGCTGTCGAACG 2085
************************************************************

Bm1065-67
clone4

ACCTCGGGCTGCTCGCGGAGGAATACGACCCGGTCGAGGGGCGGCTCGTCGGCAATTTCC 3120
ACCTCGGGCTGCTCGCGGAGGAATACGACCCGGTCGAGGGGCGGCTCGTCGGCAATTTCC 2145
************************************************************

Bm1065-67
clone4

CGCAGGCGTTCTCGCACGTCGCGCTCGTGCATACCGCGATGAACCTGATGCACCACGAAG 3180
CGCAGGCGTTCTCGCACGTCGCGCTCGTGCATACCGCGATGAACCTGATGCACCACGAAG 2205
************************************************************

Bm1065-67
clone4

AGGCGATGGCGCGCGCGGCCGGACAGCCGGCGCCGGCGGCCGCGACGGGCCGCTGACCGC 3240
AGGCGATGGCGCGCGCGGCCGGACAGCCGGCGCCGGCGGCCGCGACGGGCCGCTGACCGC 2265
************************************************************

Bm1065-67
clone4

GGCCGGTGCTATGGTAAGAGAACGTCAAATCGCAAAAATTTGATGAAAAATCCGGGAAAT 3300
GGCCGGTGCTATGGTAAGAGAACGTCAAATCGCAAAAATTTGATGAAAAATCCGGGAAAT 2325
************************************************************

Bm1065-67
clone4

GTTGCATTGCACCACGGATCGTTGTCCGATATGATCGACACGACTGTCCGGCTGCACTGC 3360
GTTGCATTGCACCACGGATCGTTGTCCGATATGATCGACACGACTGTCCGGCTGCACTGC 2385
************************************************************

Bm1065-67
clone4

AACATTGCCGGACGATGACCCACACGGCACGCCGCGACGCCCCACGCCGCCCTTGCGCAC 3420
AACATTGCCGGACGATGACCCACACGGCACGCCGCGACGCCCCACGCCGCCCTTGCGCAC 2445
************************************************************

Bm1065-67
clone4

CGTCCCCCACGCGGGAGTAGTCTGCATGCTTTACCAACTGCACGAATTCCAGCGGGCGAT 3480
CGTCCCCCACGCGGGAGTAGTCTGCATGCTTTACCAACTGCACGAATTCCAGCGGGCGAT 2505
************************************************************

Bm1065-67
clone4

GCTGAGCCCGCTCACGGCCTGGGCCCAGGCCGCGTCGAAGTCCTTCGCCAATCCGTCGAG 3540
GCTGAGCCCGCTCACGGCCTGGGCCCAGGCCGCGTCGAAGTCCTTCGCCAATCCGTCGAG 2565
************************************************************

Bm1065-67
clone4

CCCGTTTTCGCTGATCCCCGGCGCGCCGCGCATGGCGGCTGCGTACGAGCTGCTGTACCG 3600
CCCGTTTTCGCTGATCCCCGGCGCGCCGCGCATGGCGGCTGCGTACGAGCTGCTGTACCG 2625
************************************************************

Bm1065

102

Bm1065-67
clone4

GCTCGGCAAGGATTACGAGAAGCCGGAGTTCAACATTCATCAGATCGTCAAGGACGGCCA 3660
GCTCGGCAAGGATTACGAGAAGCCGGAGTTCAACATTCATCAGATCGTCAAGGACGGCCA 2685
************************************************************

Bm1065-67
clone4

CAACATTCCGATCGTCGAGCAGACGATCGTCGAAAAGCCGTTCTGCCGGCTGCTGCGCTT 3720
CAACATTCCGATCGTCGAGCAGACGATCGTCGAAAAGCCGTTCTGCCGGCTGCTGCGCTT 2745
************************************************************

Bm1065-67
clone4

CAAGCGCTATTCGGACGATGCCGATGCGGTCACGCAGCTGAAGGACGAACCGGTCGTGCT 3780
CAAGCGCTATTCGGACGATGCCGATGCGGTCACGCAGCTGAAGGACGAACCGGTCGTGCT 2805
************************************************************

Bm1065-67
clone4

GGTCTGCGCGCCGCTGTCGGGCCACCACTCGACGCTGCTGCGCGACACCGTGCGCACGCT 3840
GGTCTGCGCGCCGCTGTCGGGCCACCACTCGACGCTGCTGCGCGACACCGTGCGCACGCT 2865
************************************************************

Bm1065-67
clone4

GCTGCAGGATCACAAGGTCTACATCACCGACTGGATCGACGCGCGGATGGTGCCGGTCGA 3900
GCTGCAGGATCACAAGGTCTACATCACCGACTGGATCGACGCGCGGATGGTGCCGGTCGA 2925
************************************************************

Bm1065-67
clone4

GGTCGGCCCGTTCCATCTGCACGACTACGTCGAGTACATCCAGGAATTCATCCGCCACAT 3960
GGTCGGCCCGTTCCATCTGCACGACTACGTCGAGTACATCCAGGAATTCATCCGCCACAT 2985
************************************************************

Bm1065-67
clone4

CGGTGCGCGCAATCTGCACGTCGTATCGGTGTGTCAGCCGACGGTGCCCGTGCTCGCGGC 4020
CGGTGCGCGCAATCTGCACGTCGTATCGGTGTGTCAGCCGACGGTGCCCGTGCTCGCGGC 3045
************************************************************

Bm1065-67
clone4

GATCTCGCTGATGGCGAGCCGCGGCGAGGACACGCCGCTCACGATGACGATGATGGGCGG 4080
GATCTCGCTGATGGCGAGCCGCGGCGAGGACACGCCGCTCACGATGACGATGATGGGCGG 3105
************************************************************

Bm1065-67
clone4

CCCGATCGACGCGCGCCGCAGCCCGACTTCGGTGAACTCGCTCGCGACGCAGCATTCGCT 4140
CCCGATCGACGCGCGCCGCAGCCCGACTTCGGTGAACTCGCTCGCGACGCAGCATTCGCT 3165
************************************************************

Bm1065-67
clone4

CGCGTGGTTCGAGAACAACGTGATCCACACGGTGCCGGCGAACTATCCGGGCGAAGGCCG 4200
CGCGTGGTTCGAGAACAACGTGATCCACACGGTGCCGGCGAACTATCCGGGCGAAGGCCG 3225
************************************************************

Bm1065-67
clone4

TCAGGTGTATCCGGGCTTCCTGCAGCACACGGGCTTCGTCGCGATGAATCCGGAGCGCCA 4260
TCAGGTGTATCCGGGCTTCCTGCAGCACACGGGCTTCGTCGCGATGAATCCGGAGCGCCA 3285
************************************************************

Bm1065-67
clone4

CGCGCAATCGCACTGGGACTTCTATCAGAGCCTGCTGCGGGGCGACGAGGAAGACGCCGA 4320
CGCGCAATCGCACTGGGACTTCTATCAGAGCCTGCTGCGGGGCGACGAGGAAGACGCCGA 3345
************************************************************

Bm1065-67
clone4

AGCGCACCGCCGCTTCTATGACGAATACAACGCGGTGCTCGACATGGCCGCCGAGTACTA 4380
AGCGCACCGCCGCTTCTATGACGAATACAACGCGGTGCTCGACATGGCCGCCGAGTACTA 3405
************************************************************

Bm1065-67
clone4

CCTCGAGACGATCCGCGTCGTGTTCCAGGAATTCCGCCTCGCGGAAGGCACGTGGGACGT 4440
CCTCGAGACGATCCGCGTCGTGTTCCAGGAATTCCGCCTCGCGGAAGGCACGTGGGACGT 3465
************************************************************

Bm1065-67
clone4

CAACGGCGAACGCGTACGCCCGCAGGACATCAAGCGCACCGCACTGATGACGATCGAAGG 4500
CAACGGCGAACGCGTACGCCCGCAGGACATCAA--------------------------- 3498
*********************************

Bm1065-67
clone4

CGAGCTCGACGACATCTCGGGCAGCGGCCAGACGCACGTCGCGCACGAGCTGTGCACGGG 4560
------------------------------------------------------------

Bm1065-67
clone4

CATTCCGCAGGATCAGCGCCGCAGCTTGACCGCCGAGAAGTGCGGCCATTACGGGATCTT 4620
------------------------------------------------------------

Bm1065-67
clone4

CTCCGGCCGCCGCTGGCGCACGATCATCTACCCGCAACTGCGCGACTTCATCCGCGAGCA 4680
------------------------------------------------------------
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Bm1065-67
clone4

TGCGCCGGAGCCGAAGAACGGCAGCGCGAAGGATCGCCCGGACGCAACGGCCGGCACGTC 4740
------------------------------------------------------------

Bm1065-67
clone4

CGACACGCCGGCCGCATCGGCGCCCGCGCTCGCGGCCGTCCCGGCCGGCCAGGCCCAGCG 4800
------------------------------------------------------------

Bm1065-67
clone4

CGAAACCGCGAAGGCCCCGGCCACGCTCGCGAAACGCGCGCGCGCGAAATCGTCGGGCAC 4860
------------------------------------------------------------

Bm1065-67
clone4

GCTGTCGCCGAAGGCCGCACCGGCCGCCAAGCGCGCGAGCGGCACACGCGCGAAGCCGGT 4920
------------------------------------------------------------

Bm1065-67
clone4

TCGCGCACGCAAGGCCGCCTGA 4942
----------------------

Figure 3-5 Blast result of clone 6 of B. multivorans (ATCC17616) genome library
a. Genome organization of clone 6 of B. multivorans (ATCC17616). Clone 6 encoded for
amidohydrolase II and 4-hydroxybenzoate transporter proteins. Both proteins were
encoded partially.

Bm6110

Bm6111

Clone 6

Bm6110: amidohydrolase II
Bm6111:4-hydroxybenzoate transporter

b. Alignment result of clone 6 and Bm6110-11 of B. multivorans (ATCC17616)
Bm6110
Bm6110-11
clone6

ATGGCGAAGCGAAGCGCGGGTCGCCGCCAAGGAGACAGGAGAAACAGGATGGCAAGTGGA 60
------------------------------------------------------------

Bm6110-11
clone6

AAGACAATCGACATCAAGTCGTTCATCGACGACCGGCCGGTGTCGCGCTACCAGTGGCTG 120
------------------------------------------------------------

Bm6110-11
clone6

CTGGTCGCGCTGTGCTGCCTCGTCGTGATCGCGGACGGGATGGACGTCGCGATCATGGGG 180
------------------------------------------------------------

Bm6110-11
clone6

TTCGTCGCACCGTCGGTGATTCGCGACTGGGCGATCTCGCGGCCGGAATTCGGGCTCGTG 240
------------------------------------------------------------

Bm6110-11
clone6

ATGAGCGCGGCGCCGATCGGTCTCGTGATCGGTGCGCTCGTCGCCGGCCCGAGCGCGGAC 300
------------------------------------------------------------

Bm6110-11
clone6

CGGTTCGGGCGCAAGCGCGTGCTGATCGCGTCGGTGTTGCTGTTCGGCCTCTTCACGATC 360
------------------------------------------------------------
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Bm6110-11
clone6

GCGACCGCGTATGCGGGCTCGCCGGTTCAGATGGCCGTGCTGCGGCTGCTGACCGGCATC 420
------------------------------------------------------------

Bm6110-11
clone6

GGGCTCGGCGCCGCGATGCCGAACACGACGACGCTGCTGTCGGAGTATGCGCCGCAGCGG 480
------------------------------------------------------------

Bm6110-11
clone6

ATGCGGTCGCTGATGATCACGATCATGTTCACGGGCTTCAATCTCGGCTCGGCGCTGATC 540
------------------------------------------------------------

Bm6110-11
clone6

GGCTTCGTCGCCGGCTGGCTGATTCCGCTGCACGGCTGGCGCGCGGTACTGCTGTTCGGC 600
------------------------------------------------------------

Bm6110-11
clone6

GGCGCGCTGCCGCTGCTGCTGATTCCGCTGCAACTGTGGCTGCTGCCCGAATCGGCGCGG 660
------------------------------------------------------------

Bm6110-11
clone6

CTGCTCGCCGTGCGCGGTGCGCCGTCGCAGCGCATCGGCGCGTTGCTGAACCGCGTCTGC 720
------------------------------------------------------------

Bm6110-11
clone6

GGCGCACGCTTCGACGGCAACGAGACGTTCGTCTCGAACGAGCCGCCGCTGCCGACGCGC 780
------------------------------------------------------------

Bm6110-11
clone6

AAGCCGATCGGCGTGCTGTTCTCGCAAGGCTACGGCGTCGTCACGGTATCGCTGTGGATC 840
------------------------------------------------------------

Bm6110-11
clone6

ACGTACTTCATGGGACTGCTCGTGATCTATCTGCTGACCGGCTGGCTGCCGACACTGATC 900
------------------------------------------------------------

Bm6110-11
clone6

AAGGATGCGGGCCTGTCGGTCAGCACGGCCGCGAACGTGACGGCGATGTTCCAGATCGGC 960
------------------------------------------------------------

Bm6110-11
clone6

GGGACGATCGGCGCGATCGGCGTCGGCTGGCTGATGGACAAGGTGCGGCCGGCACCCGTG 1020
------------------------------------------------------------

Bm6110-11
clone6

ATCGGCGCCGCGTATCTCGGTGGCGCACTGTGCGTGGCCGTGCTCGCGTGGGCCGGCGCG 1080
------------------------------------------------------------

Bm6110-11
clone6

CTGTCGTCGTCGCTCGCGCTGCTCGTGTTTGCGGCGGGCTTCTGCATGAGCGGCGCGCAG 1140
------------------------------------------------------------

Bm6110-11
clone6

ACGGGGCTGAACGCGTATGCGCCGGGCCGCTACCCGACCGTTGCGCGCGCAACCGGCGTG 1200
------------------------------------------------------------

Bm6110-11
clone6

AGCTGGATGCTCGGCATGGGCCGCTTCGGCAGCATTTTCGGTTCGGCGATCGGCGGCGCG 1260
-------------GCATGGGCCGCTTCGGCAGCATTTTCGGTTCGGCGATCGGCGGCGCG 47
***********************************************

Bm6110-11
clone6

CTGCTCGGCCTCGGCTGGAAGTTCGACGCGATCCTGTCGATGCTCGCGGTGCCCGCCACG 1320
CTGCTCGGCCTCGGCTGGAAGTTCGACGCGATCCTGTCGATGCTCGCGGTGCCCGCCACG 107
************************************************************

Bm6110-11
clone6

CTTGCGGCGATCGCGATCGTCACGACGCAGCGCGCGGCCGCACCTGAACCGAAGGAAATG 1380
CTTGCGGCGATCGCGATCGTCACGACGCAGCGCGCGGCCGCACCTGAACCGAAGGAAATG 167
************************************************************

Bm6110-11
clone6

GAAAAACCGGCGCACTGACCGCGTCCGCACGATCGCGCGTCCCGCGTCGCGGGCCGGCGC 1440
GAAAAACCGGCGCACTGACCGCGTCCGCACGATCGCGCGTCCCGCGTCGCGGGCCGGCGC 227
************************************************************

105

Bm6111
Bm6110-11
clone6

CGACACGCGGCATCCGGCCAGCACGTCATGCAACAGGAGTGTCAATGATCATCGATATTC 1500
CGACACGCGGCATCCGGCCAGCACGTCATGCAACAGGAGTGTCAATGATCATCGATATTC 287
************************************************************

Bm6110-11
clone6

ACGGCCACTACACGACCGCGCCGAAGGCGCTCGAGACCTGGCGCAATCGCCAGATCGCGG 1560
ACGGCCACTACACGACCGCGCCGAAGGCGCTCGAGACCTGGCGCAATCGCCAGATCGCGG 347
************************************************************

Bm6110-11
clone6

CGATTCACAGCCCGTCCGAGCGGCCGAAGGTCGCGGAACTGAACATCAGCGACGACGAGC 1620
CGATTCACAGCCCGTCCGAGCGGCCGAAGGTCGCGGAACTGAACATCAGCGACGACGAGC 407
************************************************************

Bm6110-11
clone6

TGCGCGAGTCGCTCGAGCCCAACCAGTTGCGGCTGATGCGCGAGCGCGGCCTCGACCTGA 1680
TGCGCGAGTCGCTCGAGCCCAACCAGTTGCGGCTGATGCGCGAGCGCGGCCTCGACCTGA 467
************************************************************

Bm6110-11
clone6

CGATCTTCAGCCCGCGCGCGAGCTTCATGGCACACCACATCGGCGACTTCGACGTGTCGA 1740
CGATCTTCAGCCCGCGCGCGAGCTTCATGGCACACCACATCGGCGACTTCGACGTGTCGA 527
************************************************************

Bm6110-11
clone6

GCACCTGGGCCGCCGTCTGCAACGAGCTGTGCTACCGCGTGCACCGGCTGTACCCCGACC 1800
GCACCTGGGCCGCCGTCTGCAACGAGCTGTGCTACCGCGTGCACCGGCTGTACCCCGACC 587
************************************************************

Bm6110-11
clone6

GCTTCGTGCCGGCGGCGATGCTGCCGCAAAGCCCCGGCGTCGACGTGGCGACCTGCATTC 1860
GCTTCGTGCCGGCGGCGATGCTGCCGCAAAGCCCCGGCGTCGACGTGGCGACCTGCATTC 647
************************************************************

Bm6110-11
clone6

CGGAGCTCGTCCGGTGCGTCGAGGCGTACGGCAACGTCGCGGTCAACCTGAATCCCGATC 1920
CGGAGCTCGTCCGGTGCGTCGAGGCGTACG------------------------------ 677
******************************

Bm6110-11
clone6

CGTCCGGCGGCCACTGGACGAGCCCGCCGCTGTCGGACCGCTACTGGTATCCGCTGTACG 1980
------------------------------------------------------------

Bm6110-11
clone6

AGAAGATGGTCGAGTACGACATCCCCGCGATGATCCACGTGAGCACGAGCTGCAACGCGT 2040
------------------------------------------------------------

Bm6110-11
clone6

GCTTTCACACGACCGGCGCGCACTACCTGAACGCGGACACGACCGCGTTCATGCAGTGCC 2100
------------------------------------------------------------

Bm6110-11
clone6

TGACGTCGGATCTGTTCAAGGACTTTCCGACGCTGCGCTTCGTGATTCCGCACGGCGGCG 2160
------------------------------------------------------------

Bm6110-11
clone6

GCGCGGTGCCGTATCACTGGGGGCGCTTTCGCGGCCTCGCACAGGAACTGAAGAAGCCGC 2220
------------------------------------------------------------

Bm6110-11
clone6

TCCTGACCGAGCATCTACTCAACAACGTGTTCTTCGATACGTGCGTCTATCACCAGCCGG 2280
------------------------------------------------------------

Bm6110-11
clone6

GCATCGATCTGCTGACCGGCGTGATTCCGGTCGACAACATCCTGTTCGCGAGCGAGATGA 2340
------------------------------------------------------------

Bm6110-11
clone6

TCGGCGCGGTTCGCGGCATCGATCCGGAGACCGGGCACTACTACGACGACACGAAGCGCT 2400
------------------------------------------------------------

Bm6110-11
clone6

ACATCGAAGCGTCGGCACTCGACGCGCAGGCGCGCTACAAGATTTACGAAGGCAATGCGC 2460
------------------------------------------------------------

Bm6110-11
clone6

GCCGCGTGTATCCGCGCCTGGATGCGCAACTGAAAGCGAAGGGGAAGTGA 2510
--------------------------------------------------
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Figure 3-6 Blast result of clone 7 of B. multivorans (ATCC17616) genome library
a. Genomic organization of clone 7 of B. multivorans (ATCC17616). Clone 7 encoded
for 3-isopropylmalate dehydratase large subunit, entericidinAB, 3-isopropylmalate
dehydratase small subunit, 3-isopropylmalate dehydrogenase, and Aspartatesemialdehyde dehydrogenase proteins. 3-isopropylmalate dehydratase large subunit (Bm
4760) was partially encoded. Remainder genes were encoded as full length proteins.

Bm4760

Bm4759 Bm4758 Bm4757 Bm4756

Clone 7
Bm4756: Aspartate-semialdehyde dehydrogenase
Bm4757: 3-isopropylmalate dehydrogenase
Bm4758: 3-isopropylmalate dehydratase small subunit
Bm4759: entericidinAB
Bm4760: 3-isopropylmalate dehydratase large subunit
b. Alignment of genome 7 and Bm4756-60 of B. multivorans (ATCC17616)
Bm4760
Bm4756-60
clone7

TTGATGTCACAACGACCCCGCATACCCATGGCACAGACTCTCTACGACAAACTGTGGAAT 60
------------------------------------------------------------

Bm4756-60
clone7

TCCCACGTCGTCCACACCGAGGAAGACGGCACGGCATTGCTGTATATCGACCGTCAACTG 120
------------------------------------------------------------

Bm4756-60
clone7

CTGCATGAAGTCACGAGCCCGCAGGCGTTCGAAGGGCTGAAGATCGCGCAGCGTCCGGTG 180
------------------------------------------------------------

Bm4756-60
clone7

TGGCGCATCAGCGCGAACCTGGCCGTGTCCGACCACAACGTGCCGACCACCGATCGCAGC 240
------------------------------------------------------------

Bm4756-60
clone7

CACGGCATCGCCGATCCCGTCTCGAAGCTGCAGGTCGACACGCTCGACGCGAACTGCGAT 300
------------------------------------------------------------

Bm4756-60
clone7

GCGTTCGGCATCACGCAGTTCAAGATGAACGACGTGCGTCAGGGCATCGTGCACATCATC 360
------------------------------------------------------------

Bm4756-60
clone7

GGGCCGGAGCAGGGCGCGACGCTGCCGGGCATGACGATCGTGTGCGGCGATTCGCACACG 420
------------------------------------------------------------
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Bm4756-60
clone7

TCGACGCACGGCGCGTTCGGCGCGCTCGCGCACGGCATCGGCACGTCGGAAGTCGAGCAC 480
------------------------------------------------------------

Bm4756-60
clone7

GTGCTCGCGACGCAGACTTTGCTGCAGAAGAAGAGCAAGAACATGCTCGTGAAGGTCGAG 540
------------------------------------------------------------

Bm4756-60
clone7

GGCGCACTGCCGCGCGGCTGCACCGCGAAGGACATCGTGCTCGCGATCATCGGCAAGATC 600
------------------------------------------------------------

Bm4756-60
clone7

GGCACGGCAGGCGGCACCGGCTATGCGATCGAATTCGGCGGCTCGACGATCCGCGCGCTG 660
------------------------------------------------------------

Bm4756-60
clone7

TCGATGGAAGGCCGGATGACGGTCTGCAACATGGCGATCGAAGCCGGCGCGCGCGCGGGC 720
------------------------------------------------------------

Bm4756-60
clone7

ATGGTCGCCGTCGACGACACGACGATCGACTACCTGAAGGGCCGTCCGTTCGTGCCGACC 780
------------------------------------------------------------

Bm4756-60
clone7

GGCGCGGAATGGGATCAGGCCGTCGAATACTGGCGCCAGTTCAAGTCGGACGAAGGCGCG 840
------------------------------------------------------------

Bm4756-60
clone7

CATTTCGATCGCGTCGTCGAGCTGAACGCGGCCGAGATCGTCCCGCAGGTCACGTGGGGC 900
------------------------------------------------------------

Bm4756-60
clone7

ACGTCGCCGGAAATGGTCACGTCGATCGACGGTCGCGTGCCCGATCCCGAGCGCGAGAAG 960
------------------------------------------------------------

Bm4756-60
clone7

GATCCGGTCAAGCGCGACGCGATGGAGCGCGCGCTCGCCTACATGGCGCTCGAACCGAAC 1020
------------------------------------------------------------

Bm4756-60
clone7

ACGCCGATCGAATCGATCAAGGTCGACAAGATCTTCATCGGCTCGTGCACGAACGCGCGC 1080
------ATCGAATCGATCAAGGTCGACAAGATCTTCATCGGCTCGTGCACGAACGCGCGC 54
******************************************************

Bm4756-60
clone7

ATCGAGGACATCCGCGCGGCCGCGTACGTCGTGAAGAAGCTGAACCGTCGCGTCGCCTCG 1140
ATCGAGGACATCCGCGCGGCCGCGTACGTCGTGAAGAAGCTGAACCGTCGCGTCGCCTCG 114
************************************************************

Bm4756-60
clone7

AACGTGCGGCTCGCGATGGTCGTGCCGGGCTCGGGCCTCGTGAAGGCGCAGGCCGAGCGC 1200
AACGTGCGGCTCGCGATGGTCGTGCCGGGCTCGGGCCTCGTGAAGGCGCAGGCCGAGCGC 174
************************************************************

Bm4756-60
clone7

GAAGGCCTCGACAAGGTGTTTACCGATGCGGGCTTCGAATGGCGCGAGCCGGGCTGCTCG 1260
GAAGGCCTCGACAAGGTGTTTACCGATGCGGGCTTCGAATGGCGCGAGCCGGGCTGCTCG 234
************************************************************

Bm4756-60
clone7

ATGTGTCTCGCGATGAACGCCGACCGCCTCGAGCCGGGCGAGCGCTGCGCCTCGACGTCG 1320
ATGTGTCTCGCGATGAACGCCGACCGCCTCGAGCCGGGCGAGCGCTGCGCCTCGACGTCG 294
************************************************************

Bm4756-60
clone7

AACCGCAACTTCGAAGGCCGGCAGGGCGCGGGCGGCCGCACGCACCTCGTCAGCCCCGCG 1380
AACCGCAACTTCGAAGGCCGGCAGGGCGCGGGCGGCCGCACGCACCTCGTCAGCCCCGCG 354
************************************************************

Bm4756-60
clone7

ATGGCGGCGGCCGCGGCGATCGAAGGCCATTTCGTCGACATTCGCAAGCTGGGGTAACGC 1440
ATGGCGGCGGCCGCGGCGATCGAAGGCCATTTCGTCGACATTCGCAAGCTGGGGTAACGC 414
************************************************************

Bm4756-60
clone7

GTGACGGCATCGAAATGGGTTGCGCGGCTCGCCGCCGCGCTGGCGCTCGCGGGGCTCGGC 1500
GTGACGGCATCGAAATGGGTTGCGCGGCTCGCCGCCGCGCTGGCGCTCGCGGGGCTCGGC 474
************************************************************

Bm4759

108

Bm4756-60
clone7

TTCGGTCTCGCGGGCTGCAACACCGTCCGAGGCTTCGGCGAGGACGTCAATGCCGCCGGC 1560
TTCGGTCTCGCGGGCTGCAACACCGTCCGAGGCTTCGGCGAGGACGTCAATGCCGCCGGC 534
************************************************************

Bm4756-60
clone7

AGCGCACTGAAGCGCGCCGCGGAGTGACCCCGCCGAGAATTTGTCGATGTGCGCCGGCCG 1620
AGCGCACTGAAGCGCGCCGCGGAGTGACCCCGCCGAGAATTTGTCGATGTGCGCCGGCCG 594
************************************************************

Bm4756-60
clone7

CGGGCCGGCCCTTCAACCGGATAGACGGATCATGGAAAAATTCACAGTGCATACCGGCGT 1680
CGGGCCGGCCCTTCAACCGGATAGACGGATCATGGAAAAATTCACAGTGCATACCGGCGT 654
************************************************************

Bm4756-60
clone7

CGTGGCGCCGCTCGATCGCGAGAACGTCGACACCGACGCGATCATTCCGAAGCAGTTCCT 1740
CGTGGCGCCGCTCGATCGCGAGAACGTCGACACCGACGCGATCATTCCGAAGCAGTTCCT 714
************************************************************

Bm4756-60
clone7

GAAGTCGATCAAGCGCACGGGCTTCGGTCCGAACGCGTTCGACGAGTGGCGCTATCTTGA 1800
GAAGTCGATCAAGCGCACGGGCTTCGGTCCGAACGCGTTCGACGAGTGGCGCTATCTTGA 774
************************************************************

Bm4756-60
clone7

CCACGGCGAGCCGGGCCAGGACAACTCGAAGCGTCCGCTGAACCCGGACTTCGTGCTGAA 1860
CCACGGCGAGCCGGGCCAGGACAACTCGAAGCGTCCGCTGAACCCGGACTTCGTGCTGAA 834
************************************************************

Bm4756-60
clone7

CCAGCCGCGCTACCAGGGCGCGTCGATTCTCGTCACGCGCAAGAACTTCGGCTGCGGCAG 1920
CCAGCCGCGCTACCAGGGCGCGTCGATTCTCGTCACGCGCAAGAACTTCGGCTGCGGCAG 894
************************************************************

Bm4756-60
clone7

CTCGCGCGAGCACGCGCCGTGGGCGCTGCAGCAGTACGGCTTCCGCGCGATCATCGCGCC 1980
CTCGCGCGAGCACGCGCCGTGGGCGCTGCAGCAGTACGGCTTCCGCGCGATCATCGCGCC 954
************************************************************

Bm4756-60
clone7

GAGCTTCGCGGACATCTTCTTCAACAACTGCTTCAAGAACGGGCTGCTGCCGATCGTGCT 2040
GAGCTTCGCGGACATCTTCTTCAACAACTGCTTCAAGAACGGGCTGCTGCCGATCGTGCT 1014
************************************************************

Bm4756-60
clone7

GACCGAGCAGCAGGTCGATCATCTGATCAACGAGACGGTCGCGTTCAACGGCTATCAGCT 2100
GACCGAGCAGCAGGTCGATCATCTGATCAACGAGACGGTCGCGTTCAACGGCTATCAGCT 1074
************************************************************

Bm4756-60
clone7

GACGATCGATCTCGAGGCGCAGGTCGTGCGCACGCCGGACGGCCGCGACTATCCGTTCGA 2160
GACGATCGATCTCGAGGCGCAGGTCGTGCGCACGCCGGACGGCCGCGACTATCCGTTCGA 1134
************************************************************

Bm4756-60
clone7

GATCACCGCGTTCCGCAAGTACTGCCTGCTGAACGGTTTCGACGACATCGGCCTCACGCT 2220
GATCACCGCGTTCCGCAAGTACTGCCTGCTGAACGGTTTCGACGACATCGGCCTCACGCT 1194
************************************************************

Bm4756-60
clone7

GCGTCACGCGGACAAGATCCGCCAGTTCGAAGCGGAGCGGCTCGCGAAGCAGCCGTGGCT 2280
GCGTCACGCGGACAAGATCCGCCAGTTCGAAGCGGAGCGGCTCGCGAAGCAGCCGTGGCT 1254
************************************************************

Bm4756-60
clone7

CAACAACAAGCTGGTCGGCTGAAGTCGTCCTTCGGGCGGGCGCGCACGCCGCGCGTTCGC 2340
CAACAACAAGCTGGTCGGCTGAAGTCGTCCTTCGGGCGGGCGCGCACGCCGCGCGTTCGC 1314
************************************************************

Bm4756-60
clone7

CCGCCAGCCATCACCCCTTATTCAGTCAGGAACAACGCATGAAGATTGCAGTGCTGCCGG 2400
CCGCCAGCCATCACCCCTTATTCAGTCAGGAACAACGCATGAAGATTGCAGTGCTGCCGG 1374
************************************************************

Bm4756-60
clone7

GCGACGGCATCGGTCCGGAAATCGTCACCGAAGCGGTGAAGGTGCTGAACGCACTCGACG 2460
GCGACGGCATCGGTCCGGAAATCGTCACCGAAGCGGTGAAGGTGCTGAACGCACTCGACG 1434
************************************************************

Bm4756-60
clone7

AGAAGTTCGAACTCGAACAGGCGCCGGTCGGCGGCGCGGGCTACGAGGCGAGGGGTCATC 2520
AGAAGTTCGAACTCGAACAGGCGCCGGTCGGCGGCGCGGGCTACGAGGCGAGGGGTCATC 1494
************************************************************

Bm4756-60
clone7

CGCTGCCGGACGCGACGCTGAAGCTCGCGAAGGAAGCCGACGCGATCCTGTTCGGCGCGG 2580
CGCTGCCGGACGCGACGCTGAAGCTCGCGAAGGAAGCCGACGCGATCCTGTTCGGCGCGG 1554

Bm4758

Bm4757
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************************************************************
Bm4756-60
clone7

TCGGCGACTGGAAGTACGACTCGCTCGAACGCGCGCTGCGTCCCGAGCAGGCGATTCTCG 2640
TCGGCGACTGGAAGTACGACTCGCTCGAACGCGCGCTGCGTCCCGAGCAGGCGATTCTCG 1614
************************************************************

Bm4756-60
clone7

GCCTGCGCAAGCACCTCGAGCTGTTCGCGAACTTCCGTCCGGCGATCTGCTATCCGCAGC 2700
GCCTGCGCAAGCACCTCGAGCTGTTCGCGAACTTCCGTCCGGCGATCTGCTATCCGCAGC 1674
************************************************************

Bm4756-60
clone7

TCGTCGACGCGTCGCCGCTGAAGCCCGAACTTGTCGCGGGCCTCGACATCCTGATCGTGC 2760
TCGTCGACGCGTCGCCGCTGAAGCCCGAACTTGTCGCGGGCCTCGACATCCTGATCGTGC 1734
************************************************************

Bm4756-60
clone7

GCGAACTGAACGGCGACATCTATTTCGGCCAGCCGCGCGGCGTGCGCGCGGCACCGGACG 2820
GCGAACTGAACGGCGACATCTATTTCGGCCAGCCGCGCGGCGTGCGCGCGGCACCGGACG 1794
************************************************************

Bm4756-60
clone7

GCCCGTTCGCGGGCGAGCGCGAAGGCTTCGACACGATGCGCTATTCGGAGCCGGAAGTGC 2880
GCCCGTTCGCGGGCGAGCGCGAAGGCTTCGACACGATGCGCTATTCGGAGCCGGAAGTGC 1854
************************************************************

Bm4756-60
clone7

GCCGCATCGCGCACGTCGCGTTCCAGGCCGCGCAAAAGCGCGCGAAGAAGCTGCTGTCGG 2940
GCCGCATCGCGCACGTCGCGTTCCAGGCCGCGCAAAAGCGCGCGAAGAAGCTGCTGTCGG 1914
************************************************************

Bm4756-60
clone7

TCGACAAGTCGAACGTGCTCGAGACGTCGCAGTTCTGGCGCGACATCATGATCGACGTGT 3000
TCGACAAGTCGAACGTGCTCGAGACGTCGCAGTTCTGGCGCGACATCATGATCGACGTGT 1974
************************************************************

Bm4756-60
clone7

CGAAGGAATATGCGGACGTCGAGCTGTCGCACATGTACGTCGACAACGCGGCGATGCAGC 3060
CGAAGGAATATGCGGACGTCGAGCTGTCGCACATGTACGTCGACAACGCGGCGATGCAGC 2034
************************************************************

Bm4756-60
clone7

TCGCGAAGGCGCCGAAGCAGTTCGACGTGATCGTGACCGGCAACATGTTCGGCGACATCC 3120
TCGCGAAGGCGCCGAAGCAGTTCGACGTGATCGTGACCGGCAACATGTTCGGCGACATCC 2094
************************************************************

Bm4756-60
clone7

TGTCGGATGAAGCGTCGATGCTGACGGGCTCGATCGGCATGCTGCCGTCGGCGTCGCTCG 3180
TGTCGGATGAAGCGTCGATGCTGACGGGCTCGATCGGCATGCTGCCGTCGGCGTCGCTCG 2154
************************************************************

Bm4756-60
clone7

ACAAGAACAACAAGGGTCTGTACGAGCCGTCGCACGGTTCGGCGCCGGACATCGCGGGCA 3240
ACAAGAACAACAAGGGTCTGTACGAGCCGTCGCACGGTTCGGCGCCGGACATCGCGGGCA 2214
************************************************************

Bm4756-60
clone7

AGGGCATCGCGAATCCGCTCGCGACGATCCTGTCGGCCGCGATGCTGCTGCGCTATTCGC 3300
AGGGCATCGCGAATCCGCTCGCGACGATCCTGTCGGCCGCGATGCTGCTGCGCTATTCGC 2274
************************************************************

Bm4756-60
clone7

TGAACCGCGCCGAGCAGGCCGACCGCATCGAGCGCGCGGTCAAAACGGTGCTCGAACAGG 3360
TGAACCGCGCCGAGCAGGCCGACCGCATCGAGCGCGCGGTCAAAACGGTGCTCGAACAGG 2334
************************************************************

Bm4756-60
clone7

GCTACCGCACCGGCGACATCGCGACGCCGGGCTGCAAGCAGGTCGGCACGGCGGCGATGG 3420
GCTACCGCACCGGCGACATCGCGACGCCGGGCTGCAAGCAGGTCGGCACGGCGGCGATGG 2394
************************************************************

Bm4756-60
clone7

GCGACGCGGTGGTCGCGGCCCTCTGAGCGGCCGGCAAGTCACGATGTAGAAAGGGCGCGA 3480
GCGACGCGGTGGTCGCGGCCCTCTGAGCGGCCGGCAAGTCACGATGTAGAAAGGGCGCGA 2454
************************************************************

Bm4756-60
clone7

ACGGGCCGAAAAAAATCGGTTCGTTCGCGCACGGTTGGCCGTTGTGCGGGCAACCGGCTT 3540
ACGGGCCGAAAAAAATCGGTTCGTTCGCGCACGGTTGGCCGTTGTGCGGGCAACCGGCTT 2514
************************************************************

Bm4756-60
clone7

TGTGTAGACTCGAACGATGGCGCTGATTTCCCTGATCTCCCCGGTCCTGAAACTCCACGG 3600
TGTGTAGACTCGAACGATGGCGCTGATTTCCCTGATCTCCCCGGTCCTGAAACTCCACGG 2574
************************************************************

Bm4756-60
clone7

CAACACTGCCCGTGCGGGTGCGCGCGCCATCGTCATCACGAAAACCATTACCACGAAAAC 3660
CAACACTGCCCGTGCGGGTGCGCGCGCCATCGTCATCACGAAAACCATTACCACGAAAAC 2634
************************************************************
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Bm4756-60
clone7

GATCATTAAACGCTGATCGTCCGTCGTGCCCGCCTGTTTCCCCGCGCGGTCACGCCGGGG 3720
GATCATTAAACGCTGATCGTCCGTCGTGCCCGCCTGTTTCCCCGCGCGGTCACGCCGGGG 2694
************************************************************

Bm4756-60
clone7

GCGGAAATGGCGGGGAAGCTCCATTCAAAGGGTTAGTCATGAACGTAGGTCTCGTAGGTT 3780
GCGGAAATGGCGGGGAAGCTCCATTCAAAGGGTTAGTCATGAACGTAGGTCTCGTAGGTT 2754
************************************************************

Bm4756-60
clone7

GGCGCGGCATGGTCGGCAGCGTCCTGATGCAGCGCATGCAGGAAGAGGGCGATTTCGACC 3840
GGCGCGGCATGGTCGGCAGCGTCCTGATGCAGCGCATGCAGGAAGAGGGCGATTTCGACC 2814
************************************************************

Bm4756-60
clone7

TGATCGAACCGGTGTTTTTCAGCACCAGCAACTCGGGCGGCAAGGCACCGTCGTTCGCGA 3900
TGATCGAACCGGTGTTTTTCAGCACCAGCAACTCGGGCGGCAAGGCACCGTCGTTCGCGA 2874
************************************************************

Bm4756-60
clone7

AAAACGAGACCACGCTGAAGGACGCGACCAACGTCGACGAACTGAAGAAGTGCGACGTCA 3960
AAAACGAGACCACGCTGAAGGACGCGACCAACGTCGACGAACTGAAGAAGTGCGACGTCA 2934
************************************************************

Bm4756-60
clone7

TCATCACGTGCCAGGGCGGCGACTACACGAATGACGTGTTCCCGAAGCTGCGCGCGGCGG 4020
TCATCACGTGCCAGGGCGGCGACTACACGAATGACGTGTTCCCGAAGCTGCGCGCGGCGG 2994
************************************************************

Bm4756-60
clone7

GCTGGAACGGCTACTGGATCGATGCGGCGTCGTCGCTGCGGATGAAGGACGACGCGGTCA 4080
GCTGGAACGGCTACTGGATCGATGCGGCGTCGTCGCTGCGGATGAAGGACGACGCGGTCA 3054
************************************************************

Bm4756-60
clone7

TCATCCTCGATCCGGTGAACCTCGACGTCATCAAGGACGCGCTCGTCAAGGGCACGAAGA 4140
TCATCCTCGATCCGGTGAACCTCGACGTCATCAAGGACGCGCTCGTCAAGGGCACGAAGA 3114
************************************************************

Bm4756-60
clone7

ACTTCATCGGCGGCAACTGCACGGTCAGCCTGATGCTGATGGCGCTCGGCGGCCTGTTCC 4200
ACTTCATCGGCGGCAACTGCACGGTCAGCCTGATGCTGATGGCGCTCGGCGGCCTGTTCC 3174
************************************************************

Bm4756-60
clone7

GCGAGAACCTCGTCGATTGGATGACGGCCATGACGTATCAGGCCGCGTCGGGCGCGGGCG 4260
GCGAGAACCTCGTCGATTGGATGACGGCCATGACGTATCAGGCCGCGTCGGGCGCGGGCG 3234
************************************************************

Bm4756-60
clone7

CGCAGAACATGCGTGAACTGCTGTCGCAGATGGGCGCGCTGCACGGCGCGGTGCAGCAGC 4320
CGCAGAACATGCGTGAACTGCTGTCGCAGATGGGCGCGCTGCACGGCGCGGTGCAGCAGC 3294
************************************************************

Bm4756-60
clone7

AGCTCGCCGATCCGGCATCGGCGATCCTCGACATCGATCGCCGCGTGCTCGCCACGATGA 4380
AGCTCGCCGATCCGGCATCGGCGATCCTCGACATCGATCGCCGCGTGCTCGCCACGATGA 3354
************************************************************

Bm4756-60
clone7

ACAGCGACGCGATGCCGACGAGCCACTTCGGCGTGCCGCTCGCGGGTTCGCTGATTCCGT 4440
ACAGCGACGCGATGCCGACGAGCCACTTCGGCGTGCCGCTCGCGGGTTCGCTGATTCCGT 3414
************************************************************

Bm4756-60
clone7

GGATCGACAAGGATCTCGGCAACGGCATGTCGAAGGAAGAATGGAAGGGCGGCGCGGAAA 4500
GGATCGACAAGGATCTCGGCAACGGCATGTCGAAGGAAGAATGGAAGGGCGGCGCGGAAA 3474
************************************************************

Bm4756-60
clone7

CGAACAAGATCCTCGGCAAGCCGGCGATGGGCGAGCCGGGCTCGATTCCGGTCGACGGGC 4560
CGAACAAGATCCTCGGCAAGCCGGCGATGGGCGAGCCGGGCTCGATTCCGGTCGACGGGC 3534
************************************************************

Bm4756-60
clone7

TGTGCGTGCGGATCGGCGCGATGCGCTGCCACTCGCAGGCGCTGACGATCAAGCTGAAGA 4620
TGTGCGTGCGGATCGGCGCGATGCGCTGCCACTCGCAGGCGCTGACGATCAAGCTGAAGA 3594
************************************************************

Bm4756-60
clone7

AGGACGTGCCGCTCGACGAGATCAACGGCATTCTCGCGTCGGCGAACGACTGGGTGAAGG 4680
AGGACGTGCCGCTCGACGAGATCAACGGCATTCTCGCGTCGGCGAACGACTGGGTGAAGG 3654
************************************************************

Bm4756-60
clone7

TCGTGCCGAACGAGCGCGAAGCGTCGATGCACGATCTGTCGCCGGCGAAGGTCACCGGCA 4740
TCGTGCCGAACGAGCGCGAAGCGTCGATGCACGATCTGTCGCCGGCGAAGGTCACCGGCA 3714

Bm4756

111

************************************************************
Bm4756-60
clone7

CGCTGACCGTGCCGGTCGGCCGTCTGCGCAAGCTCGCGATGGGCGGCGAATACCTGTCGG 4800
CGCTGACCGTGCCGGTCGGCCGTCTGCGCAAGCTCGCGATGGGCGGCGAATACCTGTCGG 3774
************************************************************

Bm4756-60
clone7

CGTTCACGGTCGGCGATCAGTTGCTGTGGGGCGCGGCCGAACCGCTGCGCCGCATGCTGC 4860
CGTTCACGGTCGGCGATCAGTTGCTGTGGGGCGCGGCCGAACCGCTGCGCCGCATGCTGC 3834
************************************************************

Bm4756-60
clone7

GCATCCTGCTCGACAAGTAAGACGAGATCGTGCGCCGGCCGGCGCGCGATGCGACGCGCC 4920
GCATCCTGCTCGACAAGTAAGACGAGATCGTGCGCCGGCCGGCGCGCGATGCGACGCGCC 3894
************************************************************

Bm4756-60
clone7

TGCGTGCCTTCAACGGGCCGCAGGCGCGTTTTTTATCGGCGGGCGCCGTGCCCGAAAATG 4980
TGCGTGCCTTCAACGGGCCGCAGGCGCGTTTTTTATCGGCGGGCGCCGTGCCCGAAAATG 3954
************************************************************

Bm4756-60
clone7

CGAAAGCCCCGAACCGCTCTCCCGGCCGGGGCTTTCTTGCATCGATTCCTTTGGCACGAG 5040
CG---------------------------------------------------------- 3956
**

Bm4756-60
clone7

GAAGTGACGCGGTGCGCAGTATAAGGCACGCAGTTCGTCGGCATGTTGATAATGTTGTCG 5100
------------------------------------------------------------

Bm4756-60
clone7

GGATTTACATCAATTGATGCTCGATTTTTGATAATGGCGTGCGGCGCGCAGTGGCGCATC 5160
------------------------------------------------------------

Bm4756-60
clone7

GGCCGCCTGTTCCCGGTCGTGCGCGCCGACGAATTCGGCCCGAACGCGATCGTGTGA 5217
---------------------------------------------------------

Figure 3-7 Blast result of clone 9 of B. multivorans (ATCC17616) genome library
a. Genome organization of the clone 9 of B. multivorans (ATCC17616). Clone 9
encoded for GGDEF domain. This domain was partially encoded in clone 9.

Bm4824

Clone 9
Bm4824: GGDEF domain
b. Alignment of the clone 9 and Bm4824 of B. multivorans (ATCC17616)
Bm4824
Bm4825
clone9

TCAGGCAGTCGGTTCGAATTGCGTGACCTTGTTGCGTCCCGTCGCTTTCGCGTAATAAAG 60
------------------------------------------------------------

Bm4825
clone9

CGCTTCGTCGGCAGCCTTGATGATCGCGTCGGGTTCGACGTCCTGATCGGGTTTCCAGCT 120
------------------------------------------------------------

Bm4825
clone9

CGCCAGGCCGATGCTCGCGGTGACGCGTCCGAACTCGCTGCCGACATGTTCGAGGCCCAG 180
------------------------------------------------------------
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Bm4825
clone9

TTCGTTGATGGCGATTCGAATCCGTTCGGCAATCTGCGCGGCGCCGTTCTCCGCCGTATC 240
------------------------------------------------------------

Bm4825
clone9

GGGCAGCAGGACGACGAACTCTTCGCCGCCGTAGCGGGCGGCGACGTCCGCGGGCCGGCG 300
------------------------------------------------------------

Bm4825
clone9

AATGTTCTCGCCGATGCAGCGCGCGACTGCAGCGAGCGCATCGTCGCCGGCCTGGTGGCC 360
------------------------------------------------------------

Bm4825
clone9

GTACGTGTCGTTGTAGGCCTTGAAGCGGTCGACGTCGACGAAGAGCAGCGAAAAGACCGA 420
------------------------------------------------------------

Bm4825
clone9

TCGTACCCGGCGTGCGCGGCGCCATTCGCGATCGAGCACCTCGCCGAAGCTGCGGCGGTT 480
------------------------------------------------------------

Bm4825
clone9

GTTGAGACCCGTGAGCCCGTCGGTGCGCGCGAGCAGGATCAGCTCCGATTCGGCTCGCAT 540
------------------------------------------------------------

Bm4825
clone9

CCTGCGCCGCAGCTGCGCGCCGAGCAATACGGAAAGCGCGATGAACGCAGCGCCGAACGT 600
------------------------------------------------------------

Bm4825
clone9

CGCGACCAGCGCGCCGATCGTGAGCGCGCGACGATGCCATGCCGCGTAAATGTCCTGTTC 660
------------------------------------------------------------

Bm4825
clone9

GGCCTCGGCGACCATCACGATCAGCGGCAGGTTCGGCAATGTCTTGAAGTAATACAGGCG 720
------------------------------------------------------------

Bm4825
clone9

GCGCACGCCGTCGATGGACGAGCGCTCGAGAAACGATCCTTCGGGTGCGCTTCGGAAGCG 780
------------------------------------TCCTTCGGGTGCGCTTCGGAAGCG 24
************************

Bm4825
clone9

GCGGAACGTGGCGGCCTGGCTGATGTCCCGTCCGATCGTATTCAGTTCGTAAGGCTGGCG 840
GCGGAACGTGGCG----------------------------------------------- 37
*************

Bm4825
clone9

CATGACCATGATGCCGTCGGTGCCGATTAGGGAAATCGATCCGTGCGGACCCAGCGCGAG 900
------------------------------------------------------------

Bm4825
clone9

CCCGGCAAACAACTTGTGGAAATACTCGAGGTTGATCGCGATCAATGCGACGCCGGCGAA 960
------------------------------------------------------------

Bm4825
clone9

GGAGCCGTCCGGGTTCGATACGCGACGGCTCAGCACGATGCTTGGTGTACCGCCGCGCAG 1020
------------------------------------------------------------

Bm4825
clone9

CCGCGATGCGAATGGATCGCTGACGTAAAGCCCCACGTCGGCGCGGTCGCGGTGGACGGT 1080
------------------------------------------------------------

Bm4825
clone9

GAAATATTTTCGATCCGAGAAGTTGCCGTGGCGCGGCACGTCGTTCTGCGAGTCGAGAAC 1140
------------------------------------------------------------

Bm4825
clone9

GATATTGCCCTGCGCATCGAGGACCAGCATCGAACCGAGATATTGGGCCGTCATCGCGTG 1200
------------------------------------------------------------

Bm4825
clone9

GTCGAACAGCACGCCGCGGCGAAGCGCAGGCGAAGCCGCCATCACGTCGGGGCGCCGAAG 1260
------------------------------------------------------------
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Bm4825
clone9

CCCCTGGAGGACGGCCTCGAGCGACAGATTGTAGAGCTCGACGTTGCGCGTGATGTCGCG 1320
------------------------------------------------------------

Bm4825
clone9

TTCGGCGACGAGCGCGAGATTGCGCGAAGTCTCGCGTGCCCTGTCCAGCGCATCCTGGCG 1380
------------------------------------------------------------

Bm4825
clone9

GCTCTGGAACAGCTGGAGTATGCAAAGCCCCATCAGCGCGAAGGCGATCAGCACGCCGAC 1440
------------------------------------------------------------

Bm4825
clone9

GGCGACGACATAGTGAGGCGCTGATGAGCGCGGTTGCAT 1479
---------------------------------------

Figure 3-8 Blast result of clone 1 of Pa PAO1 genome library
a. Genome organization of clone 1 of Pa PAO1. Clone 1 of Pa PAO1 encoded pyocin S2
(Pa 1152) and corresponding immunity protein (Pa1153).

Pa1150

Pa1152

Pa1153

Clone 1
b. Alignment of clone 1 and Pa PAO1
Pa1151-53
clone1

GTCGGGCGAGCCGGCGGAGAGCGGCGGGGCGTCTAGGGTGCGGGTTGCGGGGAGGCTGGC 60
GTCGGGCGAGCCGGCGGAGAGCGGCGGGGCGTCTAGGGTGCGGGTTGCGGGGAGGCTGGC 60
************************************************************

Pa1151-53
clone1

GGGGAGCGGAAGAGAGCTTTTATGGGATTTATGAACTGGATTGCAGAGTGGTGAATGTGC 120
GGGGAGCGGAAGAGAGCTTTTATGGGATTTATGAACTGGATTGCAGAGTGGTGAATGTGC 120
************************************************************

Pa1151-53
clone1

GAACGGGAGGCTTGCCGATCGGAGGATACATGCAGGGCGTCCATCTCGGCCTGGTGGTGG 180
GAACGGGAGGCTTGCCGATCGGAGGATACATGCAGGGCGTCCATCTCGGCCTGGTGGTGG 180
************************************************************

Pa1151-53
clone1

CAGCCCGGCCTGTCAGTCAGGCGCCTGACAACCCAGGGTGACGACCAGTTCGCGGCCGCT 240
CAGCCCGGCCTGTCAGTCAGGCGCCTGACAACCCAGGGTGACGACCAGTTCGCGGCCGCT 240
************************************************************

Pa1151-53
clone1

CGCCAAGCCGGCGTCCGCCGCCAGGGTCAGCGTGCGCGGCGTGTCCTGGCGACTATCGAG 300
CGCCAAGCCGGCGTCCGCCGCCAGGGTCAGCGTGCGCGGCGTGTCCTGGCGACTATCGAG 300
************************************************************

Pa1151-53
clone1

CAGCCCCTCTTGAAGCACGAGGCTGTCGGCGCTGGCGCCCCTGGCCAGCAGCCGATATCG 360
CAGCCCCTCTTGAAGCACGAGGCTGTCGGCGCTGGCGCCCCTGGCCAGCAGCCGATATCG 360
************************************************************

Pa1151-53
clone1

CACCAGCGCCGAGGTACAGCCGCATTCGCCGGTGGAGCGCCGGGCCTCAAGGGTGAGTGG 420
CACCAGCGCCGAGGTACAGCCGCATTCGCCGGTGGAGCGCCGGGCCTCAAGGGTGAGTGG 420
************************************************************

Pa1151-53
clone1

CAGGTGCAACTGGCCCTCCGCCGTGTGCGGTGCACCGAGCCGGGCGGCGAGGCAGGCGGA 480
CAGGTGCAACTGGCCCTCCGCCGTGTGCGGTGCACCGAGCCGGGCGGCGAGGCAGGCGGA 480

Pa1151

114

************************************************************
Pa1151-53
clone1

GAGAGCATTGTCGAGCGTCGCCGCGTCGGCGAATGGGGCGGCCAGGCAGAGGCTGCCGAG 540
GAGAGCATTGTCGAGCGTCGCCGCGTCGGCGAATGGGGCGGCCAGGCAGAGGCTGCCGAG 540
************************************************************

Pa1151-53
clone1

GAGCAGGGCTTTGGCGTCCATGTCGGGGTTCCGCTGGGGATGGAAAGGGCATCATGGCTG 600
GAGCAGGGCTTTGGCGTCCATGTCGGGGTTCCGCTGGGGATGGAAAGGGCATCATGGCTG 600
************************************************************

Pa1151-53
clone1

AGGTGGCTTTATTCGTCGAACAATGGCTGGCCCTGCCGGTATATCGGCCAGGACTTCAAG 660
AGGTGGCTTTATTCGTCGAACAATGGCTGGCCCTGCCGGTATATCGGCCAGGACTTCAAG 660
************************************************************

Pa1151-53
clone1

CGTTGCGGAAACGGCCTGACCAGCTGCAGCGGCTTGCAATCAAAAACGCTGGGCTCGCAA 720
CGTTGCGGAAACGGCCTGACCAGCTGCAGCGGCTTGCAATCAAAAACGCTGGGCTCGCAA 720
************************************************************

Pa1151-53
clone1

TCAGCGTGGCTTTGTCCGGAAGCTCGCGAAGGGGCGGCATGGATGAATTTTGAAAGTGGG 780
TCAGCGTGGCTTTGTCCGGAAGCTCGCGAAGGGGCGGCATGGATGAATTTTGAAAGTGGG 780
************************************************************

Pa1151-53
clone1

AGTTCGTTAATGAACCGAAGGTATGCGGCTTCCGTGACTGGCCGGGGTAGATGAGGTGTG 840
AGTTCGTTAATGAACCGAAGGTATGCGGCTTCCGTGACTGGCCGGGGTAGATGAGGTGTG 840
************************************************************

Pa1151-53
clone1

CGTTAAGGAAATGACCGTTTGACGCAGGCGCGATTATAAGAGGCGAGAGAGCGCACCTTC 900
CGTTAAGGAAATGACCGTTTGACGCAGGCGCGATTATAAGAGGCGAGAGAGCGCACCTTC 900
************************************************************

Pa1151-53
clone1

TGGATCATCTAAACACGGGATATTGAAGTTGATTGCAGTGTATTGCCGATGCATTGGGGC 960
TGGATCATCTAAACACGGGATATTGAAGTTGATTGCAGTGTATTGCCGATGCATTGGGGC 960
************************************************************

Pa1151-53
clone1

TTATTGACTGGGAGAGGGTTCTCTAGGTGGGAGTCGCTCAATACATTACACTTTCAAATT 1020
TTATTGACTGGGAGAGGGTTCTCTAGGTGGGAGTCGCTCAATACATTACACTTTCAAATT 1020
************************************************************

Pa1151-53
clone1

AATGTAGGGGCGATCTATGGCTGTCAATGATTACGAACCTGGTTCGATGGTTATTACACA 1080
AATGTAGGGGCGATCTATGGCTGTCAATGATTACGAACCTGGTTCGATGGTTATTACACA 1080
************************************************************

Pa1151-53
clone1

TGTGCAGGGTGGTGGGCGTGACATAATCCAGTATATTCCTGCTCGATCAAGCTACGGTAC 1140
TGTGCAGGGTGGTGGGCGTGACATAATCCAGTATATTCCTGCTCGATCAAGCTACGGTAC 1140
************************************************************

Pa1151-53
clone1

TCCACCATTTGTCCCACCAGGACCAAGTCCGTATGTCGGTACTGGAATGCAGGAGTACAG 1200
TCCACCATTTGTCCCACCAGGACCAAGTCCGTATGTCGGTACTGGAATGCAGGAGTACAG 1200
************************************************************

Pa1151-53
clone1

GAAGCTAAGAAGTACGCTTGATAAGTCCCATTCAGAACTCAAGAAAAACCTGAAAAATGA 1260
GAAGCTAAGAAGTACGCTTGATAAGTCCCATTCAGAACTCAAGAAAAACCTGAAAAATGA 1260
************************************************************

Pa1151-53
clone1

AACCCTGAAGGAGGTTGATGAACTCAAGAGTGAAGCGGGGTTGCCAGGTAAAGCGGTCAG 1320
AACCCTGAAGGAGGTTGATGAACTCAAGAGTGAAGCGGGGTTGCCAGGTAAAGCGGTCAG 1320
************************************************************

Pa1151-53
clone1

TGCCAATGACATCCGCGATGAAAAGAGTATCGTTGATGCACTCATGGATGCCAAAGCAAA 1380
TGCCAATGACATCCGCGATGAAAAGAGTATCGTTGATGCACTCATGGATGCCAAAGCAAA 1380
************************************************************

Pa1151-53
clone1

ATCGCTAAAGGCCATTGAGGATCGCCCGGCCAATCTTTATACGGCTTCAGACTTTCCTCA 1440
ATCGCTAAAGGCCATTGAGGATCGCCCGGCCAATCTTTATACGGCTTCAGACTTTCCTCA 1440
************************************************************

Pa1151-53
clone1

GAAGTCAGAGTCGATGTACCAGAGTCAGTTGCTGGCCAGCCGAAAATTCTATGGAGAGTT 1500
GAAGTCAGAGTCGATGTACCAGAGTCAGTTGCTGGCCAGCCGAAAATTCTATGGAGAGTT 1500
************************************************************

Pa1151-53
clone1

CCTGGATCGCCATATGAGTGAGCTGGCCAAAGCGTACAGCGCCGATATCTATAAGGCGCA 1560
CCTGGATCGCCATATGAGTGAGCTGGCCAAAGCGTACAGCGCCGATATCTATAAGGCGCA 1560

Pa1152

115

************************************************************
Pa1151-53
clone1

AATCGCTATCTTGAAACAAACGTCTCAAGAGCTGGAGAATAAAGCCCGGTCATTGGAAGC 1620
AATCGCTATCTTGAAACAAACGTCTCAAGAGCTGGAGAATAAAGCCCGGTCATTGGAAGC 1620
************************************************************

Pa1151-53
clone1

AGAAGCCCAGCGAGCCGCTGCTGAGGTGGAGGCGGACTACAAGGCCAGGAAGGCAAATGT 1680
AGAAGCCCAGCGAGCCGCTGCTGAGGTGGAGGCGGACTACAAGGCCAGGAAGGCAAATGT 1680
************************************************************

Pa1151-53
clone1

CGAGAAAAAAGTGCAGTCCGAGCTTGACCAGGCTGGGAATGCTTTGCCTCAACTGACCAA 1740
CGAGAAAAAAGTGCAGTCCGAGCTTGACCAGGCTGGGAATGCTTTGCCTCAACTGACCAA 1740
************************************************************

Pa1151-53
clone1

TCCAACGCCAGAGCAGTGGCTTGAACGCGCTACTCAACTGGTTACGCAGGCGATCGCCAA 1800
TCCAACGCCAGAGCAGTGGCTTGAACGCGCTACTCAACTGGTTACGCAGGCGATCGCCAA 1800
************************************************************

Pa1151-53
clone1

TAAGAAGAAATTGCAGACTGCAAACAATGCCTTGATTGCCAAGGCACCCAATGCACTGGA 1860
TAAGAAGAAATTGCAGACTGCAAACAATGCCTTGATTGCCAAGGCACCCAATGCACTGGA 1860
************************************************************

Pa1151-53
clone1

GAAACAAAAGGCAACCTACAACGCCGATCTCCTAGTGGATGAAATCGCCAGCCTGCAAGC 1920
GAAACAAAAGGCAACCTACAACGCCGATCTCCTAGTGGATGAAATCGCCAGCCTGCAAGC 1920
************************************************************

Pa1151-53
clone1

ACGGCTGGACAAGCTGAACGCCGAAACGGCAAGGCGCAAGGAAATCGCTCGTCAAGCGGC 1980
ACGGCTGGACAAGCTGAACGCCGAAACGGCAAGGCGCAAGGAAATCGCTCGTCAAGCGGC 1980
************************************************************

Pa1151-53
clone1

GATCAGGGCTGCCAATACTTATGCCATGCCAGCCAATGGCAGCGTTGTCGCCACCGCCGC 2040
GATCAGGGCTGCCAATACTTATGCCATGCCAGCCAATGGCAGCGTTGTCGCCACCGCCGC 2040
************************************************************

Pa1151-53
clone1

AGGCCGGGGTCTGATCCAGGTCGCACAAGGCGCCGCATCCCTTGCTCAAGCGATCTCCGA 2100
AGGCCGGGGTCTGATCCAGGTCGCACAAGGCGCCGCATCCCTTGCTCAAGCGATCTCCGA 2100
************************************************************

Pa1151-53
clone1

TGCGATTGCCGTCCTGGGCCGGGTCCTGGCTTCAGCACCCTCGGTGATGGCCGTGGGCTT 2160
TGCGATTGCCGTCCTGGGCCGGGTCCTGGCTTCAGCACCCTCGGTGATGGCCGTGGGCTT 2160
************************************************************

Pa1151-53
clone1

TGCCAGTCTGACCTACTCCTCCCGGACTGCCGAGCAATGGCAGGACCAAACGCCCGATAG 2220
TGCCAGTCTGACCTACTCCTCCCGGACTGCCGAGCAATGGCAGGACCAAACGCCCGATAG 2220
************************************************************

Pa1151-53
clone1

CGTTCGTTACGCCCTGGGCATGGATGCCGCTAAATTGGGGCTTCCCCCAAGCGTAAACCT 2280
CGTTCGTTACGCCCTGGGCATGGATGCCGCTAAATTGGGGCTTCCCCCAAGCGTAAACCT 2280
************************************************************

Pa1151-53
clone1

GAACGCGGTTGCAAAAGCCAGCGGTACCGTCGATCTGCCGATGCGCCTGACCAACGAGGC 2340
GAACGCGGTTGCAAAAGCCAGCGGTACCGTCGATCTGCCGATGCGCCTGACCAACGAGGC 2340
************************************************************

Pa1151-53
clone1

ACGAGGCAACACGACGACCCTTTCGGTGGTCAGCACCGATGGTGTGAGCGTTCCGAAAGC 2400
ACGAGGCAACACGACGACCCTTTCGGTGGTCAGCACCGATGGTGTGAGCGTTCCGAAAGC 2400
************************************************************

Pa1151-53
clone1

CGTTCCGGTCCGGATGGCGGCCTACAATGCCACGACAGGCCTGTACGAGGTTACGGTTCC 2460
CGTTCCGGTCCGGATGGCGGCCTACAATGCCACGACAGGCCTGTACGAGGTTACGGTTCC 2460
************************************************************

Pa1151-53
clone1

CTCTACGACCGCAGAAGCGCCGCCACTGATCCTGACCTGGACGCCGGCGAGTCCTCCAGG 2520
CTCTACGACCGCAGAAGCGCCGCCACTGATCCTGACCTGGACGCCGGCGAGTCCTCCAGG 2520
************************************************************

Pa1151-53
clone1

AAACCAGAACCCTTCGAGTACCACTCCGGTCGTACCGAAGCCGGTGCCGGTATATGAGGG 2580
AAACCAGAACCCTTCGAGTACCACTCCGGTCGTACCGAAGCCGGTGCCGGTATATGAGGG 2580
************************************************************

Pa1151-53
clone1

AGCGACCCTTACACCGGTGAAGGCTACCCCGGAAACCTATCCTGGGGTGATTACACTACC 2640
AGCGACCCTTACACCGGTGAAGGCTACCCCGGAAACCTATCCTGGGGTGATTACACTACC 2640
************************************************************
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Pa1151-53
clone1

GGAAGACCTGATCATCGGCTTCCCGGCCGACTCGGGGATCAAGCCGATCTATGTGATGTT 2700
GGAAGACCTGATCATCGGCTTCCCGGCCGACTCGGGGATCAAGCCGATCTATGTGATGTT 2700
************************************************************

Pa1151-53
clone1

CAGGGATCCGCGGGATGTACCTGGTGCTGCGACTGGCAAGGGACAGCCCGTCAGCGGTAA 2760
CAGGGATCCGCGGGATGTACCTGGTGCTGCGACTGGCAAGGGACAGCCCGTCAGCGGTAA 2760
************************************************************

Pa1151-53
clone1

TTGGCTCGGCGCCGCCTCTCAAGGTGAGGGGGCTCCAATTCCAAGCCAGATTGCGGATAA 2820
TTGGCTCGGCGCCGCCTCTCAAGGTGAGGGGGCTCCAATTCCAAGCCAGATTGCGGATAA 2820
************************************************************

Pa1151-53
clone1

ACTACGTGGTAAGACATTCAAAAACTGGCGGGACTTTCGGGAACAATTCTGGATAGCTGT 2880
ACTACGTGGTAAGACATTCAAAAACTGGCGGGACTTTCGGGAACAATTCTGGATAGCTGT 2880
************************************************************

Pa1151-53
clone1

GGCTAATGATCCTGAGTTAAGTAAACAGTTTAATCCTGGTAGTTTAGCTGTAATGAGAGA 2940
GGCTAATGATCCTGAGTTAAGTAAACAGTTTAATCCTGGTAGTTTAGCTGTAATGAGAGA 2940
************************************************************

Pa1151-53
clone1

TGGAGGGGCTCCTTATGTCAGAGAGTCAGAACAGGCTGGCGGGAGAATAAAGATCGAAAT 3000
TGGAGGGGCTCCTTATGTCAGAGAGTCAGAACAGGCTGGCGGGAGAATAAAGATCGAAAT 3000
************************************************************

Pa1151-53
clone1

CCACCACAAGGTTCGAATAGCAGATGGAGGCGGCGTTTACAATATGGGGAACCTTGTTGC 3060
CCACCACAAGGTTCGAATAGCAGATGGAGGCGGCGTTTACAATATGGGGAACCTTGTTGC 3060
************************************************************

Pa1151-53
clone1

AGTAACGCCAAAACGTCATATAGAAATCCACAAGGGAGGGAAGTGATATGAAGTCCAAGA 3120
AGTAACGCCAAAACGTCATATAGAAATCCACAAGGGAGGGAAGTGATATGAAGTCCAAGA 3120
************************************************************

Pa1151-53
clone1

TTTCCGAATATACGGAAAAAGAGTTTCTTGAGTTTGTTAAAGACATATACACAAACAATA 3180
TTTCCGAATATACGGAAAAAGAGTTTCTTGAGTTTGTTAAAGACATATACACAAACAATA 3180
************************************************************

Pa1151-53
clone1

AGAAAAAGTTCCCTACCGAGGAGTCTCATATTCAAGCCGTGCTTGAATTTAAAAAACTAA 3240
AGAAAAAGTTCCCTACCGAGGAGTCTCATATTCAAGCCGTGCTTGAATTTAAAAAACTAA 3240
************************************************************

Pa1151-53
clone1

CGGAACACCCAAGCGGCTCAGACCTTCTTTACTACCCCAACGAAAATAGAGAAGATAGCC 3300
CGGAACACCCAAGCGGCTCAGACCTTCTTTACTACCCCAACGAAAATAGAGAAGATAGCC 3300
************************************************************

Pa1151-53
clone1

CAGCTGGAGTTGTAAAGGAAGTTAAAGAATGGCGTGCTTCCAAGGGGCTTCCTGGCTTTA 3360
CAGCTGGAGTTGTAAAGGAAGTTAAAGAATGGCGTGCTTCCAAGGGGCTTCCTGGCTTTA 3360
************************************************************

Pa1151-53
clone1

AGGCCGGTTAGTTGGCCATCAACAAGCCCCGTTTCGACGGGGCTTGTTCCATGTTGACGC 3420
AGGCCGGTTAGTTGGCCATCAACAAGCCCCGTTTCGACGGGGCTTGTTCCATGTTGACGC 3420
************************************************************

Pa1151-53
clone1

TGCTCTATCTTGACAGTCTGTCCTGAATATTCTTGAAGACAATCACATTATGAGCCGCAA 3480
TGCTCTATCTTGACAGTCTGTCCTGAATATTCTTGAAGACAATCACATTATGAGCCGCAA 3480
************************************************************

Pa1151-53
clone1

CCACCGCAAAACACCCATCGTCGGGCGCACGAGCTGCCGTAGCGAGCTCTCCACGTTGGC 3540
CCACCGCAAAACACCCATCGTCGGGCGCACGAGCTGCCGTAGCGAGCTCTCCACGTTGGC 3540
************************************************************

Pa1151-53
clone1

CAGCAGCCCACCTCTCCCTACTGGAAAGTCAGGTCAATAACACTGGTGCCACGTAAGGAT 3600
CAGCAGCCCACCTCTCCCTACTGGAAAGTCAGGTCAATAACACTGGTGCCACGTAAGGAT 3600
************************************************************

Pa1151-53
clone1

GGGCGTTCCTACTGGCCCCTCATACGCCAGGCTGCTACGGCAGATCGTGTCGCTAACCTC 3660
GGGCGTTCCTACTGGCCCCTCATACGCCAGGCTGCTACGGCAGATCGTGTCGCTAACCTC 3660
************************************************************

Pa1151-53
clone1

AAGGGACACAACCCGCAAGAACGCGCGTCCCTGAAAAAGCGCCTGCTGCGCAAGTGGATG 3720
AAGGGACACAACCCGCAAGAACGCGCGTCCCTGAAAAAGCGCCTGCTGCGCAAGTGGATG 3720
************************************************************

Pa1153
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Pa1151-53
clone1

AGCAAATGAGTACATCCAACATCCAGGCATTGGCCAGCACTGGGCACAGCTCGCCAAAGA 3780
AGCAAATGAGTACATCCAACATCCAGGCATTGGCCAGCACTGGGCACAGCTCGCCAAAGA 3780
************************************************************

Pa1151-53
clone1

AGCGGGATTCCGAGCCGACTATGACAGCACATCAACGCCAGAAACACATCTGGTCTGCGG 3840
AGCGGGATTCCGAGCCGACTATGACAGCACATCAACGCCAGAAACACATCTGGTCTGCGG 3840
************************************************************

Pa1151-53
clone1

AGTAACCCAAGAGTGGATTCGAGAACACATCGTTGCCACCAACGATATGCGCCCGTTCGG 3900
AGTAACCCAAGAGTGGATTCGAGAACACATCGTTGCCACCAACGATATGCGCCCGTTCGG 3900
************************************************************

Pa1151-53
clone1

CCTGCTGCATTTGCTGGGTCAGGCATCGTTGCGCATGGAGCAAGCGTTGTGGCCGGAAGA 3960
CCTGCTGCATTTGCTGGGTCAGGCATCGTTGCGCATGGAGCAAGCGTTGTGGCCGGAAGA 3960
************************************************************

Pa1151-53
clone1

TTACGAGCGGATGACTCGTAAGGTCAAGGGAGTCCAGCGGGAAGCTGAAGGCGACAACGC 4020
TTACGAGCGGATGACTCGTAAGGTCAAGGGAGTCCAGCGGGAAGCTGAAGGCGACAACGC 4020
************************************************************

Pa1151-53
clone1

CAAATCATACATTTATGAAGAAGTCATGCAGATAAGGCAGGAGCGCTTCGATAAAGCACG 4080
CAAATCATACATTTATGAAGAAGTCATGCAGATAAGGCAGGAGCGCTTCGATAAAGCACG 4080
************************************************************

Pa1151-53
clone1

ACATAATTTGCAAGGGGTTTGTCATAGGTATCAAGGATCCAATTATTTTACAGTCCTGAT 4140
ACA--------------------------------------------------------- 4083
***

Pa1151-53
clone1

ACTAGTATTGTGGTTGTTCTCAAAGAGGATGGAATGTTTTTGTCAGGGTGGTATCTTGAG 4200
------------------------------------------------------------

Pa1151-53
clone1

CCAGGAAGCAGACAGGAAAAAACTATTTTGA 4231
-------------------------------
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Figure 3-9 Open reading frame organization of colicin E2, pyocin S3, and
entericidinAB
The genes encoding bacteriocins of enteric bacteria (i.e. colicin E2), Pa (i.e. pyocin S3),
and entericidin AB are organized in a similar way. These proteins are toxin/antitoxin
(immunity) complexes. An immunity gene (i.e. ceiB, pyoS3A entA) follows the toxin
gene (i.e ceaB, pyoS3I, entB).
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Figure 3-10 Genome comparison of B. multivorans (Bm) ATCC17616 and
Pseudomonas aeruginosa (Pa) PAO1
Genes of Pa and Bcc were classified into 21 functional classes. Bm ATCC17616 genome
possessed additional genes in majority of these functional classes in comparison to Pa
PAO1 genome (Pathema).
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Amino acid biosynthesis
Biosynthesis of cofactors, prosthetic groups, and carriers
Cell envelope
Cellular processes
Central intermediary metabolism
DNA metabolism
Energy metabolism
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Signal transduction
Transcription
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Hypothetical proteins
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Unclassified
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CHAPTER 4
CONCLUSION

“Two nebulisers in the morning with breathing exercises that take about half an
hour. Then oral antibiotics, vitamins and occasionally steroids. I used to do chest
physiotherapy but they gave me a PEP mask because (pause) well I just wanted to get on
(with life) really rather than spend too long on treatment” by a CF patient
Kathryn Badlan, 2006

4.1 The Life of a CF patient
Cystic Fibrosis (CF) is a rare genetic disorder that occurs in 1 in every 3,000
Americans, 1 in every 2-3,000 Europeans, and 1 in every 7,056 Africans (WHO, 2004).
CF patients have a defective cystic fibrosis transmembrane regulator (CFTR) protein,
which is a chloride ion channel on the apical surface of epithelial cells (Matthay et al.,
2005). The defective CFTR channel leads to decreased chloride secretion and increased
sodium absorption across the cytoplasmic membrane. Imbalanced sodium and chloride
transport leads to dehydration of the mucous across the epithelia, which results in failure
of multiple organ systems including the digestive, reproductive, and respiratory systems
(Gibson et al., 2003).
CF patients suffer from vitamin-A deficiency, poor growth, persistent coughing,
wheezing, shortness of breath, digestive complications, and fertility problems (Darling et
al., 1953; Freedman et al., 2000a; Freedman et al., 2000b). The most severe health
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challenge, however, is the presence of chronic lung infections, which are associated with
high mortality and shortened lifespans (George et al., 2009).
The life of a CF patient is physically and emotionally challenging. Their daily
routine includes repeated sessions of chest physiotherapy (to clear mucus from lungs), a
high energy supplemented diet, digestive enzymes (taken with all meals to improve
digestion), and finally oral and nebulized antibiotics (to treat lung infections) (Foster et
al., 2001). None of these treatments represent a cure, but significantly improve the
quality of life, as well as increase the lifespan, of CF patients. The estimated median
survival age of CF patients in the US was 37 years in 2008 . Even with aggressive
therapies, CF patients ultimately die in their mid-30s (Gibson et al., 2003; Govan &
Deretic, 1996).

4.2 The battle with bacterial infections: Pseudomonas aeruginosa and Burkholderia
cepacia complex
More than eighty percent of CF patients die due to respiratory failure (Lyczak et
al., 2002). Bacterial infections and the resulting lung tissue destruction are the major
causes of respiratory failure (Gibson et al., 2003; Govan & Deretic, 1996). Bacteria are
trapped in the dehydrated mucus covering the epithelial cells of the airway, and thus
escape from phagocytosis by the immune system, and are able to colonize in the airway
and lungs (Gibson et al., 2003). The presence of pathogens in the airway induces
inflammation. Secretory cells release antibacterial proteins and neutrophils, which are
attracted to the site of the infection (Konstan & Berger, 1997). However, rather than
killing the invading bacteria, this process results in tissue destruction due to the degraded
neutrophils releasing proteases which damage the lung tissue. The damaged tissue
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provides food for the bacterial infection. Thus, inflammation leads to more bacterial
colonization, which leads to more inflammation, resulting in a vicious cycle of
host/pathogen interaction (Gibson et al., 2003).
Most research on CF-based lung infections is focused on Staphylococcus aureus,
Haemophilus influenzae, Stenotrophomonas maltophilia, Pseudomonas aeruginosa (Pa),
and Burkholderia cepacia complex (Bcc) since these are the primary colonizers of the CF
lung (Hutchison & Govan, 1999). It has been suggested that the prevalence of these
species is age-related. S. aureus and H. influenzae are isolated in early years and are
replaced with Pa and Bcc during adolescence (Govan & Deretic, 1996).
This thesis focused on the interaction between one pair of species, Pa and Bcc,
which are associated with chronic lung infections in adult CF patients (Govan & Deretic,
1996). Once a chronic infection is established, eradication of Pa and Bcc is virtually
impossible (Hentzer et al., 2001) and the patients experience progressive lung failure and
premature death (Jones et al., 2004; Lyczak et al., 2002; Tummler et al., 1997).
Pa is the most persistent bacterial species in the CF lung. Approximately 30% of
infants and 80% of adult CF patients are colonized with Pa. During infancy and
childhood Pa is isolated only intermittently (Hansen et al., 2008). At this stage, the Pa
strains are usually in a planktonic form, which respond well to antibiotic treatment. As
the disease progresses, alginate forming variants overtake the resident strain, resulting in
mucoid production and biofilms formation (Govan & Deretic, 1996). Mucoid Pa form
biofilms, which are associated with chronic lung infections and lead to progressive lung
failure and death of CF patients (Hentzer et al., 2001).

123

Bcc secondary infections have become a major concern in the last 30 years.
Although the incidence of colonization is low (~3%), clinical outcomes are unpredictable
and various - ranging from asymptomatic to severe chronic lung infections (Whiteford et
al., 1995). A small portion of CF patients succumbs to cepacia syndrome, which is fatal
necrotizing pneumonia (Govan & Deretic, 1996). The prevalence of Bcc in infants is very
low (less than one percent), most cases are reported after 5 years of age .
Combinatorial antibiotic therapy is the only treatment option for chronic lung
infections in CF. Pa infections are usually treated with a combination of beta-lactamases
and aminoglycosides (Aaron et al., 2000; Hoiby et al., 2001). However, the success of
antibiotic treatments is limited by several factors.
The most critical factor is that both species are multi-drug resistant. One form of
resistance is conferred by actively pumping the drugs through the cytoplasmic membrane.
Five pump mechanisms have been described: resistance - nodulation - cell division
(RND), major facilitator superfamily (MFS), small multi-drug resistance family (SMR),
multidrug and toxic compound extrusion family (MATE), and ATP binding cassette
family (ABC)(Paulsen, 2003). These pumps provide intrinsic antibiotic resistance to
various classes of antibiotics including fluoroquinolones, beta-lactams, tetracycline,
macrolides, chloramphenicol, trimethoprim, and sulfonamides (Poole & Srikumar, 2001).
Genomes of Pa and Bcc encode all five mechanisms (Holden et al., 2009; Stover et al.,
2000).
Biofilm formation is another factor contributing to antibiotic resistance. Bacteria
in a biofilm are 10-1000 fold more resistant to antibiotic treatment than their planktonic
counterparts (Mah & O'Toole, 2001). Both species form biofilms in CF lungs (Conway et
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al., 2002; Singh et al., 2000), in fact, alginate-forming mucoid Pa variants are a signature
of chronic Pa infections (Hentzer et al., 2001). Antibiotic resistance in the biofilms may
result from reduced growth rate, the anaerobic environment, and the presence of
negatively charged alginate surrounding the biofilm structure, which traps the antibiotics
(Hoiby et al., 2001).
The situation is more complex with strains of Bcc. In vitro studies have shown
that strains in both planktonic and biofilm form have similar levels of resistance to
ceftazidime, ciprofloxacin, meropenem, minocycline, tobramycin, and
trimethoprim/sulfamethoxazole (Peeters et al., 2009). However, Caraher et al., 2007
found elevated levels of resistance to meropenem and piperacillin-tazobactam in biofilmbased strains in comparison to planktonic forms, whereas the both showed similar levels
of resistance to tobramycin and amikacin (Caraher et al., 2007). These contradictory
results may be due to differences in the alginates produced by the species. Alginate
produced by Pa is an acetylated copolymer of beta-D-mannuronic acid and alpha-Lglucoronic acid, whereas Bcc produces a branched acetylated heptasaccharide composed
of D-glucose, D-rhamnose, D-mannose, D-galactose, and D-glucoronic acid (Bylund et
al., 2006). Structural differences between these exopolysaccharides may explain the
differential accessibility of various antibiotics in the biofilm structure.
The presence of hypermutable strains is another factor resulting in high levels of
antibiotic resistance in CF strains. The emergence of hypermutable strains is thought to
emerge due to the adaptation of bacteria to the continuously changing lung environment.
Oliver et al., 2000 compared the levels of antibiotic resistance of hypermutable (or
mutator) and nonmutator Pa isolates from CF patients against ticarcillin, ceftazidime,
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imipenem, gentamycin, tobramycin, amikacin, norfloxacin, and fosfomycin. The
hypermutable Pa strains showed elevated resistance to all of the antibiotics (Oliver et al.,
2000).
In summary, CF patients experience long-term exposure to antibiotic treatment,
which selects for multi-drug resistant strains. In addition, the bacterial strains in residence
in their lungs encode several factors that ensure high levels of intrinsic resistance. Not
surprising, nearly half of adult CF patients are chronically infected with multi-drug
resistant Pa, which is associated with a more rapid decline in lung function (Lechtzin et
al., 2006).
New antibiotics are in the drug development pipeline, such as MP-376, a new
formulation of levofloxacin; GS9310/11, an inhaled combination of the antibiotics
fosfomycin and tobramycin; BAY Q3939, an inhaled version of ciprofloxacin;
ArikaceTM, a liposomal formulation of amikacin (CF Foundation). We can anticipate
that repeated exposure of these drugs will also result in the emergence of resistant strains.
One goal of the present study is to better understand the nature of bacterial interactions in
the CF lung, in order to identify new targets for therapeutic intervention.
Most adult CF patients are infected with Pa (Govan & Deretic, 1996). When a
secondary Bcc infection occurs, the infecting strain must compete against the resident Pa
strain(s). These competitive interactions are mediated by a variety of factors. A better
understanding of these factors and the role they play in mediating Pa and Bcc interactions
may provide novel insights into the development of alternative therapeutic approaches.
In my thesis, I specifically focused on one such factor, the bacteriocins produced
by both species, and the role that these toxins play in mediating interactions between
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these species. Bacteriocins are potent toxins produced by bacteria and are implicated in
intra- and inter-specific competition of bacteria in various environments (Riley &
Gordon, 1999; Riley et al., 2003). Although the bacteriocins of Pa have been studied in
great detail, far less is known about the corresponding toxins produced by Bcc species
and even less is know about if or how they might contribute to bacterial interactions in
the CF lung.
In my thesis, I focused on answering the following questions:
•

Do clinical strains of Pa and Bcc isolated from CF lungs produce
bacteriocins?

•

If so, what types of bacteriocins are produced and how specific or broad
are their killing activities?

•

What roles do these bacteriocins serve in mediating intra- and interspecific interactions of Pa and Bcc isolated from CF patients?

4.3 Do clinical strains of Pa and Bcc isolated from CF lungs produce bacteriocins?
To address this question, a bacteriocin assay was performed. The first step was to
obtain a collection of isolates from CF lungs. This proved to be one of the most difficult
challenges I encountered; it is extremely challenging to obtain access to such strain
collections. However, I owe a great debt to Dr. Claudia Ordonez for providing me with a
set of 66 clinical Pa (38) and Bcc (28) strains isolated from CF patients. The strain
collection can be divided into two groups. The first is composed of 14 Pa and 7 Bcc
paired isolates procured from 7 CF patients, each pair isolated from the same patient at
the same time. The second group is composed of 24 Pa and 21 Bcc isolates procured
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independently from 33 CF patients. The bacteriocin-screening assay employed each Pa
and Bcc strain as a sensitive lawn and potential bacteriocin producer.
Previous studies of bacteriocin production in Pa and Bcc focused on bacteriocin
typing and the use of such types to rapidly screen clinical isolates. These studies revealed
that Pa is one of the most prolific Gram-negative producers of bacteriocins. Indeed, more
than 90% of the strains tested produce bacteriocins, known as pyocins (B.Bouhaddioui,
2002; Bruun et al., 1976; Edmonds et al., 1972a; Farmer & Herman, 1969; Jones et al.,
1974b; Zabransky & Day, 1969). In contrast, prior typing of a much smaller number of
Bcc strains from clinical sources revealed that only 30% produce bacteriocins, known as
cepaciacins (Govan & Harris, 1985).
Our phenotypic assay revealed that 97% of Pa strains (37 strains) and 68% of Bcc
strains (19 strains) possess bacteriocin-like inhibitory activity (Table 2-1). The frequency
of production in Pa isolated from CF lungs is indistinguishable from strains isolated from
other clinical sources. In contrast, the frequency of production in Bcc is far higher in
strains isolated from CF lungs than from strains isolated from other clinical sources
(Govan & Harris, 1985). The higher frequency of Bcc inhibitory activity in our study
could be due to the fact that certain Bcc isolates (i.e. those which produce bacteriocins)
are so successful in invading the CF lung, which requires interacting and/or competing
with resident Pa strains. Further, the strains used to assay for inhibition activity were
different in the prior study. The survey described here involved 28 strains of Bcc,
representing 4 genomovars (B. multivorans, B. dolosa, B. vietnamiensis, and B.
cenocepacia) and identified 19 bacteriocin-producing strains, of which ten are B.
multivorans, six B. dolosa, two B. cenocepacia, and one B. vietnamiensis. B. multivorans
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and B. cenocepacia are the most frequently isolated species from CF patients (LiPuma et
al., 2001). The previous study typed only B. cepacia (Govan & Harris, 1985).

4.4 What types of bacteriocins are produced and how specific or broad are their
killing activities?
A set of reference strains was used in the bacteriocin screen identification of
bacteriocin types. This collection included strains producing S and RF type pyocins and
those sensitive to pyocins, as well as strains carrying plasmids with cloned S-type
pyocins (pyocin S1, S2, S3, and AP41) (de Chial et al., 2003; Duport et al., 1995;
Kageyama et al., 1979; Kuroda & Kagiyama, 1983; Sano & Kageyama, 1981; Sano et
al., 1993a; Sano et al., 1993b; Williams et al., 2008). Unfortunately, no cepaciacins have
been fully characterized and there are no corresponding reference strains.
The Pa strains produced seven distinct bacteriocin phenotypes (based upon
patterns of sensitivity to the reference collection), while the Bcc strains produced four
phenotypes. Further, each Pa phenotype resulted from a combination of S and RF
pyocins. In contrast to the bacteriocins of enteric bacteria, Pa is unique in producing
numerous different pyocins per strain. However, there is no correlation between the
number of bacteriocins produced and the number of strains inhibited. For example the Pa
I bacteriocin phenotype produced at least eight pyocins (S1, S2, S3, AP41, R2, R4, F2,
and F3) and inhibited 31 strains, of which 19 are Pa and 12 strains are Bcc (Table 2.2). Pa
III pyocin phenotype III produces only 4 pyocins (S1, R2, R4, and F2), yet inhibited 44
strains of which, 18 were Pa and 26 Bcc (Table 2-2). The enhanced inhibition by strains
with fewer pyocins could be due to the fact that particular combinations of pyocins may
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be more inhibitory, or the fact that these strains may have also produced additional
virulence factors, or novel bacteriocins.
Bacteriocin typing of Bcc strains was relatively challenging since there is no
indicator strain collection including bacteriocin producer and sensitive Bcc strains.
Burkholderia and Pseudomonas are closely related. They do co-exist in the same natural
environment, and interact with each other. Further, their genome organization allows
these bacteria to swap genes via horizontal gene transfer (Holden et al., 2009; Stover et
al., 2000). In fact, Burkholderia species were formerly included within the genus
Pseudomonas (for example, as Pseudomonas cepacia) (Yabuuchi et al., 1992). Thus, I
decided to use the same Pa reference strains to characterize bacteriocin phenotype of
clinical Bcc strains. Indeed, this study revealed that 3 Bcc strains possessed bacteriocin
phenotypes similar to those found in Pa. Bcc I phenotype produces 4 pyocins (S1, S2,
AP41, F3), Bcc II phenotype produces F3 pyocin, and finally Bcc III phenotype produces
R2 and F2 pyocins (Table 2-2). The bacteriocin phenotype of the remaining 15 Bcc
strains could not be characterized, which suggests that they possessed novel toxins that
provided inhibitory activity (Table 2-2).

4.5 What roles do these bacteriocins serve in mediating intra- and inter-specific
interactions of Pa and Bcc strains isolated from CF lung patients?
The screening study revealed Pa and Bcc strains produced significantly different
levels of intra- and inter-specific inhibition. The Pa strains showed similar levels of intraand inter-specific inhibition (92 % and 81%, respectively) (Table 2-1). Bcc strains also
showed similar levels of intra- and inter-specific inhibition, but at a much lower level
(54% and 57%, respectively) (Table 2-1).
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This study also revealed that the source(s) of the inhibitory activity is different for
the two species. The intra-specific inhibitory activity for Pa strains was due primarily to
S- and RF-pyocins, while inter-specific inhibition appeared to due to only RF pyocins
(Figure 2-3). Not enough is known yet about cepaciacins to determine what types of
toxins (i.e protease sensitive or phage-tail like) are acting.

4.6 Further characterization of Bcc inhibitory activity
Phenotypic and molecular studies revealed that the source of Bcc inhibitory
activity is novel. Thus, genome libraries of three Bcc strains were constructed and
screened against sensitive Pa and Bcc lawns to identify the source of the inhibition
observed (Bakkal et al., 2010). Fifteen genomic clones with putative inhibitory activity
were identified from three Bcc genomes. Ten of the clones (B. dolosa and B.
cenocepacia) did not have replicable inhibitory activity. The five remaining clones,
which consistently maintained their inhibitory activity, were all from B. multivorans. The
loss of inhibition in some of the clones is not surprising. The proteins produced could be
toxic to the recipient E. coli due to the lack of cloned immunity gene, which confer
resistance to the toxin.
The DNA inserts from the remaining five genomic clones were sequenced and
compared to the genome sequence of B. multivorans. Instead, the Bcc genes identified are
involved in amino acid biosynthesis, sugar metabolism, degradation of aromatic
compounds, and bacterial apoptosis (Table 3-2). One explanation could be failure to
detect Bcc bacteriocin genes due to technical challenges (Chapter 3.5). Another
explanation could be Bcc strains use different strategies when it comes to bacterial
competition. The genomes of Bcc strains possess numerous additional genes (Figure 3131

10), including the genes involved in primary metabolic pathways. Perhaps, instead of
killing their competitors with highly costly bacteriocins, Bcc they used the advantage of
their gene potential to grow and to adapt faster to any environment, where they are in
competition with other species.

4.7 The lessons learned from phenotypic bacteriocin screening and genome library
of Pa and Bcc
My thesis research has revealed that Bcc inhibitory agents appear to be
phenotypically and genotypically different from that observed in the majority of Gramnegative bacteria. Most bacterial strains surveyed for an inhibition or killing activity are
found, under further characterization, to encode one or more bacteriocin proteins. Riley
(Riley & Gordon, 1999; Riley & Wertz, 2002a; Riley & Wertz, 2002b; Riley et al., 2003)
has gone so far as to label bacteriocins as the “weapon of choice” in bacteria. Even
among the strains surveyed here, half of which were isolates of Pa, a plethora of
bacteriocins were identified – all of which were encoded in the Pa genomes. In sharp
contrast, none of the functions identified in the genome screens of Bcc bore any
detectable similarity to the diversity of bacteriocins characterized in the literature.
(Hardy, 1987; Riley et al., 2003).
A further frustration was encountered when the standard bacteriocin assays were
employed with Bcc. Inhibition phenotypes were constantly disappearing. A clear
inhibition zone on a plate might disappear upon replication of that strain. Most of the
inhibition zones observed in the standard plate assays also disappeared when subjected to
the usual methods of concentration, such as is done with the crude lysate procedure
(Bakkal et al.). Even with 20-fold concentrations during crude lysate preparation,
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inhibition was lost in all of the Bcc strains. Further, only three of the 19 Bcc strains
examined showed inhibition against the Pa indicator strain collection. These three Bcc
strains were predicted to possess RF-like pyocins. Unfortunately, the PCR-based
molecular screening methods employed here were unable to confirm the presence of any
known RF-pyocin genes. Whether this absence is due to the fact that the pyocin-like
genes are present but too divergent to amplify or they represent entirely novel
bacteriocins remains unclear. BLAST-based examination of the 38 available Bcc
genomes has also failed to detect the presence of any previously characterized
bacteriocins.
The genome library of one of the Bcc strains surveyed was screened to identify
the source of Bcc inhibitory activity. More than 10,000 genomic clones were screened on
an appropriate sensitive lawn. As a positive control for the library construction and
screening methods, a Pa strain, whose genome has been sequenced and is known to
encode pyocin S2, was screened in an identical manner. It is surprising that no
bacteriocin gene was identified from Bcc genome, while the first and the only gene
detected from Pa PAO1 library was pyocin S2 as the source of inhibitory activity. Five
inhibitory clones were identified from the Bcc strain. Sequence analysis determined that
the Bcc clones are responsible for primary metabolic pathways including amino acid
metabolism, carbohydrate metabolism, degradation of aromatic compounds, and bacterial
apoptosis. Surprisingly, no bacteriocin-like genes were detected.
This library screen outcome was quite surprising. To our knowledge, no other
Gram negative bacterial species examined at this level of detail has failed to reveal the
presence of one or more recognizable bacteriocins. This result suggests that we should
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not extrapolate from the existing surveys of bacteriocin-based inhibition. It is possible
that some, or even much, of the inhibitory activities of Gram-negative bacteria are not
bacteriocin-based. Until further molecular characterizations are carried out; it is
premature to conclude the presence of bacteriocins, as was done even in the Bcc literature
(Govan & Harris, 1985).
How then does Bcc produce inhibitory activity with the genes identified in the
library screen? It is difficult to answer this question. First, we identified a number of
primary metabolism genes, which are involved at specific steps of amino acid,
carbohydrate metabolisms, and degradation of aromatic compounds. The remaining
genes involved in these pathways are not isolated from our genomic clones. One
explanation would be the proteins expressed in E. coli could be involved the very same
metabolic pathways used in E. coli, and thus provided E. coli a growth advantage over
the Pa lawn. Second, some of these genes are represented partially in E. coli, so the
genomic clones do not express some of these genes (such as GGDEF domain,
amidohydrolyse II) as functional proteins. Thus, the complete DNA sequence of these
genes needs to be cloned to prove the Bcc inhibitory phenotype observed in genomic
clones. Third, one apoptosis gene (Entericidin AB) was identified in clone 7. Like
bacteriocins, entericidinAB is a toxin-antitoxin complex, whose open reading frame is
organized similar to colicins of enteric bacteria and pyocins of Pa (Figure 3-11). A toxin
gene and immunity gene are organized consecutively and transcribed together. Both pore
former colicins and entericidin distrupt membrane stability and lyse the bacterial
cells(Bishop et al., 1998; Michel-Briand & Baysse, 2002; Riley & Wertz, 2002a).
However, there is no sequence similarity between entericidin AB and pore former
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colicins. Further, there is no literature suggesting that E. coli use entericin to inhibit
bacterial growth. Instead, it has suggested that entericidins are produced by in a
population, which is exposed to nutrient limitation (stationary phase). Thus, bacteria lyse
themselves to provide nutrients to the remaining members of the population (Bishop et
al., 1998). Another interesting gene was glucoamylase from clone 4 of B. multivorans
(ATCC17616). Glucoamylase is an extracellular enzyme, common in fungus Aspergillus.
This enzyme hydrolyzes starch into glucose (Sauer et al., 2000). More importantly,
glucoamylase has a second function, which is induction of a fungal toxin (aflatoxin)
biosynthesis (Mellon et al., 2007). Bcc may be using this secondary function to induce
similar toxin genes in its genome to inhibit other species. Finally, the inhibitory activity
of the clones detected might be artifacts of the genomic library construction. Cloning and
expression of identified Bcc genes is required to further verification and characterization
of inhibitory activity in Bcc.
One goal of the present study is to better understand the nature of bacterial
interactions in the CF lung in order to identify new targets for therapeutic intervention. In
recent years, bacteriocins have been considered for therapeutic use in human health
(Gillor et al., 2005; Gillor & Ghazaryan, 2007). For example, bacteriocins from
Staphylococcus aureus are used to treat skin infections. Bacteriocins from Bacillus
subtilis are employed to treat vancomycin-resistant bacterial infections, while bacteriocin
from Lactococus lactis are effective in the treatment of peptic ulcers and bacteriocin from
enteric bacteria are used to treat urinary tract infections (Gillor et al., 2004; Gillor et al.,
2005). Future studies should focus on the efficacy of S and RF type pyocins on in vitro
and in vivo single and mixed species biofilms of Pa and Bcc strains.
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Finally, this study showed that Bcc strains might use primary metabolism to
become more competent against Pa strains. We isolated five clones of B. multivorans
(ATCC17616), which possessed inhibitory activity on a Pa lawn. Additional study needs
to be done on these genomic clones to further prove this conclusion. First, genes
possessed by these five clones should be cloned separately and the effect of protein
expression on the Pa lawn should be investigated. Second approach could be creation of
deletion mutants of Bcc for the genes detected in the genome library study. Finally,
genome libraries of Bcc clones should be tested on Bcc lawns to observe the differences
between within and between inhibitory activities.
One final study could be suggested on Pa inhibitory activity. It has been revealed
that majority of Pa inhibitory activity is due to the presence of S- and RF pyocins. Indeed,
we identified pyocin S2 in one genomic clone of Pa PAO1, which inhibits a Pa lawn.
However, there are other pyocin-like genes annotated in Pa PAO1 genome. Interestingly,
we only detected one S-pyocin (pyocin S2) in one Pa PAO1 genomic clone. This result
may be due to sensitivity phenotype of the lawn. The lawn used to screen Pa PAO1
genomic library might be resistant to the other pyocin-like genes possessed in Pa PAO1
genome. Various lawns might be used to screen genomic clones to identify other pyocins
in Pa PAO1 genome as well as in clinical Pa strains.
The treatment of Pa and Bcc chronic lung infections is a problem faced in the
treatment of chronic CF lung infections. These species will survive and infect CF lungs
as long as CF patients have defective CFTR on their epithelial cells. Antibiotics are the
only available treatment option, but the multiple drug resistant nature of these species and
emerging drug resistance to current antibiotics will make this option obsolete in the near
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future. This study revealed sources of inhibitory agents, which are responsible for within
and between species inhibitory activities of Pa and Bcc strains. Nature of bacterial
interactions in the CF lung may reveal new targets for therapeutic intervention.
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APPENDIX A
CLINICAL PSEUDOMONAS AND BURKHOLDERIA STRAIN
COLLECTION

Paired isolates1
Study

Strain

ID

ID

Study

Strain

ID

ID

Species

Species

1

03-195-0952

B. cenocepacia

19

181-0-63

P. aeruginosa

2

03-104-0962

B. multivorans

8

015-4-1076

P. aeruginosa

3

03-303-0655

B. dolosa

12

159-4-1077

P. aeruginosa

3

03-303-0655

B. dolosa

13

159-4-1078

P. aeruginosa

3

03-303-0655

B. dolosa

14

159-4-1178

P. aeruginosa

3

03-303-0655

B. dolosa

15

159-4-1606

P. aeruginosa

3

03-303-0655

B. dolosa

16

159-4-1607

P. aeruginosay

3

03-303-0655

B. dolosa

17

159-4-1674

P. aeruginosa

3

03-303-0655

B. dolosa

18

159-4-1675

P. aeruginosa

4

03-287-0857

B. multivorans

10

080-4-34

P. aeruginosa

4

03-287-0857

B. multivorans

11

080-4-1247

P. aeruginosa

5

03-350-1649

B. dolosa

20

203-1-1394

P. aeruginosa

6

03-318-1184

B. dolosa

9

030-7-33

P. aeruginosa

7

03-219-0968

B. multivorans

21

228-0-1396

P. aeruginosa
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Unpaired isolates
Study

Strain ID

Species

ID

Study

Strain ID

Species

ID

22

085-3-1211

P. aeruginosa

46

95-258-0446

B. cenocepacia

23

093-8-1498

P. aeruginosa

47

02-228-1429

B. cenocepacia

24

180-8-72

P. aeruginosa

48

03-342-1396

B. cenocepacia

25

180-8-75

P. aeruginosa

49

03-281-1317

B. dolosa

26

195-1-271

P. aeruginosa

50

03-277-0282

B. dolosa

27

195-1-272

P. aeruginosa

51

03-303-1206

B. dolosa

28

202-3-1393

P. aeruginosa

52

03-338-1539

B. dolosa

29

202-3-1504

P. aeruginosa

53

03-339-1377

B. dolosa

30

217-7-1505

P. aeruginosa

54

03-336-0575

B. multivorans

31

217-7-1506

P. aeruginosa

55

04-021-0261

B. dolosa

32

217-7-1507

P. aeruginosa

56

04-032-0605

B. dolosa

33

239-7-1215

P. aeruginosa

57

04-053-0423

B. dolosa

34

276-6-1714

P. aeruginosa

58

03-255-0518

B. multivorans

35

276-6-1715

P. aeruginosa

59

03-289-0554

B. multivorans

36

283-1-88

P. aeruginosa

60

03-338-0277

B. multivorans

37

283-1-89

P. aeruginosa

61

03-350-0955

B. multivorans

38

325-5-1421

P. aeruginosa

62

03-364-0829

B. multivorans

39

325-5-1428

P. aeruginosa

63

03-365-0241

B. multivorans

40

325-5-1533

P. aeruginosa

64

04-050-0866

B. multivorans

41

327-6-1422

P. aeruginosa

65

04-065-1420

B. multivorans
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42

327-6-1423

P. aeruginosa

43

327-6-1424

P. aeruginosa

44

327-6-1518

P. aeruginosa

45

327-6-1519

P. aeruginosa

66

03-260-0635

B. vietnamiensis

Paired isolate1: Seven Bcc strains are isolated as pairs with 14 Pa strains. Two Bcc strains
(Study ID # 3 and #4) have multiple corresponding Pa isolates.
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